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  Abstract 
Irreversible Breakdown of HIV-1 by Peptide Triazole Thiols and Multivalent Gold 
Nanoparticle Conjugates 
Arangassery Rosemary Bastian 
 
 
 
 
 
The HIV entry is a critical multi-stage process which leads to attachment to the cell 
receptor followed by co-receptor binding leading to a conformation change in the HIV 
envelope spike leading to membrane fusion. The peptide triazoles developed in the 
Chaiken  lab has previously been established to function as dual antagonists of the 
binding of gp120 at its host cell receptor binding sites for both CD4 and CCR5/CXCR4 
and have  shown to have broad neutralization In Vitro.  In this work we showed that a 
representative member of this class, peptide triazole thiol, led to HIV inhibition but also 
leads to irreversible lysis and complete inactivation of cell-free HIV-1. Further to 
improve the potency of these peptide triazole thiol inhibitors, I created multivalent 
displays of KR13 on gold nanoparticles that led to a drastic potency increase in inhibition 
of HIV-1. 
My research is focused on understanding the mechanism of action of the peptide triazole 
thiol and its gold nanoparticle conjugates that lead to the virolysis action of HIV-1. In 
order to study this intriguing breakdown of HIV-1, my studies focused on kinetic and 
thermodynamic studies. This included understanding the fate of several important viral 
proteins, including gp120, gp41 and p24, time dependent inhibition of viral entry into 
host cells and the morphological and biological state of the residual virus. Further the 
molecular, physical and functional transformations of the gold nanoparticle peptide 
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conjugates and how these properties affect their virolytic function were tested. From 
these studies it is conclusive that the peptide triazole thiol virolysis event does follow a 
time-dependent breakdown pathway of the viral machine that eventually leads to 
complete disruption of the virus. A clear correlation between peptide triazole thiol 
dependent HIV-1 virolysis and HIV-1 – host cell fusion was observed. Gold nanoparticle 
peptide triazole conjugate studies showed that the gold nanoparticle inhibitor virolysis 
works by a different mechanism all together. We further showed that increasing size of 
the nanoparticle and density of peptide coverage led to an inhibitor with almost 2000 fold 
enhancement of its anti-viral potency. These studies therefore have led to two major 
findings; one, the discovery of an innovative class of HIV-1 inhibitors that that lead to 
complete irreversible breakdown of the virus by hijacking the virus-cell fusion 
mechanism and two, the proof of concept model of nanoparticle-inhibitor constructs that 
have opened up the field to the rules required for development of highly potent 
nanoparticle inhibitor constructs that irreversibly lyse the virus. These findings have 
thereby given the HIV-1 field as well as the nanomedicine field an innovative approach 
that can be further developed and nurtured.  
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Summary 
 
The human immunodeficiency virus which is the viral precursor that is 
responsible for the disease that is still a challenge and an epidemic, AIDS [4-6]. Several 
top physicians as well as scientists in the field have been trying to combat this virus and 
trying to inhibit the infection and spread of the disease. Due to the constant mutation 
tendencies of the HIV virion it has become a big challenge to target this virus and 
eradication of the virus infection all together [7]. Our group at Drexel University College 
of medicine has developed several inhibitors that target the virus directly that not only 
leads to very potent entry inhibitors  but further have gone a step further to create 
microbicides that target the virion Env and lead it to irreversible self-destruction[8-10]. 
This innovative approach has led to the development of a class of microbicides that can 
be used at several stages of AIDS progression which include, initial entry, reduction of 
new virus production as well as cell-cell transmission of the virion leading to complete 
virus abolition of the disease progression.  
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Figure 1: Fusion of HIV-1 with host cell. The HIV proteins gp120 and gp41, 
together known as the HIV-1 spike interacts with the receptor CD4 and 
coreceptor CCR5 or CXCR4. The gp120 sheds off the spike and the gp41 is 
exposed on the cell surface. Gp41 follows a 6-helix bundle formation and the 
virus and cell surface fuse and the capsid is released. The inhibitors that are 
currently approved for therapy that target HIV-1 fusion with cell are indicated in 
red with maraviroc that targets the co-receptor, CCR5 binding to gp120 and T20 
(enfurvitide) that targets gp41 blocking 6-helix bundle formation and therefore 
fusion of the two membranes.  
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Host cell infection by HIV-1 is mediated by cell receptor interactions with 
trimeric envelope glycoprotein (Env) spikes that are exposed on the virus membrane 
surface.  Env is the only virus-specific protein on the virion surface, and is essential for 
cell receptor interactions and subsequent virus-cell fusion [11-13] (Figure 1).  Hence, 
Env presents an obvious target to attack the virus directly in order to block the cascade of 
integrated binding and conformational change steps that lead to host cell infection.  Env-
specific inhibitors that could inactivate the virus before receptor encounter would hold 
great promise of preventing AIDS transmission and progression. The proteins of the 
HIV-1 Env include gp120 and gp41 on the viral envelope spike and the cell surface 
receptors include CD4 and a chemokine receptor, either the CCR5 or CXCR4. The fusion 
inhibitor T20[14], and the CCR5 inhibitor maraviroc[15] are approved drugs used 
currently for salvage therapy in HIV-infected patients, though trials are ongoing to assess 
their addition to first line regimen (Figure 1).  T20 targets the N-terminal heptad repeat 
region of gp41, blocking gp41 conformational changes essential for 6-helix bundle 
formation and membrane fusion. This inhibitor however has a relatively short time 
window to act on the transiently exposed N-helix of gp41 at the cell-virus synapse. In 
addition, T20 is logistically difficult to administer, as it can only be given parentally, and 
adverse reactions at sites of injection are common. Maraviroc only blocks R5-tropic HIV-
1 and its use requires that CXCR4-tropic viruses are not present [15]. While there are 
other small molecule entry inhibitors[16, 17], peptidomimetics[18, 19] and anti-CD4 
antibodies[20, 21] that block or interfere with proteins at the cell-virus interface, they are 
still not advanced to clinical use as a first line regimen. 
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Figure 2: The schematic representation of the peptide triazole mode of action. It is an 
allosteric diverter that puts the gp120 protein in an inactive state that is insensitive to 
CD4 and CCR5 binding leading to complete inhibition of HIV fusion and therefore entry 
of the virion into the host cell.  
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These groups of microbicides are called peptide triazole inhibitors, made with amino 
acids just like proteins in the body and hence they are very biocompatible[22]. They have 
been engineered by using a technology called click chemistry to create a pharmacophore 
[22] that binds close the CD4 binding pocket, which is a highly conserved region among 
the several drug resistant mutants strains of the virus that are currently present. The 
peptide triazoles compete with the CD4 as well as co-receptor binding site which 
therefore inhibits the virus from initial contact with the host cell, blocking its entry [9, 
23-25]. The peptide triazoles revert gp120 to an alternate inactivate state which will not 
proceed towards CD4 or coreceptor binding, hence blocking virus cell fusion as shown in 
figure 2. This class of peptides was further developed to create the virolytic class of the 
peptide triazole inhibitors called peptide triazole thiols [6, 8]. These virolytic peptides 
have an additional characteristic in addition to entry inhibition, which is the cell-free 
virolysis. This unique effect of the peptide triazole thiol is still under investigation but we 
have shown that the cysteine in the C-terminus is very crucial for this lytic effect[6]. 
Further we also have demonstrated that this effect follows a similar pathway as regular 
virus fusion with the host cell. This was proven by showing that peptide induced virus 
breakdown followed a similar time-line as virus fusion as demonstrated in Bastian et al. 
2013 [6]. Also further the fusion inhibitor, T20 that targets HIV-1 spike protein gp41 and 
blocks the 6 helix bundle formation of the virion, also inhibits the peptide induced virus 
breakdown. These two striking results have led to exploration of how the peptide triazole 
thiols are hi-jacking the virus fusion machinery and mocking the virion to think it is 
fusing with a cell but instead leading to complete release of the protein (p24) that is in the 
virus nucleus into the surrounding environment. One additional component that makes 
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there peptides very unique is that they can target multiple clades of the HIV-1 virus 
including the founder viruses. Several inhibitors that are currently in the pipeline have 
very few specific clades that they are more active against, and therefore are limited to 
their inhibitory action. The results of these are elaborated in the Bastian et al. 2013 paper 
[6].  
This novel finding is not only creating a new class of virus targeted inhibitors but 
also can answer some unknown questions about virus fusion with a host cell that is yet to 
be answered. We have also led to several discoveries juxtapositioning this finding that 
can lead to the creation of inhibitors that can completely and irreversible destruct the 
virion at the site of initial contact with the host. Our current research is focused on 
several aspects of this potent class of virus disrupting inhibitors. We had previously 
shown that multivalent display of this virolytic peptide triazole thiols lead to a 20 fold 
enhancement of the antiviral effects making it a much more potent inhibitor [8]. But 
recently we found that if we use nanotechnology to present an increased local 
concentration of this virolytic inhibitor on a single virion we can lead to nearly 200 fold 
potency enhancement of virolysis compared to peptide alone and also further we saw that 
this leads to disruption of the infected cells that act as a virus producing factory.  
Therefore figure 3 summarizes the effects of peptide triazole inhibitors as well as their 
multivalent gold nanoparticle conjugates and shows how they target different stages of 
the virus infection as well as how they act as a multi level process that can be used as 
microbicides to exterminate the disease completely. This therefore is a innovative 
approach that can be developed further for longer bioavailability as well as microbicidal 
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preparations in order to create a multi-process inhibitor that can target the virus and lead 
to pre-infective inactivation and complete breakdown of the virus.  
 
 
Figure 3: Schematic representation of the different effects of peptide triazoles and its 
conjugates. It summarizes the different stages of HIV infection 
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Specific Aims 
 
My overall aim is to study these very intriguing phenomena of irreversible HIV-1 
breakdown induced by peptide triazole and its multivalent conjugates and to 
understand the mechanism of this action. There is an urgent need for antiretroviral 
agents to combat the spread of HIV-1 [26].  With the exception of the recently approved 
fusion inhibitor enfuvirtide (T20), most of the currently approved HIV drugs target viral 
enzymes, in particular reverse transcriptase, protease and recently integrase [27-29].  In 
contrast, current first-line therapies include no antagonist that targets the entry process 
and remains a compelling and yet elusive means to prevent infection and spread of the 
virus.  Entry is dependent on the ability of the virus envelope protein spike to interact 
with specific cell receptors in a multistage process that triggers conformational 
rearragements in Env  and consequent fusion of virus and cell membrane to deliver virus 
contents to the host.  Agents that could either block virus Env – host cell receptor 
interactions or inactivate the Env spike before cell encounter would be powerful tools for 
AIDS prevention and treatment. The HIV-1 envelop (spike) is known to be metastable in 
its native form and becomes much more conformationally stable post CD4 receptor 
binding [30]. A peptide triazole (PT) class of entry inhibitors has been identified 
previously and found to be able to bind to HIV-1 gp120 with close to nanomolar affinity, 
to suppress protein ligand interactions of the Env protein at both its CD4 and co-receptor 
binding sites and to inhibit cell infection by a broad range of virus subtypes[10, 22, 31, 
32].   
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The HIV-1 virion envelop has been shown previously to be metastable in its native state 
[30, 33, 34]. Once gp120 binds to CD4 on the host cell, the envelope becomes very stable 
and following the coreceoptor binding leads to the trigger of the remaining cascade 
structural changes in the envelope that eventually leads to fusion[35-38]. Previously, 
Emileh et al. has demonstrated that the peptide triazoles put the gp120 env protein in an 
altered confirmation that stabilizes the inactive state. This therefore stops the cascade 
conformational changes of the envelope required for fusion to occur[24, 39]. The figure 
below demonstrates the structural changes the HIV-1 Env goes through post CD4 binding 
and also post peptide triazole binding (Figure 4). This led me to the development of my 
thesis development and hypothesis;  
  
Figure 4: Schematic showing the state of the HIV-1 env post CD4 binding (bottom left) and peptide 
triazole binding (bottom right). The structures shown for the gp120 are adapted and modified from 
Emileh et al. 2013. 
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The metastability of the HIV-1 envelope protein provides a target for irreversible 
inactivation of HIV-1 and suppression of host cell entry. There is a need to create an  
agent  that combines,  for  the  first  time,  two  functionalities  uniquely  suited  to  
attacking  HIV as soon as it presents itself in the host body.   (1)  strong  and  
selective  binding  to  the HIV  envelope  spike  glycoprotein  gp120,  and  (2)  
destabilize the virus membrane leading to complete HIV breakdown.  The  rationale  
behind  this  design  objective  is  based  on  the  idea  that  is to  destabilize the HIV 
membrane either by using protein structural modifications or physical membrane 
stress to disrupt  the  membrane  integrity and enhance inhibitory potency  
sufficiently  to  cause  irreversible  leakage  of  viral  contents,  rendering  the  virus  
noninfectious.  This work can help identify HIV-1-specific virucidal agents to use in 
AIDS treatment and prevention by promoting cell-free virus destabilization and 
inactivation of HIV-1.  
 
4 specific aims for this project include:  
Aim 1. Characterize the irreversible inactivation by peptide triazole thiol and the 
relationship of this peptide induced virolysis to the virus-cell fusion process: Using 
coordinated virus infection and study of viral content release, the effects of peptide 
triazole thiol (PTT) on the virion. To better understand the intrinsic mechanism of PTT 
induced virolysis, the effects of the virolytic PT on molecular and physical transitions 
that occur in the metastable HIV-1 virion, including gp120 shedding (ELISA), release of 
intraviral components (ELISA for p24), gp41 on the residual virion, loss of membrane 
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integrity (TEM) and loss of cell infection activity will be measured. Specific focus on 
understanding the mechanism of PTT induced virolysis will be tested by comparing PTT 
induced virolysis relation to virus-cell fusion.  
Aim 2. Develop multivalent nanoparticle constructs of the virolytic peptide triazole, 
understand the mechanism of action of these nanoparticle conjugates and determine 
the rules necessary to create highly potent nanoparticle conjugates. To increase the 
potency of the virolytic PTT action on HIV-1, gold nanoparticle conjugates of PTT will 
be constructed. The mechanism of action of these nanoparticle conjugates, on the 
metastable HIV-1 will be conducted by testing the release profiles of viral proteins and 
morphological analysis of the treated virion. From these studies, rules required to create a 
nanoparticle construct will be established and also a model of the gold nanoparticle – 
PTT conjugate and HIV-1 interface will be created.  
Aim 3: Determine the effects of virolytically active peptide triazole thiols and 
nanoparticle conjugates on new virus formation and proliferation. Peptide triazoles 
are known to target the HIV-1 entry, but due to its known unique function, the virolytic 
peptide triazoles ability to inhibit viral production and infected cells was tested. Virus 
harvested in the presence of peptide triazoles and gold nanoparticle peptide triazole 
conjugates will be tested for infectivity, p24 content, gp120 release and gp41 recognition 
patterns.   
Aim 4: Understand the mechanism of PTT induced virolysis by testing stabilizing 
viral capsid mutants and immature virus particles and development of an 
immunogen using residual post PTT treatment. In order to better understand the 
mechanism of the virolytic breakdown by PTT, the effect of PTT on stabilized p24 core 
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mutant HIV-1 as well as immature HIV-1 will be tested. The residual virion post PTT 
treatment will be used as an immunogen to develop antibodies against viral envelope 
protein gp41.  
Overall, this work will derive principles for designing virolytic agents that 
specifically target HIV-1. The functional and molecular transitions of the virolytic 
process will give more insight towards understanding the viral fusion mechanism. The 
NP’s will help expand understanding of the extent to which the Env metastability that is 
critical for pathogenic host cell entry can be hijacked for therapeutic and microbicide 
functions. The results will provide precedent for how other gp120 inhibitor compositions 
can be devised for HIV-1 virus inactivation as well as how ligand-specific pathogen 
rupture can potentially be achieved for other viruses, such as influenza, ebola and dengue, 
that contain metastable prefusion surface protein complexes. 
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CHAPTER 1: INTRODUCTION 
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1. Introduction 
 
Acute immunodeficiency syndrome or AIDS is caused by the Human immunodeficiency 
virus (HIV-1) [40, 41].  Since the first reported case of AIDS in the US, it has been 
nearly 30 years and the progress that has been made to understand and treat the disease is 
exceptional[41]. In the 30 years since the discovery of the HIV virus, 31 medicines have 
been approved to treat HIV infection, and a 20 year old diagnosed with HIV can expect 
to live 50 years. With nearly 90 medicines in development for the treatment of 
HIV/AIDS, promising treatment gains are on the horizon. All this started with the 
introduction of highly active antiretroviral therapy (HAART) in 1996[42, 43]; this 
changed the outlook of treatment for this epidemic and had an exponential improvement 
of treatment regimens. HAART lead to 70% drop in mortalities and this lead to a ray of 
hope for this deadly disease [41, 44]. Although HAART therapy has progressed very well 
and has resulted in a drastic decrease of the new infections as well as reducing the 
number of deaths resulting from AIDS, it is still not a cure for this disease. The HAART 
therapy although leading to success does come with baggage, as in, people getting 
treatment are more prone to creating new resistant variants of the virus making the virus 
much more difficult to tackle [40, 45]. Currently, according to the 2013 UNAIDS Global 
report, there are currently 33.3 million people living with HIV globally and 2.6 million 
newly infections. Although the HAART therapy coverage is improving exponentially, it 
is till limited because the number of new infections outweighs the treatment availability 
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[40, 41]. Therefore, there is a huge requirement for the development of novel drugs, drug 
targets and/or vaccine that can control and eventually eradicate the AIDS epidemic [40, 
41]. In order for the development of novel drug and drug targets, it is important to study 
the structure/configuration of the virus itself and further understand how the epidemic has 
evolved and what drugs and drug targets is currently used to target the virus or the virus 
infection. Further we will explore focus on the microbicides that target virus entry 
specifically because we believe that this is one of the most important areas of the HIV 
lifecycle to focus on for drug development in order to eliminate the disease progression.  
 
1.1 Structure and Lifecycle of the virus 
 
1.1.1 Structure of the Virus 
 
HIV-1 is an enveloped retrovirus that is slowly replicating and hence specifically 
belongs to the lentivirus genus [46]. It is approximately 100-120 nm diameter and 
mostly is spherical in shape[47]. The structure can be simply stated as a collection of 
fifteen proteins and an RNA encapsulated by a lipid bilayer [46, 47]. There are 
twelve of these proteins present in the viral particle: The four Gag proteins MA 
(matrix), CA/ p24 (capsid), NC (nucleocapsid) and p6 plus the two Env proteins 
gp120 and gp41 are the structural components of the virus. The three Pol proteins PR 
(protease), RT (reverse transcriptase) and IN (integrase) provide essential enzymatic 
functions and along with the accessory proteins Vif, Vpr and Nef, are packaged into 
the virion [46]. The three other HIV-1 encoded proteins Tat, Rev and Vpu are gene 
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regulatory proteins that help with the HIV infection and lifecycle. The lipid bilayer 
that encapsulates the virus is taken from the membrane of the hot cell when a new 
virion buds off the host cell. The lipid bilayer of the virus has a higher level of 
several lipids compared to the human t-cell membrane with composition percentages 
similar to a lipid raft on a host cell lipid membrane [48-50].  
 
HIV-1 is very highly genetically variable due to its ease to mutate in order to survive 
and become resistant. There are three groups of HIV-1 based on the differences in 
the envelope (env) region: M, N, and O [51]. Group M is the most prevalent and is 
subdivided into eight subtypes (or clades), based on the whole genome, which are 
geographically distinct. The most prevalent are subtypes B (found mainly in North 
America and Europe), A and D (found mainly in Africa), and C (found mainly in 
Africa and Asia); these subtypes form branches in the phylogenetic tree representing 
the lineage of the M group of HIV-1[52, 53]. Because most of this divergence and 
mutations arise in the env of the HIV it is important to study the envelope and 
develop drugs that target this very vulnerable yet important protein of the virus.  
 
Structure of the HIV Envelope:  
The envelope glycoprotein (Env) is presented as a trimer on the viral envelope and it 
is the only virally encoded antigen on the surface of HIV-1[54]. This is the first 
trigger that leads to viral entry into host cells, and is the region of the virus that 
morphs itself in order to survive in the cell environment [52, 54-56]. The trimer is 
composed of heterodimers of gp120/gp41 complexes and the two proteins are 
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attached to each other through a non-covalent association [57]. The gp120 
glycoprotein must be flexible to allow conformational change, yet retain sufficient 
contact with gp41 to maintain the integrity of the unliganded trimer and, after CD4 
binding, to arrest gp41 transitions at a prehairpin intermediate stage. The shedding of 
gp120 from the trimer and functional inactivation of the CD4-bound spike are well 
documented consequences of missteps in this demanding process. Various structures 
of components of gp120 and gp41, alone and in complex with different ligands have 
been determined [12, 58].  
Gp120 is a heavily glycosylated protein with up to 50% of its molecular weight 
contributed by carbohydrates [59, 60]. The gp120 sequence contains five conserved 
regions (C1-C5) interspersed with five variable loops (V1-V5) as shown in Figure 5 
[57]. It has been shown by very extensive studies that the five conservative regions 
make up the core and the variable loops extend out of it. Most of the literature 
depicts the gp120 architecture to be thought as a series of domains/layers that move 
according to the binding with receptor and co-receptor. Figure 5A and 5B 
demonstrate how these layers move respect to each other post ligand/receptor 
binding [1, 57]. And Figure 5C demonstrates the first crystal structure showing 
gp120 presented as a structural complex of gp120 with sCD4 and 17b for 
crystallization purposes. 17b is an antibody that binds to the coreceptor binding site 
on gp120 and thus acts like a coreceptor surrogate for structural studies [61].  
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Figure 5: A. Model of the conformational changes in the HIV-1 gp120 monomer induced 
by CD4 binding (B) (Image adopted from Xiang etl al. 2010)[1]. The viral membrane is 
on the top of the image. The gp120 outer domain (OD) is yellow. The HIV-1 gp120 inner 
domain consists of a β-sandwich (red) and loops that form three topological layers (layer 
1 [magenta], layer 2 [green], and layer 3 [yellow]). B. Changes in the V3 loop and the β 
20 – β 21 which form the bridging sheet post CD4 binding to expose gp120 for 
coreceptor binding. Image adapted from Xiang et al. 2010[1]. C. The crystal structure 
revealing the complex of gp120 (HXBC-2), sCD4 and 17b (a coreceptor surrogate 
antibody), PDB: 1G9M. 
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 Although this structure presented in figure 5C did lack the variable loops, the 
protein was modified to contain no N and C-termini, deglycosylated and in complex 
with CD4 and 17b for crystallization purposes, this finding revealed several potential 
inhibitor development against gp120 [61-63]. Several structural studies have been 
conducted in the past 16 years resulting in a more complete picture of this state of 
gp120 by adding other components like the V3 and V4 loops and the N and C-
termini[57, 64, 65]. In 2013, for the first time ever using cryo electron tomography 
the 6-Å structure of the membrane bound fully glycosylated, HIV-1 Env trimer was 
revealed in its uncleaved and unliganded stage (Figure 6) [2]. This was further 
demonstrated also by several groups in the same year using the cryo- EM 
methodology as described by Mao et al. 2013 [66-70]. This lead to a giant leap in the 
field which lead to several discoveries of antibodies, conservative binding sites in the 
native trimer, as well as new inhibitor target sites on the HIV env. Further one of the 
greatest and most encouraging rewards of last year to the field was the crystal 
structure of the native cleaved trimer (SOSIP) – pdb structure 4NCO [54]. This has 
led to the discovery of several key sites on the HIV-1 env that is highly 
immunodominant and immunoactive which brings an HIV vaccine creation closer to 
reality [71-73].  
Gp41 is a 41 amino acid glycoprotein that contains three domains, the extracellular 
domain (ED), the transmembrane domain (TMD) as well as the cytoplasmic domain 
(CD). The extracellular domain consists of a fusion peptide (FP), a N- heptad repeat 
(NHR), a loop region, a C- heptad repeat (CHR) as well as the membrane proximal 
external region (MPER) (Figure 6) [74-78]. In the currently accepted model, HIV-1 
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fusion cascade begins with the binding of surface subunit gp120 to target cell 
receptors. Activation of the fusion leads to structural rearrangements of the gp41 
ectodomain leading to a final structure that as shown in Figure 6 and which was 
crystallographically resolved in 1997 as the 6-helix bundle[49, 79]. These structural 
rearrangements include the reorientation of the NHR and CHR and collapse into a 
folded 6 helix bundle with the fusion peptide anchored to the cell membrane and the 
TMD to the viral membrane. In this 6 helix bundle structure the carboxyl-terminal 
helices arrange in the reverse direction against hydrophobic grooves outside the 
coiled coil, so that the amino- and carboxyl-termini are placed at the same end of the 
molecule. This therefore is speculated to result in both the membranes moving closer 
to each other and leading to lipid mixing [80, 81]. Following the lipids start mixing 
between both the membranes that lead to a hemi-fusion intermediate and eventually 
complete fusion [82-85].  
 
The HIV-1 env structural information has advanced due to the new structures that 
have evolved over the past 10 years and this has brought new insight into building 
new targets for inhibition as well as immunogen creation. The Figure 6, is from the 
recent paper by Kwong et al. 2012, shows us how the cryo-EM structure of the Env 
trimer is giving us information on developing new target sites for antibodies. 
Especially recent advances towards the PGT antibodies that target the V3 loop 
glycans are becoming increasing interesting due to their broad neutralization activity 
[86-90].  
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Figure 6: Currently available crystal structure at 2°A resolution of gp41 6 helix bundle. 
Figure on the left (A) shows the 6 helix bundle structure including the membrane 
proximal external region (MPER) and fusion peptide proximal region (FPPR). The dark 
blue is the HR1 (NHR) andlight blue is HR1 (CHR). B. Close up of the MPER (grey) and 
FPPR (light blue) region showing hydrophobic interactions. C. Showing the bottom view 
of the 6 helix bundle. For the 6-helix bundle core, the structure used is the modified 
version of pdb 1AIK and the MPER structure is pdb 1P5A. The figure is a modified 
figure from Buzon et al. 2010[4]. 
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Figure 7: A. Sites of HIV‑1 vulnerability to neutralizing antibodies. The HIV‑1 
envelope spike is the cryo EM structure of the uncleaved trimer obtained by Mao et 
al. 2013[2]. 
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1.1.2 HIV Life cycle  
 
The HIV virus is a sexually transmitted virus that enters the body through sexual contact 
that lead to fluid exchange or other forms of fluid exchange like breast feeding, blood 
transfusions or needle sharing [82, 91-93]. The HIV lifecycle is split into six major parts, 
these includes, (a) virus entry, (b) reverse transcription, (c) integration, (d) transcription, 
assembly, and (e) budding and maturation[94]. HIV-1 infects cells that display the CD4 
receptor on their surface (CD4+) along a mandatory coreceptor, a member of the 
chemokine receptor family, either CCR5 or CXCR4 [95]. These cells include immune 
cells present in our body such as the CD4+ve T-cells (lymphocytes), macrophages and 
microglial cells [96]. Further HIV-1 is known to latch on to dendritic cells that assist with 
spread of infection [97]. The virus lifecycle can be summarized as follows; The HIV-1 
Env protein gp120 binds to the receptor (CD4) and then the coreceptor. Following, gp120 
is shed off exposing the gp41 that inserts its fusion peptide into the cell membrane. The 
gp41 protein undergoes conformational changes that lead to virus-cell membrane fusion 
and allow the virion core, composed of MA, RT, IN, Vpr and RNA, to enter the cell [46]. 
This complex is transported to the cell nucleus where the viral genetic code encoding 
RNA is transcribed into DNA by RT and integrated into the host genome by IN [46, 95]. 
At this point, the cell becomes a HIV protein production factory and is ready to produce 
more viral proteins. These viral proteins are then transported to the cell surface 
membrane and assembled and budded off. Post budding, the immature virion goes 
through a protease digestion of the capsid in order to create a fully mature infectious 
virion, and continue the virus life cycle by infecting other targets. Because my project 
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focused on developing inhibitors that target the first interaction in the HIV lifecycle, the 
HIV-1 entry, it is important to understand this step in more detail.  
 
HIV-1 Entry: 
 
The HIV-1 entry is an elusive target for drug development because it’s the first 
step in the HIV-1 lifecycle that leads to infection. One of the first steps of the 
entry process is the interactions of the positively charged domains on gp120 with 
negatively charged proteoglycans on the surface of the cell [98, 99]. This is an 
important step but is not critical for the processes that follow during viral entry. 
The entry process happens as a sequence of events which are schematically 
illustrated in Figure 2. Next is one of the most crucial steps for entry, the 
interaction of Env glycoprotein gp120 with the T cell co-receptor CD4 [37, 100-
103]. CD4 binding results in extensive conformational changes within gp120 
that induces a greater exposure of gp41 and the formation of the co-receptor 
binding site [37, 104-106]. This is structurally described as two sets of beta 
sheets brought together by CD4 binding to form a 4 stranded beta sheet called 
the bridging sheet and also movement and exposure of the V1/V2 and V3 loops 
structures which in turn exposes the co-receptor binding site [88, 106, 107]. 
Gp120 binding to the coreceptor, CCR5 or CXCR4 depending on the virus 
tropism,  results in further conformational changes in the Env that leads to the 
exposure of gp41 and insertion of a hydrophobic sequence of residues on its N-
terminus called the fusion peptide into the host cell membrane[108-110]. Once 
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the fusion peptide is inserted into the host cell membrane, the extended 
conformation of gp41 with its C-terminus in the viral membrane and its N-
terminus in the cell membrane is called the “prehairpin intermediate”[109, 111]. 
Following this short lived state the two heptad repeats of gp41 fold into a hairpin 
structure which results in an energetically favorable structure known as the six 
helix bundle[78, 80, 112, 113]. This brings the two membranes together and 
leads to membrane fusion and insertion of the virion core into the cell, 
effectively starting the infection[114]. The 6 helix bundle formation have two 
distinct depictions as shown is figure 8, Figure 8A shows that for efficient 
fusion and virus-cell membrane fusion you require two spikes to be triggered, 
while Figure 8B shows that for fusion you require only one spike trigger. Both 
these theories have been proved with evidence, and so it is very much debated to 
whether we require more than one spike for efficient fusion and hence HIV 
infection [85, 115].  
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Figure 8: Schematic diagram of gp41 function during HIV fusion.  A. The model 
adapted from Dr.Salzwedel in which he demonstrates the 6 helix bundle formed with one 
spike and folded perpendicular to the viral membrane. The gp41 HR1 and HR2 regions 
are depicted in blue and yellow, respectively. B. The 6- helix bundle formation adapted 
from adapted from Chan and Kim [116]. The gp41 HR1 and HR2 regions are depicted in 
purple and green, respectively.  
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1.2 HIV inhibitors 
 
There are several inhibitors currently in market as well as currently in clinical trials 
and in preliminary development that targets several stages of the virus lifecycle. It is 
important to develop these inhibitors that target different stages of the virus life cycle 
so that they can be used in combination as well as individually. Further the UNAIDS 
and other global health initiatives are funding the development of HIV inhibitors in 
order to get closer to the eradication of this epidemic and reduce the number of 
deaths. Further it is important to create inhibitors that are easy to produce in large 
quantities at low rates so that this can be served as a drug for a globally spreading 
disease. Highly active antiretroviral therapy (HAART) was initiated in the 1970s 
when the virus was very less known. This was mostly done by several independent 
researchers and biologists trying to understand the virus and the disease better [117]. 
But the first known treatment used and also known as the initial HAART therapy 
was in 1986 in a double blind study. They used azidothymidine (AZT) to treat AIDS 
symptoms showing individuals [118]. In 1996, the introduced using the combination 
therapy for AIDS treatment and this resulted in a decline of deaths and 
hospitalizations from 60% to 80% [43, 119]. Now more than a decade later HAART 
therapy has brought down the deaths from AIDS to nearly 85%. Further there are 
more than 30 FDA approved HIV drugs that can be used in several combination 
HAART [117, 120]. This wonderful progress has led to hope of survival increasing 
and also our hope of completely eradicating the disease is becoming reality. The 
UNAIDS last year has come up with a complete eradication initiative called “Getting 
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to Zero”, and this is a combination of patient and people awareness, treatment 
approach, treatment breadth around the world and a very important factor, new drug 
development[41]. A report by UNAIDS showed that a record 9.7 million people 
living with HIV were accessing treatment in 2012 compared to just over 8.1 million 
in 2011––an increase of 1.6 million in one year alone. This is mostly due to the 
increased availability and also the increased awareness and rapid free HIV testing 
that is provided around the world. Hence it is important to know the overview of the 
current drugs used in HAART therapy and what are the challenges faced [2, 121].  
 
1.2.1 Current Inhibitors in the market 
 
There are currently over 30 inhibitors that are approved by FDA for HAART 
therapy. These inhibitors are divided into six different classes. These include; 
nucleoside reverse transcriptase inhibitors (NRTIs, nonnucleoside reverse 
transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase inhibitors 
(IIs), fusion inhibitors (FIs) and Chemokine receptor antagonists (CRAs). The 
inhibitors that are in each class target a different step in the virus life cycle and 
therefore HAART used a minimum of two inhibitors in combination[122, 123]. 
The regimens of HAART are decided based on several factors that have been a 
learning process and is set up by the WHO in collaboration with the UNAIDS 
committee and FDA [121, 124-126]. These factors include the ease of use, the 
allergies of patients, the stage of infection based on the CD4 counts and largely 
by the availability and clinical preferences in developing countries [126-128]. 
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There are several challenges that are faced during HAART; the first and the 
most challenging is the resistance to the drug. A study was conducted recently in 
order to assess why there was failure in HAART first line therapy and one of the 
main reasons was resistant mutants of the virus developing very quickly [129]. 
The other challenging include adverse side effects specific to different patients, 
pregnant women having limited treatment and hence disease spread and co-
infection with hepatitis B or C virus or tuberculosis which makes it very difficult 
to maintain treatment[129-134].  
 
1.2.2 Inhibitors that target HIV entry in HAART 
 
There are currently only two FDA approved inhibitors that target HIV fusion and 
entry, these include T-20 or enfurvitide, which targets the pre-fusion 
intermediate gp41 N-termini, and maraviroc, which targets the co-receptor 
CCR5, present on the host cell [135, 136]. Both of these inhibitors are only used 
salvage therapy during HAART treatment due to several reasons and challenges 
which are detailed in this section.  
 
T-20: 
 
Enfuvirtide also marketed under the name FUZEON, is a synthetic peptide 
inhibitor that is 36-amino acid long and targets gp41[137]. T20 is a peptide from 
the gp41 protein extending from Tyr638 in the middle of the C-HR to Phe673 in 
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the Trp-rich membrane proximal external region (MPER) that before the 
TMD[137]. Therefore tis gp41 C-HR peptide targets the gp41 N-terminal heptad 
repeat region (N-HR), blocking gp41 conformational changes essential for the 
entry process. But as we know from above, during the fusion process, the N-HR 
is exposed from 10-20 minutes and hence the time of action of T-20 is very 
limited[138]. There are several mutants on the N-HR that have developed as 
resistant/escape mutants of T20 which reduce the binding affinity of the inhibitor 
nearly 40-80 fold [139-142]. One of the major mutants includes V38A, N34D as 
well as I37K and these have different range of resistance but do not affect HIV-1 
fusion and infection[14, 141]. This therefore is one of the reasons why T20 is not 
used in the first line regimen of HAART. The other reasons include the allergies, 
diarrhea and skin irritation and rash in region of delivery [143, 144]. T20 is 
usually administered by subcutaneous injection at a dose of 90 mg (1 ml) twice-
daily and a paediatric dose of 2 mg/kg to provide comparable exposure to the 
adult 90 mg dose independent of age group, pubertal stage, body weight or body 
surface area[136, 145, 146]. And other limitation of use of T20 in first line 
therapy include the availability, the expenses of production as well as the 
amount of social awareness because it is still new to HAART[136, 147].  
 
Maraviroc:  
 
Marviroc is the product of a high-throughput screen conducted by Pfizer in order 
to identify an imidazopyridine CCR5 ligand [148, 149]. The CCR5 belongs to a 
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G-protein coupled receptor superfamily and is the co-receptor that is required by 
most HIV-1 clades for complete fusion [150, 151].  Further CCR5 is a very 
compelling target for therapeutic intervention because of its natural absence in 
the Δ32 homozygous genotype populations and hence are also protected greatly 
from HIV-1 infection [152, 153]. The crystal structure of maraviroc with CCR5 
was solved by Tan et al. in 2013, pdb No. 4MDS and from this it is observed that 
maraviroc binds specific to the extracellular loop -2 of CCR5 [154]. Maraviroc 
was FDA approved in 2007 for use as an antiretroviral but its use was limited to 
special cases of patients for salvage therapy [155, 156]. Maraviroc blocks R5-
tropic but not X4-tropic HIV-1; thus, clinical use requires co-receptor tropism 
assays to be performed prior to initiating treatment [16, 155, 157, 158]. In 
addition there are challenges that rise with the use of the drug, which is 
administered orally at 600 mg/day, such as rash, dizziness, and upper respiratory 
infections. In addition overdose or patients with hepatic abnormalities will be 
subjected to severe adverse effects due to its toxicity [155, 159, 160]. Resistance 
of the drug has been reported with resistant variants of the virus developing with 
mutations in the v3 loop [161].  
 
From the above it is clearly observed that there is a huge necessity and huge gap 
in the advance of fusion and entry inhibitors of HIV. Therefore it is important 
for us, the scientific community to conduct a major therapeutic intervention 
advancing the development of inhibitors that target HIV fusion and entry.  
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1.2.3 Microbicides that target HIV virus entry 
 
There are currently several inhibitors as well as antibodies that are currently in the 
pipeline that target different stages of HIV-1 entry into host cells. The following 
section will conduct a review of the current entry and fusion inhibitors that are in 
either phase I, II or III clinical trials and also the new inhibitors that are in early 
development. The inhibitors currently in development will be listed based on 
different stages of the HIV-1 entry.  
 
The gp120 and CD4 interaction:  
 
There are several inhibitors that target this interaction, either that bind to gp120 or 
the CD4. This is a very critical stage due to its importance in initial contact with 
the host cell. CD4 is a single transmembrane protein with four extracellular 
domains from which the 3rd and 4th domains seem to be crucial for gp120 binding, 
especially the beta hairpin that contains the Phe 43 residue [162]. Further years of 
biochemical and mutational analysis have revealed that the Phe 43 and Arg 59 on 
CD4 are important for binding to gp120[163, 164]. In 1998 Kwong et al. derived 
the crystal structure of gp120 bound to CD4 and showed that there are several 
interactions that are important for the CD4 and gp120, where CD4 binds to a 
region on gp120 between the inner and outer domains[61, 164, 165]. This area on 
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gp120 was later on known to be the phe 43 cavity and contains amino acids that 
are nearly 98-99% conserved in a glycoprotein that is highly mutated [61-63].  
This important interaction is a very attractive one but has not given very many 
success stories. Although they are very many inhibitors in the pipeline very few 
have managed to surpass several factors and reach to a stage of clinical trials. One 
of the first attempts was the development of soluble CD4 protein in order to target 
the virus prior to host cell encounter and thus resulting in blockade of the phe 43 
cavity necessary for the CD4 receptor binding. Although this showed good 
potency of inhibition in vitro there was limited success in patients in clinical trials 
due to high resistance to the drug by primary isolates[166]. Following this the 
crystal structure of the gp120-CD4 became available and there were many 
attempts to develop small molecule inhibitors that targeted the phe 43 cavity. 
These included a class of BMS compounds specifically BMS 378806, BMS 
448043 and BMS 626529[167]. These compounds mostly did not process any 
further than phase 2 clinical trials due to its poor pharmacokinetics although they 
did have very potent inhibition IC50s[18]. The BMS compounds mostly appear to 
stabilize gp120 in a conformation that is incapable of binding to CD4 but some 
also show to interfere with conformational changes in gp120[168, 169]. 
Following these attempts there was an era of the CD4 mimetics, in which there 
were screens conducted in order to find small molecules that fit/bind deep into the 
phe 43 pocket of gp120. These included M33 peptide, the NBD group of 
compounds as well other small molecule inhibitors. The main problem that arose 
from these compounds was the conformational entrapment of gp120 by these 
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compounds resulted in increased coreceptor binding which led to enhancement of 
infection at lower concentrations [64, 168, 170-173].  
There were also antibodies that targeted this interaction that was developed both 
through screen studies as well artificial creations. Ibalizumab (TNX-355) is an 
antibody that binds to CD4 D1-D2 domain, this does not directly block the CD4-
gp120 interaction but stops the interactions that follow [174, 175]. There are 
antibodies that have evolved that conformational entrap gp120 in a state where the 
phe 43 pocket is either sterically hindered or no longer accessible, these include, 
F105, b12, and the VRC group of antibodies which is currently going into human 
clinical trials, trial -VRC-HIVMAB060-00-AB [176-182]. One of the most recent 
and hyped antibody developments is the PGT group of antibodies that target the 
glycans of gp120 specifically close to the V3 loop region [86, 183]. These are 
similar to 2G12 which was one of the first glycan antibodies that target the 
glycans on gp120 [184]. But these PGT antibodies are much more specific and 
have a specific region of binding which has been mapped out on the native trimer 
using PG9 antibody through cryo tomography[185]. Although there are very 
potent antibodies against the binding of CD4 to gp120, they are still very 
expensive to mass produce and resistant mutants are very easy to develop [182, 
186]. But these antibodies are heading in a vaccine direction due to their stability 
and biocompatibility for patients at risk and currently there are many attempts that 
are being made in the direction of vaccine development [89, 187, 188].  
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The gp120 and coreceptor engagement:  
 
There are several chemokines in the body that include CCL3 (MIP-1α), CCL4 
(MIP-1β), and the most studied RANTES [189]. These induce internalization of 
the coreceptor CCR5 for a brief period but it is not an irreversible action, the 
CCR5 is recycled back onto the cell surface [190]. There have been several 
different types RANTES derivatives that have been developed to improve its 
function and have also been used as topical microbicides [191-193]. The 
limitation is the dual effect of the chemokines and also that it works more 
efficiently with CCR5 and not CXCR4 [193]. The next category is the small 
molecule inhibitors, which are the newer versions of marviroc such as viciviroc, 
aplaviroc and cenicriviroc. These inhibitors are developing still and cenicriviroc 
has an additional property of being anti-inflammatory which might be beneficial 
due to the immune activation by HIV [194-197]. These inhibitors however have 
cell toxicity issues and severe side effects which might be challenging to 
overcome and still produce an affordable inhibitor[194, 195]. Several drugs have 
also been developed against CXCR4 coreceptor specifically such as AMD3100 
but have not proceeded to clinical trials due to its medical complications and poor 
pharmacokinetics [198]. The other direction of approach is the antibody 
development against the coreceptor interaction with gp120 and the top antibodies 
developed include 17b, 2D7 and PA14 [199, 200]. Although these antibodies, also 
known as CD4 induced antibodies, do have a low nano molar inhibitory 
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concentration, they are specific to CCR5 [21, 187]. And also they act in a short 
time window of action and hence cannot be used as a microbicide efficiently.  
 
The fusion of HIV and host cell membrane: 
 
As seen in figure 6 and figure 8, the last step of HIV entry is the exposure of 
gp41, insertion of the FP into the cellular membrane and following the 6 helix 
bundle formation both the membranes fuse together and result in complete fusion 
and virus entry. This step of HIV entry is one of the most developed and oldest 
areas where inhibitor development is focused. These have been mostly been 
conducted by peptide sequences that have been developed from heptad repeats 
that could bind to their respective partner heptad repeats blocking the major step 
in fusion, the 6 helix bundle formation [79, 137]. These inhibitors include the 
inhibitors that are peptides from the CHR of gp41 which include T20, C34, T1249 
and sifuvirtide [163, 201, 202]. There are also peptides from the NHR of gp41 
which include N36, NCCG41, 5 helix and T21 [201, 203, 204]. These inhibitors 
target the fusion process but their time of action is very limited to the fasted step 
in HIV-1 entry which is the pre-fusion intermediate of gp41 [76]. Although these 
C-peptides described above have a very high clearance rate due to their 
vulnerability to proteases present in the cell. Hence recent developments have 
been on developing other more biocompatible and bioavailable fusion inhibitors. 
These include the D-peptide inhibitors that bind the N-HR pocket with high 
affinity and potently inhibit viral entry [205, 206]. These d-peptides are also 
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known to be active against resistant mutants of the 5-helix and T20, making it 
more broadly active [205, 207]. The progress of these inhibitors is progressing 
slowly and lately multivalent versions are being created [208]. Once again the 
limiting factor is the time window of action, which is during the pre-fusion 
intermediate state of gp41, which is very short lived [114, 157, 209-211].  
 
1.2.4 Virucidal agents that lead to virus disruption 
 
Virucidal agents are microbicides that lead to destruction of the virus particles 
upon contact. These agents differ from the regular microbicides due to the fact 
that they act directly or indirectly on the viral membrane leading to irreversible 
or reversible lysis [212, 213]. The current virucides are small molecules and 
peptides that target the viral membrane directly. These inhibitors are used as 
preventatives due to its early on action on the virus leading to damage of the 
virus to proceed towards infection. The virucides include surfactants like 
nonoxynol-9, [214] which is a spermicidal molecule [215]. Others include bile 
salts derivatives that can target the virus using a surfactant mechanism [212]. 
These surfactants are effective virucides but they have very adverse effects on 
the other cells in the body due to their surfactant mechanism. This was shown 
during the pharmacokinetic test of nonoxynol-9 in a vaginal gel, they showed 
severe damaging effects on the epithelial linings of the female vagina [215]. 
There are other multivalent conjugated virucides such as polyamide nucleic acid-
membrane transducing peptide conjugates lead not only to HIV-1 replication 
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inhibition but also have virucidal properties [216]. The dendrimer microbicide 
SPL7013 is a broad spectrum inhibitor that targets not only HIV but also Herpes 
simplex virus (HSV) and human papillomavirus. These have also shown to have 
virucidal properties leading to rupture of virus [217, 218]. Although these 
inhibitors have good virucidal properties they have drawbacks such as their 
limited knowledge of mechanism of action, specificity and also the risk of cell 
toxicity [218, 219].  
 
1.3 A Unique HIV-1 Entry Inhibitor 
 
From the above group of inhibitors it is clearly evident that there is a need for HIV 
entry inhibitors that are non-toxic, have low clearance rate and are specific the HIV 
inhibition. Further the inhibitors that are currently in market for HIV fusion and entry 
are limited due to their availability, expense of production, specificity to 
receptor/target and finally resistant mutations developing in the virus. This therefore 
led us to the search for a potent inhibitor that is novel and could target the gp120-CD4 
interaction which is one of the first stages of virus and host cell encounter.  
 
We have discovered a family of peptide triazoles (PTs) that function as dual receptor 
site antagonists of HIV-1 Env gp120 by targeting a conserved functional site that 
overlaps the CD4 binding region of the Env protein[9, 22].  High affinity PTs were 
found to bind to HIV-1 gp120 with nano molar affinity, suppress protein ligand 
interactions of the Env protein at both the CD4 and co-receptor binding sites, and to 
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stabilize a partially structured conformational state, suggesting allosteric aspects of 
the inhibitory mode of action (Figure 9) [23].  The parent peptide of PTs was 12p1 
which is a peptide that as obtained from a random phage library screen to identify 
peptides targeting gp120 [220]. 12p1 was one of the most potent peptides in the 
screen with a gp120 binding affinity of 3.7 µM Kd value, and showed good specificity 
[221]. In order to understand the mechanism of action of 12p1, alanine scanning 
mutants and truncations of the peptide were produced.  From this it was found out 
that 2-8th residues of 12p1 was important for activity and importantly the proline-
tryptophan cluster was important for binding and mimicked the Phe43 of CD4[9, 23]. 
Following this our lab modified 12p1 by adding an azidoproline group to substitute 
the proline group on 12p1 in order to create the first generation of peptide triazoles. 
This enhanced the potency of inhibition nearly two orders of magnitude and also had 
an additional feature of dual antagonism [23, 221]. Further a ferrocene group was 
added on the azidoproline ring in order to enhance potency. This addition was 
conducted by click chemistry on the peptide which had an azidoproline substitution in 
order to add the ferrocenyl group [221]. This generated the second generation of PTs 
with HNG156 being the most studied PT (Figure 9).  It was important to understand 
the mechanism of action of this unique PT and this led us to a series of peptide 
truncations and residue substitutions [32]. This showed that the c-terminal was 
important for activity and also the isoleucine, azidoproline and tryptophan (IXW) in 
that order is important for function(Figure 9) [32]. Further it was important to 
understand the binding site of the peptide, for this we used the truncated version, 
UM15 and UM24 as the ligand and alanine mutations in gp120 in order to map out 
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the binding site. From this we saw that the residues close to the phe 43 cavity of 
gp120 is important for PT binding, namely, D474, T257, M475 and E370[25]. These 
residues are highly conserved in gp120 and are present overlapping the phe 43 cavity 
(Figure 9) [222, 223].  Further, the lab has been converting the peptide to its D-
peptide variants for increased stability in physiological conditions, one of the variants 
are shown in figure 9 – KR42 [224]. This therefore demonstrates a unique and novel 
approach to microbicide development. 
 
Further modifications on the PT are presented in this thesis to make it a much more 
modified and improved inhibitor. These include modification of the AA in the PT and 
creation of multivalent constructs of PT in order to increase the local concentration of 
the inhibitor on the virus.  
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Figure 9: Summary figure showing the generations and characteristics of peptide 
triazoles. The figure above shows the modifications made to the parent peptide 12p1 
structurally and the increase in potency of CD4 and 17b competition to gp120 monomer 
binding and the HIV-1 BaL-01 pseudotyped infection inhibition by these PTs. The blue 
highlighted are on the structures show the active pharmacophore of PTs. The figure 
below shows how the PTs transition the unliganded gp120 to an open activated state 
which is a conformational entrapment of gp120 from proceeding to the CD4 bound state.  
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1.4 Nanoparticles and HIV-1 
 
There have been several developments that have been conducted over the years in 
order to generate nanocarriers of anti-hiv drugs. There have been many types 
including polymeric nanoparticles, non-polymeric nanoparticles as well as biological 
carriers such as viral vectors (Figure 10) [225, 226]. Most of these have been 
developed to increase stability of the drug in vivo as well as enhance their targeted 
delivery in order to make the drug long lasting[227]. Targeted delivery of some 
drugs to very difficult regions of the human body (especially the central nervous 
system) are easily achieved using nanoparticle carriers with drug mostly loaded in 
the particle lumen and the nanoparticle membrane mostly hydrophobic such as 
liposomes (Figure 10) [225, 228-230]. In a recent study based on polymeric systems, 
nanosuspensions (200 nm) of the drug rilpivirine stabilized by polyethylene-
polypropylene glycol and PEGylated tocopheryl succinate ester (TPGS 1000) were 
studied [231]. One of the most recent development by GSK which is becoming great 
success as a long-acting single dose injectable is the GSK-1265744 which is an 
analogue of the HIV integrase inhibitor dolutegravir. This crystalline active drug is 
then milled to an average nanoparticle size of 200 nm with 100% active drug with 
surfactant, polymer, tonicity agent and water for injection (ViiV healthcare). The 
pharmacokinetics are very promising and the drug is available in sera for more than 
30 days with only one injection at 200mg/ml [232, 233].  
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Another category of nanocarriers is nanoparticle conjugations of low potency anti-
HIV inhibitors to enhance their potency. The two studies that inspired me to use gold 
nanoparticles are the Bowman et al. study of conjugating a derivative TAK779 on a 
gold nanoparticle and the study by Elechiguerra et al. that used naked silver 
nanoparticles to target cell-free virus and lyse them prior to cell encounter[234, 235]. 
Bowman et al. showed that by conjugating SDC-1721 a derivative of TAK779 with a 
very low antiviral activity was conjugated onto 2 nm diameter AuNPs. There was 
approximately 2000 fold increase in potency and thus proving that nanoparticle 
conjugation increases local concentration of the drug on the virion surface making it 
highly active antivirals[235]. Therefore this was an inspiration to creating AuNP-
peptide triazole conjugates in this study. However bowman et al. used 2 nm AuNP 
which might have non-specific cellular uptake as shown previously[236]. The silver 
nanoparticles were approximately 20 nm to avoid non-specific cellular uptake, and 
this showed that there was sulfur interaction with the silver nanoparticle surface 
lysing the virion. But this also led to slight cell-toxicity which might be a limiting 
factor in its development and the specificity is low[234].  
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Figure 10: Schematic representing the different nanocarriers currently used in HIV-1 field 
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CHAPTER 2: SYNTHESIS AND ANTIVIRAL ACTIVITIES OF THE FIRST 
GENERATION OF VIROLYTIC AGENTS  
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2.  Introduction 
 
There is an urgent need for antiretroviral agents to combat the spread of HIV-1[41]. 
Other than T20 and maraviroc used in salvage therapy, there is limited first-line anti-HIV 
drugs target the entry process [14, 16, 28, 237, 238]. The fusion inhibitor enfuvirtide 
(T20) [14] and the CCR5 inhibitor maraviroc [15] are the only currently approved HIV 
entry drugs for both first-line and salvage therapy [16, 157, 158].  T20 targets the N-
terminal heptad repeat region of gp41, blocking gp41 conformational changes essential 
for 6-helix bundle formation and membrane fusion [14]; however, T20 has a relatively 
short time window to act on the transiently exposed N-helix of gp41 at the cell-virus 
synapse [239]. In addition, T20 is logistically difficult to administer, as it can only be 
given parentally, and adverse reactions at sites of injection are common [16, 240]. 
Maraviroc blocks R5-tropic but not X4-tropic HIV-1; thus, clinical use requires co-
receptor tropism assays prior to initiating treatment [16, 155, 157, 158]. Other small 
molecule entry inhibitors in development include: small molecules against gp120, gp41 
and co-receptor [16-18, 241-244]; monoclonal antibodies targeting CD4 [20] and CCR5 
[245, 246]; and neutralizing antibodies targeting the virion [21, 89, 247]. However, none 
of these latter agents have as yet advanced to first-line clinical use [248-250]. Therefore 
initial entry of HIV-1 into host cells remains a compelling and yet elusive target for 
developing agents to prevent infection[238]. This step is mediated by a sequence of 
interactions of a trimeric gp120/gp41 envelope (Env) protein complex with host cells, 
including initial gp120 encounter with the cellular receptor CD4 and a chemokine co-
receptor usually either CCR5 or CXCR4[116].   
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Since gp120 is the first viral protein to interact with the host cell, it is an attractive 
target for inhibiting infection.  We previously identified a peptide triazole class of HIV-1 
Env gp120 inhibitors that are highly active on R5-and X4-tropic viruses and exhibit 
remarkable breadth among different HIV-1 subgroups [10, 32]. This inhibition is 
mediated by binding to a region of gp120 that partially overlaps the CD4 binding site [9, 
10, 22-25, 32, 224].  The peptide triazole inhibitors appear to function mechanistically by 
trapping gp120 in an inactive conformation that is distinct from either the flexible, 
unliganded conformation or the highly structured, CD4-activated state [9, 10, 22-25, 32, 
224]. This conformational entrapment serves to prevent entry prior to virion attachment 
to CD4 or coreceptor on target cells [9, 23].  In this study we report the first ever peptide 
triazole derivative that is virucidal leading to irreversible disruption of the viral particle. 
Following the discovery, we more elaborately characterize the mechanism of action of 
these unique and novel PTs and its relation to HIV-1 fusion with host cell. This therefore 
will showcase the first ever virucide that is  not toxic to cell, broadly action and acts on 
the virus by hijacking the virus-cell fusion mechanism for complete irreversible lysis of 
the virus particle. We herein report this unexpected finding, which has significant 
implications for both prevention and therapeutic applications. 
 
We found that, while all peptide triazoles tested induced shedding of gp120, only those 
containing a C-terminal sulfhydryl group induced p24 release.  The apparent poration of 
virions leading to p24 release occurred on replication competent HIV-1 as well as on 
pseudoviruses bearing an HIV-1 Env.  Remarkably, the lysis activity of the peptide 
triazole thiols (PTTs) was completely inhibited by fusion inhibitors that target gp41 such 
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as T20, C34, 5 Helix and N36. This desensitization by the fusion inhibitors suggested that 
the disruption of viral membranes was coupled to physiological activation of gp41 and 
formation of the 6-helix bundle post initial binding of gp120 to CD4 during HIV entry to 
host cells.  We also defined kinetic and biochemical differences between inhibition of 
viral infectivity and phases of virion disruption.  Our findings strongly suggest that the 
novel virolytic effect induced by KR13 is related to physiological triggering of fusion 
machinery on the envelope glycoprotein trimer, which in the absence of CD4 or 
coreceptor engagement leads to disruption of the viral membrane and potent, irreversible 
viral inhibition. 
 
2.1 Production and validation of the virolytic peptide triazole thiol, KR13 
 
2.1.1 Materials 
 
All Fmoc-protected α- and β-amino acids, O-Benzotriazole-N,N,N’,N’-
tetramethyl- uranium-hexafluoro-phosphate  (HBTU),  1-
Hydroxybenzotriazole  (HOBt), Rink  amide resin (4-(2',4'-
Dimethoxyphenyl-Fmoc-aminomethyl) phenoxy resin) with a 0.55 
mmol/g substitution, N,N- dimethylformamide (DMF), Pyridine and N,N-
Diisopropylethylamine (DIPEA)  were  purchased  from  Chem-Impex  
International  Inc,  Ethynylferrocene  and Cu(I)I was purchased from 
Sigma-Aldrich and used without further purification. Fmoc- cis-4-
azidoproline was synthesized starting with commercially available trans-
Hyp-OH. Monomeric YU2 gp120 and sCD4 were produced in-house in 
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293F cells following a previously established protocol [10, 25]. Ten mM 
phosphate buffer was prepared using monosodium phosphate, 
monohydrate and disodium phosphate heptahydrate to reach pH 7.2. All 
other materials were obtained from Fisher Scientific. 
 
2.1.2 Synthesis of Peptide Triazole and peptide triazole thiol Inhibitors 
 
Peptide triazole and peptide triazole thiol (KR13) were synthesized by 
manual solid phase synthesis using Fmoc chemistry on a Rink amide resin 
at 0.25mmol scale. The [3 + 2] cyclo addition of azide and 
ethynylferrocene was carried out by copper catalyzed, on resin method 
[22]. Once the synthesis was complete, the peptide was removed from 
solid-phase resin using a cleavage cocktail mixture of 95:2:2:1 
trifluoroacetic acid (TFA)/1, 2- ethanedithiol/water/thioanisole for 3 h. 
Crude peptide was isolated by precipitation into 20 volumes of cold ether 
and purified by reverse-phase HPLC (Beckmann Coulter) on a C18 
column with a linear gradient of 5-95 % of acetonitrile/water in 0.1% TFA 
(Figure 11A). The final purified peptide was confirmed by MALDI-TOF-
MS, m/z of KR-13: 2084.79 [M+H] +   (Mcal = 2083.5 Da) (Figure 11B). 
The sequences of the main peptides produced are; HNG156 
(RINNIXWSEAMM-CONH2) and KR13 (RINNIXWSEAMMβAQβAC-
CONH2), where X is ferrocenyltriazole-Pro, were synthesized by manual 
solid phase synthesis using Fmoc chemistry on a Rink amide resin at a 
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0.25 mmol scale (Figure 12) [8, 22]. Control peptide triazoles, KR13s and 
KR13b were also prepared and validated as described above (Figure 12).  
Purity of produced peptides was confirmed by RP-HPLC and MALDI-
TOF. Prior to cellular assays using peptide triazoles, we tested for their 
possible effects on cell viability with HOS CD4+ve CCR5+ve cells after 24 
hours of inhibitor exposure. The cell viability was measured using the 
tetrazolium salt premix reagent, WST-1 from Takara Bio Inc. following 
the manufacturer’s protocol.  The formazan product was measured using 
the micro plate reader at absorbance wavelength 460 nm (Molecular 
Devices). 
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Figure 11:  Validation of the lab synthesized KR13. A. HPLC profile of KR13: 
VYDAC-C18 analytical column: 5-95% Acetonitrile/water in 0.1%TFA. B. MALDI-
TOF spectrum of KR13; m/z Obs : 2084.79 [M+H]+ (Mcal = 2083.5 Da) (data from 
Wistar Inc.) 
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Figure 12: Chemical structures (left) and sequences (right) of the peptide triazoles 
HNG156, KR13, KR13s and KR13b.  The chemical structures were generated in 
Chemdraw Pro 13.0. The underlined residues in the one letter coded sequences on the 
right denote the changes made to the parent peptide triazole (HNG156) to derive the three 
additional peptide triazoles investigated in this paper.  X = ferrocenyl-triazole-Pro and 
Acm = Acetamidomethyl.  
 
 
 
 
 
 
 
2.1.3 Peptide Characterization and Optical Biosensor Binding Assays 
 
The effects of the synthesized PTs on gp120 binding of sCD4 and mAb 17b were 
screened by competition ELISA (Enzyme Linked Immunosorbent Assay), Figure 12. 
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In a typical assay, HIV-1YU-2 gp120 (100 ng) was immobilized on a 96-well 
microtiter plate overnight at 4 °C, followed by three times washing with PBST buffer 
(1x PBS with 0.1 % Tween-20 v/v) and blocked with 3 % BSA (Bovine Serum 
Albumin) in 1× PBS for 2 h. Serial dilution peptide (5uM to down 0.001 µ M) was 
premixed with 0.1µg/ml sCD4 and the mixture was added to the plate in triplicate 
(65µ/well) and incubated for 1 hour. The plate was washed three times with PBST 
followed by 1 hour incubation with biotinylated anti-CD4 antibody at 65µl/well 
(eBioscience). The PBST wash step was repeated followed by 1 hour incubation with 
streptavidin-bound horseradish peroxidase (AnaSpec) at 1:3000 dilution and 
65µl/well. The above experiment was repeated using Serial dilution peptide (5uM to 
down 0.001 µ M) mixed mAb 17b (protein A purified) at 0.1 µg/ml. After 1 h 
incubation followed by washing three times, goat-anti-human-HRP antibody 
(Chemcon) was added and incubated for 1 h. The extent of HRP conjugate binding 
was detected in both assays by adding 200 μl o-phenylenediamine (Sigma–Aldrich) 
reagent for 30 min followed by measuring optical density (OD) at  450 nm using a 
micro plate reader (Molecular Devices). All incubation was done at room temperature 
unless otherwise mention and the samples were loaded in triplicate.  
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Figure 13: ELISA-derived competition of sCD4 (a) and m17b (b) binding to plate-
immobilized gp120 by KR13, HNG156, KR13s, and KR13b. The optical density values 
obtained for sCD4 and 17b binding to the gp120 in the absence of peptide were taken as 
100% binding controls. The IC50 values calculated for sCD4 competition by KR13, 
KR13b, HNG156 and KR13s were 22.2 ± 3.2 nM, 15.8 ± 2.9 nM, 12.4 ± 1.2 nM and 
undetected. The IC50 values calculated for 17b competition by KR13, KR13b, HNG156 
and KR13s were 20.5 ± 3.5 nM, 415.8 ± 22.9 nM, 165.7 ± 27.6 nM and undetected. Error 
bars represent the standard deviation of the mean, n > 3. 
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Surface Plasmon resonance (SPR) interaction analyses were performed on a Biacore 
3000 optical biosensor (GE Healthcare) (Figure 14) at 25°C using standard 1× PBS, pH 
7.3, with 0.005% Tween-20. A CM5 sensor chip was derivatized by amine coupling by 
using N-ethyl-N-(3-dimethylaminopropyl) carbodiimide /N-hydroxysuccinimide-1 with 
HIV-1YU-2 gp120 (Fc2 cell) and as a control surface, mAb 2B6R (antibody to human 
IL-5 receptor α, Fc1 cell). For direct binding experiments, HIV-1YU-2 gp120 was 
immobilized on the sensor surface (~5500 RU); peptide analyte in PBS buffer 
(concentration range of 125nM to 0.98 nM) was passed over the surface at a flow rate of 
50 μL min−1 with a 5 min association phase and a 5 min dissociation phase. 
Regeneration of the surface was achieved by a single 5 second pulse of 10 mM glycine, 
pH 1.5. Data analysis was performed using BIAEvaluation 4.0 software (GE). A double 
reference subtraction was performed for each data set to account for non-specific binding. 
The steady state affinity analysis was performed by plotting data of association 
equilibrium value selected from 10 sec before dissociation phase for each concentration 
v/s peptide concentration (Figure 14).  
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Figure 14: Sensorgrams obtained from SPR analysis of direct binding of KR13, 
HNG156, KR13b and KR13s to gp120. The peptides at concentrations ranging from 
0.0003 µM to 0.156 µM were injected at a constant flow rate of 100 µl/min with 250 µl 
injection volume onto the surface of immobilized YU2 monomeric recombinant gp120. 
YU2 monomeric recombinant gp120 produced in 293F cells was immobilized on a 
Biacore CM5 chip at surface density of 2500 RU using EDC/NHS chemistry explained in 
detail in the Supplementary Text section. The graphs on the left show the sensorgrams 
obtained post double reference subtraction using the BiaEvaluation software. The graphs 
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on the right show steady state fit analysis of the Req values for each peptide 
concentration. The Req values were calculated using the BiaEvaluation software, with 
separate kon and koff fit analysis using the Langmuir equation described in Supplementary 
Text section.  Error bars represent standard deviation of the mean, n = 3. 
 
 
2.1.4 Cell viability analysis in presence of peptide triazoles 
 
Viability of cells in the presence of peptides KR13, HNG156, KR13b and KR13s 
was assessed using the tetrazolium salt premix reagent, WST-1, from Takara Bio 
Inc. following the manufacturer’s protocol (Figure 15). HOS CD4+ve CCR5+ve 
cells were treated with increasing concentrations of each peptide ranging from 0.1 
µM to 250 µM and incubated overnight at 37°C. Following media change, 10 µl 
of the tetrazolium salt was added to each sample and incubated for 30 minutes at 
37°C. The formazan product was measured using the micro-plate reader at 
absorbance wavelength 460 nm (Molecular Devices). 
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Figure 15: Cell Viability of HOS CD4+ve CCR5+ve cells in the presence of HNG156, 
KR13, KR13b and KR13s. The samples were tested using the WST-1 assay following 
manufacturer’s protocol. The viability of HOS CD4+ve CCR5+ve cells in the absence of 
inhibitor was the 100% control.  
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2.1.5 Results 
 
The synthesis of the virolytic peptide triazole is the same as the regular 
peptide triazole with the same pharmacophore (shown in blue in Figure 
11). Except the scrambled sequence of KR13 (KR13s) the other PTs 
compete with both CD4 and 17b binding to gp120 monomer showing that 
these peptides are dual acting, blocking both CD4 and 17b interaction 
(Figure 13). Peptide binding to gp120 was determined using surface 
plasmon resonance (SPR) interaction analysis, with Kd values for KR13, 
KR13b, and HNG156 found to be 2.71nM, 6.13 nM, and 13.4 nM, 
respectively (Figure 14). Binding analysis of KR13s by SPR direct 
analysis yielded low and inconsistent dose dependent signals, and no Kd 
was determined in this case.  The Kd values were determined using 
BiaEvaluation software using the steady state affinity model. It was also 
confirmed that the peptide triazoles in this study did not induce any 
significant cell toxicity by testing viability of HOS CD4+ve CCR5+ve 
cells exposed to these inhibitors for 24 hours at 37 °C (Figure 15). 
 
2.2 Antiviral functions of peptide triazoles and the peptide triazole thiol 
 
The antiviral functions of the peptide triazole variants were tested both on the 
virus-host cell interaction as well as on the cell-free virus. This is important to test 
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so that when these peptides are transitioned into microbicides we can target on 
different stages of the virus lifecycle depending on their anti-viral functions 
observed.  
 
2.2.1 Materials 
 
Modified Human Osteosarcoma Cells (HOS CD4+ve CCR5+ve) engineered to 
express CD4 and CCR5, receptor and co-receptor respectively, as well as pNL4-
3.Luc R-E- backbone DNA, were obtained from Dr. Nathaniel Landau[251].  The 
HOS CD4+ve CCR5+ve cells were grown in DMEM supplemented with 10% FBS, 
2.5% HEPES, 1% Penicillin- Streptomycin, 2% L-Glutamine and 1 mg of 
puromycin. 293T cells were obtained from American Type Culture Collection and 
grown in the same culture medium as the HOS CD4+ve CCR5+ve cells except 
without puromycin. The plasmids for HIV-1 BaL-01 gp160 and VSV-G Env 
DNA were gifts from Dr. Julio Martin-Garcia. The antibodies mouse anti-p24, 
rabbit anti-p24, and the protein p24, were from Abcam. Monomeric YU2 gp120 
and sCD4 were produced in-house in 293F cells following a previously 
established protocol [10, 25]. Fully Infectious HIV-1 (BaL) was a gift from Dr. 
Michele Kutzler and obtained from Penn Center For AIDS Research (CFAR). The 
protein gp120 monomer was produced using already-established protocols [25], 
anti-gp120 was from Alto chemicals. Gp41 protein, enfuvirtide (T20) and anti-
gp41 antibodies 4E10, 2F5 and 98-6 were from NIH AIDS Research and 
Reference Reagent Program (ARRRP). Enhanced chemiluminescence western 
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blot detection system was from Amersham. O-phenylenediamine (OPD) was from 
Sigma Aldrich.  All other materials were from Fisher Scientific.  
 
2.2.2 Pseudoviral infection assay 
 
2.2.2.1 Production of single-round recombinant luciferase producing HIV-1 
virus like particles (VLPs): 
 
The recombinant virus consisted of (1) the pro-viral envelope plasmid 
sequence corresponding to the CCR5 targeting HIV-1BaL strain or a VSV 
(Vesicular Stomatitis Virus) pseudotype and (2) the backbone sequence 
corresponding to an envelope-deficient pNL4-3-Fluc+env– provirus 
developed by N. Landau[252]. 4 µg of envelope and 8 µg of backbone DNA 
were co-transfected into 293T cells using FuGene 6 as the transfection reagent 
[253].  Fourteen hours post-transfection, the medium was changed, and 
subsequently the VLP-containing supernatants were collected at 48 hours post 
transfection.  The VLP-containing supernatants were cleared using a 0.45 µm 
syringe filter and purified further by spinning the sample on an iodixanol 
gradient, using a Hoefer continuous gradient maker, ranging from 6 - 20 % 
iodixanol, at 30,000 rpm for 2 hours at 4 °C (Figure 16).  The collected 
fractions were validated for p24 content using capture ELISA and for gp120 
content using western blot detection as described in the main text. Virions 
purified on the 6-20% iodixanol gradient exhibited a characteristic distribution 
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profile of p24 and gp120 content (Figure 16), enabling viral (18-19.2% 
iodixanol) and soluble protein (6-8% iodixanol) fractions to be isolated. The 
purified virus samples were collected between the 18.2%-19% iodixanol 
fractions on the gradient, aliquoted and stored at -80°C until further use 
(Figure 16).  
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Figure 16: Scheme depicting method of purification of intact virus and peptide-triazole 
derived virus breakdown products by gradient centrifugation. (A) Scheme of location of 
sample loading and the positions of the 20% and the 6% optiprep fractions after 
centrifugation.  (B) Plot of the virus infection, gp120 release and p24 release activities for 
the iodixanol fractions collected from the gradient post  KR13 (1 µM) treatment. The 
soluble protein fraction corresponded to 6-8% iodixanol, and the treated virus fraction to 
the 16-18% fraction, based on the presence respectively of freely soluble p24 and gp120 
in the former and viral infection activity in the latter.  The controls include virus treated 
with PBS (intact virus) and virus treated with 1% triton X and boiled for 5 min at 95°C 
before gradient purification (solubilized proteins). 
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2.2.2.2  Luciferase reporter assay: 
 
A luciferase reporter assay was used to monitor cell infection activity of 
pseudovirion preparations as well as the inhibition of infection. For the infection 
profiles, 8,000 cells per well in a 96 well plate were incubated for 24 hours 
followed by addition of serial dilutions of the gradient purified virus fractions. 
Forty-eight hours post infection, luciferase activity was measured [8].  Cells were 
lysed with 50 µl of Passive Lysis Buffer (Promega) per well for 5 minutes 
followed by quick freeze/thaw cycles. Luciferase assay was performed using 1 
mM D-luciferin salt (Anaspec) as substrate and detected on a 1450 Microbeta 
Liquid Scintillation and Luminescence Counter (Wallac and Jet). For inhibition of 
infection assays with the peptide triazoles, infectious dilutions (1 million RLU 
(Relative Luminescence Units)) of the pre-tested purified virions were pre-
incubated with serial dilutions of the inhibitor for 30 minutes at 37°C. HOS 
CD4+ve CCR5+ve cells, seeded at 8,000 cells per well in a 96 well plate, were 
incubated for 24 hours followed by addition of the pre-incubated inhibitor-virus 
complex. Forty eight hours post infection, luciferase activity was measured as 
explained above [8]. The same method was used in order to measure the effect of 
the peptides, KR13 and HNG156, on the HOS CD4-ve CCR5+ve cells in order to 
check for possible enhancement of infection (Figure 16). Non-linear regression 
analysis was used with Origin Pro.8 (Origin Lab) to determine IC50 values. All 
experiments were performed at least in triplicate, and results were expressed as 
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relative infection with respect to cells infected with virus in the absence of 
inhibitor (taken as 100% infection).  
 
2.2.3 P24 Release assay 
 
Serial dilutions of peptide triazole starting from 50 µM were incubated for 30 
minutes with working dilution of the purified pseudotyped HIV-1 BaL virus.  
Control samples included (1) PBS with virus and (2) 1% Triton X-100 with virus. 
Ten 1 ml fractions were collected from the gradient.  Each fraction was tested for 
p24 content using capture ELISA. High binding polystyrene ELISA plates were 
coated overnight at 4°C with 50 ng of mouse anti-p24 and blocked with 3% BSA. 
The blocked plate was rinsed 3 times with PBS-T (PBS and 0.05% Tween 20), 
and 1 ml gradient fractions were loaded onto the plate using a 1:10 dilution factor 
with 0.5% BSA in triplicate.  After two hour incubation, rabbit anti-p24 was 
added to the plate for 1 hour, following PBST rinse (3 times, 5 minutes each), and 
then anti-rabbit IgG fused to horseradish peroxidase (HRP) was added to the plate 
and incubated for another hour. Following further PBST rinse, o-
Phenylenediamine (OPD) was added to the plate and incubated in the dark for 30 
minutes. The optical density (OD) was measured at 450 nm using a micro plate 
reader (Molecular Devices).   
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2.2.4 Gp120 shedding assay 
 
The HIV-1 BaL pseudovirions were treated with the peptide triazole of interest 
for 30 minutes at 37 °C, and the fractions were collected from centrifugation in a 
6-20% iodixanol gradient. Fractions were boiled with SDS loading buffer for 5 
minutes and proteins separated on a 12% SDS non-reducing polyacrylamide gel 
(NuPAGE – Invitrogen). As a control in the gels, YU2 recombinant gp120 
monomer produced in 293F cells was used at 500ng/ml.  This control usually runs 
as a lower molecular weight species compared to the BaL virus gp120.   We 
surmise that this is due to an altered glycosylation pattern for the cell type (293F) 
used to express the recombinant protein versus the cells (293T) used to produce 
the BaL virus. The 293T cells produced gp120 runs approximately at 100 kDa 
while the gp120 from 293F cells runs approximately at 120 kDa (data shown in 
bastian et al. 2013)[6].  The separated proteins in the gels were electrophoretically 
transferred onto (Polyvinylidene Fluoride) PVDF membrane at 100 mV for 1 
hour. The blotted membrane was blocked with 5% skimmed milk in PBST for 1 
hour at room temperature. After washing the membrane with PBST, sheep gp120 
antibody (D3724) diluted in 5% skimmed milk was added and incubated for 1 
hour at room temperature. The bound antibodies were detected by horseradish 
peroxidase-conjugated anti-sheep IgG secondary antibody followed by the 
enhanced chemiluminescence detection system (Amersham) according to the 
manufacturer's protocol.  
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2.2.5 Viral infection inhibition and viral breakdown of fully infectious HIV-1 by 
peptide triazoles 
 
Virions were purified using 6-20% iodixanol gradient and p24 content measured 
using ELISA. The TCID50 was determined using Origin Pro.8 (Origin Lab). The 
working dilution of virus was pre-treated with a serial dilution of KR13 or 
HNG156 starting from 100 µM for 30 min at 37 °C. HOS CD4+ve CCR5+ve cells 
seeded, at 8,000 cells per well in a 96 well plate, were incubated for 24 hours 
followed by addition of pre-incubated inhibitor-virus mixture.  After 48 hours 
infection, p24 content of virions in the supernatant was measured in order to 
determine the IC50 value of viral inhibition. Further, the peptide triazole and cell-
free virus were pre-incubated for 30 min at 37°C followed by spinning for 2 
hours at 13,600 rpm in a table top centrifuge (Eppendorf) at 4°C. Supernatant 
was separated and p24 content determined using the p24 capture ELISA 
explained above. The extents of viral inhibition and p24 release from fully 
infectious HIV-1 BaL were also evaluated for control peptide HNG156.  
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2.2.6 Results of the antiviral effects of peptide triazoles 
 
2.2.6.1 Separation of virus components derived from HIV-1 breakdown 
induced by peptide triazoles: 
 
To probe the effects of peptide triazoles on HIV-1, gradient-purified viral 
pseudotype particles containing the HIV-1 BaL Env were treated with 
various peptide triazole variants and then fractionated using iodixanol 
gradient centrifugation [254]. The density gradient enabled separation of 
the solubilized proteins from the residual virion fraction. Each gradient 
fraction was tested for viral infectivity and protein content.  Proteins 
released from virus particles were present in the 6-8% Optiprep fraction 
(soluble protein fraction), while the intact virions were present in the 18.2-
19% Optiprep fraction (residual virion fraction). Solubilized protein and 
residual virion fractions were evaluated for infectivity and for p24, gp120 
and gp41 content (Figure 16).    
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2.2.6.2 Dose dependence and specificity of KR13-induced virus 
breakdown: 
 
We compared the effects of KR13 and control peptides on HIV-1 infectivity 
and structure.  Peptides included KR13b (KR13 with the thiol blocked with 
an acetamidomethyl (ACM) group); KR13s, which contains a WX 
scrambled KR13 amino acid sequence in the gp120-binding IXW 
pharmacophore [10, 22, 32]; and the parent peptide triazole HNG156, which 
contains no free thiol group [22] (Figure 12). These peptides were 
chemically synthesized using previously established methods [22, 23, 31, 
32].  Anti-viral effects of the peptide triazoles were initially measured using 
HIV-1 BaL pseudotyped virions.  As shown in Figure 17A, peptides KR13, 
KR13b, and HNG156 each inhibited infection, with KR13 and KR13b 
exhibiting the greatest potency, while the sequence-scrambled peptide 
control KR13s was inactive.  Peptide effects on the contents of the virions 
were determined by treating gradient-purified pseudotyped particles with 
increasing concentrations of each peptide and determining gp120 shedding 
and p24 release. The peptides KR13, KR13b and HNG156, but not the 
KR13s control, caused gp120 shedding (Figure 17B; see Appendix Fig. 1 
for western blot images). IC50 values for gp120 shedding by the active 
peptides were comparable (Table 1) and similar to IC50 values for inhibition 
of cell infection. In contrast, KR13, but not the other peptide triazoles, 
induced p24 release (IC50 32 ± 10 nM) (Figure 17C). The samples were 
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normalized to the untreated virus, for which spontaneous p24 release and 
gp120 shedding were both <5% of the total protein contents as determined 
by solubilization of the virus particles with 1% triton X treatment 
(Appendix Fig. 1). No inhibition of infection was observed on viruses 
pseudotyped with either VSV-G or AMLV envelope, indicating that the 
effects on HIV-1 were highly specific (Appendix Fig. 2).  All the IC50 and 
EC50 values were obtained using sigmoidal plot fit in Origin Pro. 8. 
 
 
71 
 
 
 
 
 
 
 
Figure 17: Dose response of the effects of peptide triazoles on HIV-1 BaL pseudovirus.  (A) Inhibition of 
cell infection was measured using a single round infection assay.  The EC50 values are reported in Table 1. 
(B) Relative gp120 shedding was determined for the peptides KR13, KR13b, HNG156 and KR13s using 
western blot analysis. Electrophoretic bands of gp120 in soluble protein and residual virus fractions were 
quantified using Image J analysis; IC50 values obtained are in Table 1. A low level of gp120 shedding 
(<5%) was observed with the intact virus used as the negative control.   Data were normalized to 100% 
gp120 shedding observed with 1% triton X treated lysed virus. (C) Relative p24 release induced by peptides 
was measured using ELISA.  The data were normalized using untreated virus as negative control (<5% p24 
release), and p24 release observed with 1% triton X treated virus was taken as 100% p24 content.  The p24 
release IC50 value for KR13 was 500 ± 80 nM, while the other peptide triazoles exhibited no significant p24 
leakage. Sigmoidal curve fits of data were obtained using Origin Pro.8 (Origin Lab). Error bars represent 
the standard deviation of the mean, n > 3. 
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2.2.6.3 Effects of KR13 on fully-infectious virus: 
 
To determine if the effects of peptide triazoles on pseudotyped HIV-1 BaL 
particles would also occur on infectious viruses, we performed a dose 
response analysis for viral infection inhibition and p24 release on fully 
infectious HIV-1 BaL. As shown in Table 1 and figure 17, both HNG156 and 
KR13 inhibited viral infectivity on HOS CD4+ve CCR5+ve cells (IC50 values of 
0.53 µM and 5.5 µM, respectively), and caused both gp120 shedding (IC50 
value of 1.2 µM) and p24 release (IC50 value of 4.4 µM) (Figure 18).  Thus, 
the virolytic activity induced by KR13 on pseudotyped HIV-1 virions was 
also seen with replication competent HIV-1. All the IC50 and EC50 values were 
obtained using sigmoidal plot fit in Origin Pro. 8. 
 
2.2.6.4 Breadth analysis of peptide triazole thiol induced virolysis 
 
In order to examine if the virolytic effect induced by KR13 occurs broadly 
with multiple clades of the HIV-1 virus family, we tested several variants 
from each of clades A, B and C. We also examined transmitted founder 
viruses prepared from Env plasmids ZM246F.C1G, ZM247Ffs and 
ZM249M.B10.D4. From the p24 release effects observed (Figure 19), it is 
evident that the virolytic effect induced by KR13 indeed occurs broadly, 
with IC50 values ranging from 0.7 µM to 26 µM. This range of action is 
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consistent with the viral infection inhibition breadth analysis conducted by 
McFadden et al. 2011 for the parent peptide HNG156 [10]. The results 
obtained show that peptide induced virolysis is conserved and inactivates 
multiple clades of HIV-1. 
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Figure 18: Inactivation (A) and virion breakdown (B and C) of HIV-1 BaL fully infectious virus by 
KR13 and HNG156. The EC50 values for inhibition of infection by KR13 and HNG156 were 639 ± 
68.9 nM and 5.5 ± 0.9 µM, respectively. Gp120 Retention (B) was tested by western blot analysis 
using D7324 anti-gp120 on the residual gp120 on the virions treated with KR13.  The IC50 of 
KR13 gp120 shedding was 1.2± 0.93 µM. Release of p24 by KR13 and HNG156 (C) was tested 
with a p24 leakage assay using ELISA as explained in the Materials and Methods section.  The 
IC50 value for KR13 induced virolysis was 4.4 ± 0.7 µM.  No p24 release was observed by 
HNG156 upto at 200 µM.  All of the above EC50 and IC50 values were obtained using the Origin 
Pro. 8 software with sigmoidal fits. Error bars represent the standard deviation of the mean, n = 3. 
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Figure 19: Antiviral breadth of KR13 induced virolysis. Dose responses, shown by 
sigmoidal curve fits, were obtained using Origin Pro. 8 (explained in Materials and 
Methods section) for p24 release induced by KR13 ranging from 1 nM to 50 µM from 
several clades of HIV-1 pseudoviruses (A) and transmitted founder viruses (B). (C) Table 
of the IC50 values obtained from (A) and (B). Error bars represent the standard deviation 
of the mean, n = 3. 
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2.3 Mechanism of the peptide triazole thiol virolysis 
 
In order to study in detail the mechanism of the KR13 virolysis, the kinetic 
breakdown of the lysis, the immunological and morphological characteristics of the 
residual virus post treatment as well as how fusion inhibitors affect this lytic event 
was studied. This lead to defining kinetic and biochemical differences between 
inhibition of viral infectivity and phases of virion disruption.  Our findings strongly 
suggest that the novel virolytic effect induced by KR13 is related to physiological 
triggering of fusion machinery on the envelope glycoprotein trimer, which in the 
absence of CD4 or coreceptor engagement leads to disruption of the viral membrane 
and potent, irreversible viral inhibition. 
 
2.1.4 Kinetic tracking of transitions during peptide-induced viral breakdown 
 
The time course of peptide triazole dependent HIV-1 breakdown was 
evaluated.  The respective peptide triazole was pre-incubated with purified 
virus at a working concentration for times ranging from 1 min to 24 hour at 
37°C. The treated samples were then purified on a 6-20 % iodixanol gradient 
as explained above. For each time point, purified virions incubated with PBS 
at 37°C and alternatively with 1% Triton-X 100 was used as negative and 
positive controls, respectively. Each fraction was collected and quantified for 
p24 (capsid protein), gp120 and viral infection as explained above. 
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Based on IC50 values (Table 1), a working dilution of gradient-purified 
pseudotyped HIV-1 particles was exposed to KR13 (1 µM) or HNG156 (100 
µM), with incubation times ranging from 1 min to 24 hours at 37 °C. The 
infectivity of viruses was evaluated, and fractions from post-exposure density 
gradient fractionation were tested for relative gp120 shedding and p24 release by 
determining the distribution of protein content between the soluble and virion-
containing fractions.  As shown in Figure 20, infectivity inhibition and gp120 
shedding had similar kinetics for both KR13 and HNG156 peptides. However, 
p24 release was only induced by the KR13 peptide and was delayed kinetically. 
Thus, p24 release from viral particles was clearly distinct from effects of 
peptides on infectivity and gp120 shedding. Each time point was normalized to 
its own negative control, which was the untreated virus, and to 100% release 
determined by 1% triton X treated virus.  The negative controls showed minimal 
spontaneous p24 release and gp120 shedding of 5 to 15% from 1 min to 24 
hours, respectively. All the IC50 and EC50 values were obtained using 
sigmoidal plot fit in Origin Pro. 8. 
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Figure 20: Time-dependence of viral breakdown by HNG156 (a) and KR13 (b) treatments of 
HIV-1 BaL pseudovirus. The % of cell infection retained after peptide treatment is shown on the 
left y-axes, and the viral protein gp120 and p24 retained in the virus fraction is shown on the right 
y-axes. All samples were adjusted to the untreated virus as 100% infection and 100% viral protein 
retention. Each time point had a control of untreated virus, and this was used to normalize each 
time point of peptide treatment.  The concentrations of KR13 and HNG156 were kept constant for 
each time point at 1 µM and 100 µM, respectively. Untreated controls showed <5% p24 release 
and gp120 shedding, and <2% loss of cell infection activity.  Error bars represent the standard 
deviation of the mean, n = 3. 
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2.1.5 Detection of immunoreactive gp41 on virions post peptide-induced 
virus breakdown 
 
Residual virus and released protein fractions obtained by gradient purification 
from KR13 and HNG156 treatments were analyzed for gp41 content.  
Initially, the presence of gp41 in the treated fractions was detected using 
western blot analysis with human mAb 98-6 followed by anti-human IgG 
HRP secondary antibody. Blots were analyzed using the Enhanced 
Chemiluminescence detection system (Amersham).  
 
We also measured the presence of gp41 epitopes for human mAb’s 2F5 and 
4E10 using an altered ELISA detection method to minimize virus particle 
disruption [255].  Pseudovirions were treated for 30 min at 37°C with 
increasing concentrations of either KR13 or HNG156, and samples spun on a 
6-20% iodixanol gradient. Virus fractions were collected and fixed with equal 
volume of 0.1% paraformaldehyde for 30 minutes at 4°C. The treated virus 
fractions were spun at 16,000 X g for 2 hours at 4°C in an Eppendorf table top 
centrifuge. Following PBS wash, fixed virions were coated on an ELISA plate 
at 50 µl per well and incubated overnight at 4°C. The plate was blocked with 
3% BSA, and ELISA was used to detect gp41 epitopes with human gp41 
antibodies 2F5 and 4E10 followed by addition of anti-human IgG HRP 
secondary antibody. This method also was used to assess time-dependent 
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exposure of gp41 epitopes on the pseudotyped HIV-1 BaL virions induced by 
KR13 and HNG156 treatment at 1 µM constant concentration.  
 
Initial western blot analysis of KR13 and HNG156 treated HIV-1 BaL 
pseudotype virions were performed using the human anti-gp41 mAb 98-6, 
which reacts with a linear epitope at residues 644-663 in the gp41 ectodomain. 
Following either KR13 or HNG156 treatment, gp41 remained associated with 
virions (Appendix Fig. 2), while gp120 was released into the soluble fraction 
(Figures 17 and 120).  
 
Remarkably, for KR13-treated particles, gp41 was detected only weakly by 
98-6 in either soluble or virion-associated fractions. To determine if this effect 
resulted from a peptide-induced conformational change that blocked exposure 
of the 98-6 epitope, binding was assessed to conformationally dependent gp41 
antibodies 4E10 and 2F5, which react with membrane-associated MPER 
epitopes at the base of the gp41 ectodomain.  To test the antibody binding, the 
peptide-treated purified virions were fixed using 0.1% paraformaldehyde in 
order to maintain gp41 conformation.  The fixed virions were evaluated by 
ELISA as described above. On untreated or HNG156-treated virions, MPER 
epitopes were poorly exposed (Figure 21).  However, on KR13-treated 
virions, reactivity to 4E10 and 2F5 increased in a dose-dependent manner and 
occurred at concentrations comparable to those required to induce gp120 
shedding and p24 release (Figure 21A).  This effect was also time-dependent, 
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with kinetics similar to that seen for p24 release (Figure 21B). Thus, while 
KR13-treatment induced p24 release, gp41 was clearly retained on virions, but 
in a conformationally altered state associated with loss of 98-6 epitope and 
exposure of MPER-associated epitopes.   
 
2.1.6 Analysis of the peptide-treated virions by transmission electron 
microscopy 
 
Transmission Electron Microscopy (TEM) was conducted to visualize the 
morphology of the virions treated with KR13. Purified pseudotyped HIV-1 BaL 
virus and KR13 were pre-incubated from 5-1440 min at 37 °C. Following 
incubation, samples were fixed with 2% gluteraldehyde for 30 minutes at room 
temperature, and then embedded in Spur’s low viscosity epoxy medium after 
acetone washes to dry the virions, slices (100 nm thick) were prepared using an 
ultra-microtome (Leica EM UC6), loaded onto a holey carbon TEM 200 mesh 
grid (Electron Microscopy Science) and imaged using the JEM 2100 operated at 
120 kV (JEOL, Japan).  Sixteen images were taken per sample, and the sizes of 
observed particles were determined, using Image J software to derive average 
diameters of the virion particles from TEM images measured from 5 angles. 
 
Transmission electron microscopy (TEM) analysis was conducted to assess the 
morphology of KR13-treated virions before and after p24 release. Pseudotyped 
HIV-1 BaL was treated with KR13 (1 µM) from 1 min to 24 hours and samples 
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removed at various time points for TEM imaging. A total of 16 images per sample 
were taken (Appendix Fig. 4), and a probability distribution was plotted to 
determine the average diameter of the virions pre- and post-KR13 treatment 
(Figure 21C). Following KR13 treatment, virion diameter was reduced by >50% 
after 24 hours.  In addition and in contrast to the pre-incubation time point when 
cores were typically condensed and clearly observed, the core morphology of 
KR13-treated virions at 24 hours was substantially different, with a shriveled and 
disordered appearance. Similar, although less impressive, morphologic changes 
were observed at 360 minutes, a time point at which a 50% reduction in virion 
p24 content was observed (Figure 20). Thus, consistent with biochemical and 
immunological changes in KR13-treated virions, striking morphologic differences 
were also evident.  
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Figure 21: The gp41 content and morphology of residual virions derived from peptide triazole 
treatments of HIV-1 BaL pseudovirus.  (a) Reactivity of residual viruses, from 18.2-19% 
Optiprep fractions, to gp41 antibodies 2F5 and 4E10 as a function of KR13 and HNG156 
concentration.  (b). Reactivity of residual viruses to gp41 antibodies as a function of time of 
treatment with KR13 and HNG156. All samples in (a) and (b) were normalized to total gp41 
content on intact virion. Error bars represent the standard deviation of the mean, n = 3.  (c) 
Average diameter of HIV-1 BaL virions untreated and post treatment with KR13 (1 µM) as 
determined by TEM.  The probability distribution box plot shows the average in red and the 
distribution in bar lines (n=16).  The diameter analysis was conducted using Image J Software.  
Inset: Representative TEM Images obtained at designated time points, with the scale bar 
representing 50 nm diameter.   
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2.1.7 Fusion inhibitor enfuvirtide (T20) effects on virolysis 
 
The effect of T20 on virus breakdown by KR13 was assessed. KR13 at 1 µM and 
serial dilutions of T20 starting at 1 µM were co-incubated with pseudotyped HIV-
1 BaL for 30 min at 37°C. Treated virion samples were fractionated on a 6-20% 
iodixanol gradient (above). Gradient fractions were quantified for p24 using 
ELISA, and relative p24 release was quantified and plotted using the Origin Pro.8 
(Origin Lab).  Collected gradient fractions also were analyzed for gp120 shedding 
using western blot analysis, with detection using primary antibody D7324 and 
secondary anti-sheep HRP. The bands of the blot were analyzed using Image J 
software. The IC50 values were calculated using Origin Pro.8 (Origin Lab). To 
further determine whether T20 inhibited peptide-induced virolysis through gp41 
interaction, a T20-resistant, gp41-mutated HIV-1 virion was validated and tested 
for T20 inhibition of KR13-induced virus breakdown.  To additionally confirm 
the specificity of the T20 inhibition, a competition surface plasmon resonance 
experiment was conducted (Appendix text). Data were analyzed using Biacore 
3000 optical biosensor (GE Healthcare) BiaEvaluation software. Steady state 
analysis was conducted using the method of Morton et al. [256] (Figure 22). 
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Figure 22: Inhibition of KR13-induced virus breakdown by the gp41-binding fusion inhibitor T20.  
(A) BaL pseudovirus.  Virus was treated with 1 µM KR13 in the absence and presence of serial 
dilutions of T20 starting from 1 µM. Relative p24 release was measured using p24 ELISA by 
comparing the residual virion (18.2 - 19% Optiprep) and soluble protein (6-8% Optiprep) fractions.  
Relative gp120 release was measured using western blot analysis by comparing content of gp120 in 
the analogous residual virion and soluble protein fractions.  Western blot values were obtained 
using Image J analysis of the protein bands. The IC50 value T20 inhibition of KR13-induced p24 
release was 15.9 ± 4.9 nM using Origin Pro .8 (Origin Lab). No significant effect on the gp120 
release in the presence of T20. Error bars represent the standard deviation of the mean, n = 3.  (B) 
R3A and R3A V38A pseudoviruses; the latter, mutant virus has been found previously to be 
resistant to T20 inhibition. Release of p24 was quantified as for BaL pseudovirus in part (a).   The 
IC50 of T20 inhibition of peptide induced p24 release from the virus R3A was calculated to be 
21.9 ± 5.9 nM.  The mutant virus V38A R3A did not exhibit inhibition of p24 release. Sigmoidal 
fits were obtained using Origin Pro .8 (Origin Lab). Error bars represent the standard deviation of 
the mean, n = 3. 
86 
 
2.1.8 Discussion  
Previously, we reported that peptide triazole inhibitors of HIV-1 infectivity target 
gp120 on the HIV-1 virion and allosterically block CD4 and coreceptor 
(CCR5/CXCR4) binding sites on gp120 [22, 23].  Recently, peptide tirazole 
containing a C-terminal sulfhydryl group caused irreversible, cell-independent 
disruption of viral particles, as shown by release of the capsid protein p24 [8].  In 
the current study, we sought to more fully characterize the underlying mechanism 
of these effects.   We detected multiple molecular transformations during peptide-
induced inactivation and disruption of viral particles.  The peptide triazole thiol, 
KR13, was unique in causing both gp120 shedding and p24 release, and this 
effect was seen with several clades as well as transmitted founder pseudovirions 
(Figure 17), showing the breadth of virolytic inactivation. The virolytic effect 
induced by KR13 was also observed with replication competent, fully infectious 
HIV-1 BaL virions (Figure 18). Of note, for the fully infectious virions, the IC50 
values for peptide induced gp120 shedding as well as virolysis  were higher.  One 
possible explanation for this difference is the reduced spike density on infectious 
virion surfaces compared to the pseudotyped virions. From our data, we observed 
that the pseudovirions used in this study have spike densities ranging from 60-70 
spikes per virion, while the fully infectious BAL-01 had approximately 12-15 
spikes per virion. The spike densities  were calculated from gp120 content 
determined by western blot analysis of the virus supernatants as described in 
above.  
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Gp120 shedding tracked kinetically with loss of cell infection activity, while p24 
release occurred more slowly (Figure 20). The free sulfhydryl group was required 
for p24 release but not gp120 shedding, as a non-sulfhydryl peptide triazole 
(HNG156) induced only gp120 shedding as did the KR13b derivative containing 
a blocked sulfhydryl group.  Strikingly, p24 release was potently inhibited by the 
entry inhibitor,T20, which specifically blocks formation of the gp41 6-helix 
bundle, on the Env trimer, that is induced following CD4 and coreceptor 
engagement by gp120 and required for membrane fusion (Figure 22)  [14].  
Moreover, membrane proximal MPER epitopes on gp41, which are 
characteristically concealed prior to CD4/coreceptor engagement, became highly 
exposed on viral particles (Figure 19).  Overall, gp120 shedding, 6-helix bundle 
formation, and perturbations in the viral membrane that cause p24 release and 
gp41 MPER epitope exposure are analogous to physiological events that occur 
during viral fusion and entry. These findings are consistent with a model in which 
peptide triazole thiols trigger native structural programs on the HIV Env trimer 
that are associated with membrane fusion.   This view is depicted schematically in 
Figure 23.  
 
The requirement for the free sulfhydryl group of KR13 in virolysis was 
demonstrated using synthetic peptide triazole variants.  Several peptides in 
addition to KR13 were examined, including the parent HNG-156 peptide that 
contained no Cys residue, the KR13b peptide in which the –SH group is blocked 
and a sequence-scrambled control peptide KR13s (Figure 12).  Both HNG156 
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and KR13b bound to gp120 and had strong antiviral activities (Figure 17 and 
Table 1).  However, neither of these peptides caused p24 release. Hence, the free 
Cys-SH group in KR13 is essential for its observed lytic activity. We cannot yet 
define the mechanistic role of the sulfhydryl group in Env protein disruption.  
However, Env protein disulfide exchange has been reported to be important in 
viral entry [257-259]. Hence, it is possible that disulfide exchange may be a 
component of the KR13-induced gp120 transitions that alter Env spike 
conformations and, in the absence of a target cell, disrupt the viral membane 
resulting in breakdown of the virion particle. 
 
We investigated the time dependence of KR13-induced viral disruption by 
tracking the fate of the viral components gp120, gp41 and capsid protein (p24). 
We observed (Figure 20) a series of breakdown steps, in which gp120 shedding 
and loss of infectivity occurred at similar rates, while loss of p24 from the viral 
capsid occurred more slowly.  The difference in rates was evident by a loss of 65-
70% of gp120 and infectivity at 30 minutes of KR13 exposure, while only 10% 
loss of p24 occurred at this time.  KR13 treatment also caused a time dependent 
exposure of the MPER epitope as tracked by the antibodies 2F5 and 4E10 (Figure 
20B). Of note, the membrane-associated MPER epitopes are not well exposed on 
unliganded viral particles and become transiently exposed during conformational 
changes associated with entry [260].  Overall, the time dependence of the 
molecular transitions that occur upon peptide triazole thiol treatment suggests a 
specific transformation pathway of lytic breakdown that can be related to the 
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organized molecular structure of the virus and changes in that structure that likely 
occur during the fusion process in virus cell entry.  
  
The presence of a specific time-dependent pathway of virion disruption also fits 
with observed changes  in the physical structure of the virus.  The morphology of 
KR13-disrupted virions was examined by TEM. From the images obtained at 
different times of KR13 exposure (Figure 21C and Appendix Fig. 4), treated 
virions were smaller, with a >50% reduction in average diameter compared to 
untreated virions.  These results indicate that, rather than resulting in a non-
specific and global fragmentation of viral particles, peptide triazole thiol causes a 
more limited poration, resulting in an intact, although collapsed, particle that 
releases p24 capsid but retains membrane-associated gp41.   
 
We further evaluated the possibility that this disruption of viral particles and 
accompanying changes in gp41 might be related to virus-cell fusion by examining 
the effect of the fusion inhibitor T20. The latter targets the gp41 N-terminal 
heptad repeat region (N-HR) and blocks 6-helix bundle formation of gp41, an 
important Env structural transition state in fusion [239].   Indeed, T20 completely 
inhibited p24 release with an IC50 of 15 ± 4.9 nM comparable to its potency in 
fusion inhibition [137].  No  effect was observed of T20 on the KR13-induced 
gp120 shedding (Figure 22).  Suppression of capsid protein (p24) release by T20 
strongly suggests that the formation of the 6-helix bundle prefusion complex may 
be coupled to peptide-induced poration of the viral membrane and virion 
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inactivation. This possibility was supported by the finding (Figure 22B) that no 
inhibition of p24 release was seen for an HIV-1 Env bearing a mutation (V38A) 
that confers resistance to T20 [261, 262] .  In addition, using surface plasmon 
resonance analysis, T20 did not interfere with KR13 binding to sensor-
immobilized gp120 (Appendix Fig. 5), indicating that this effect was not the 
result of artifactual binding of T20 to the KR13 peptide.  
 
Previous studies have shown that sCD4 [263] and some CD4 mimetic small 
molecules such as NBD-556 can activate infection in CD4-ve CCR5+ve cells [172].  
Since KR13 appears to induce gp41 6-helix bundle formation, and the latter is a 
required step in cell entry, we evaluated whether  KR13 might enhance infection 
of CD4 negative cells.   The same incubation conditions were used as for 
inhibition of HIV-1 entry into HOS CD4+ve CCR5+ve cells.  As shown in 
Appendix Fig. 6, no enhancement of infection was observed under these standard 
conditions.  Interestingly, concerning possible effects of peptide triazoles on Env-
expressing cells, we have observed using CHO-K1 cells expressing gp160 that 
KR13 caused gp120 shedding but did not lyse the cells (results shown in chapter 
4).  Hence, the virion structure is important for peptide-induced virolysis.  
 
Because peptide triazoles can inactivate virus by targeting the Env spike leading 
to irreversible virus breakdown, this class of Env inhibitors may be effective in 
prevention strategies such as microbicides as novel compounds that specifically 
inactivate viruses before attachment to host cells [10, 264].  In addition,  an 
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attractive though at this stage speculative possibility is that the gp41-antigenic 
properties of virion particles after peptide triazole thiol treatment may make such 
a process useful for forming attenuated virus products capable of stimulating a 
neutralizing immune response.   
 
Previous studies have reported several other agents, including peptide NS5A 
[265], antibodies 2F5 and 4E10 [266] and sCD4 [267] that lead to HIV-1 
breakdown.  Peptide triazoles are more HIV-1 specific than NS5A.  In addition, 
viral breakdown triggered by these peptides appears to occur faster than 
breakdown caused by the antibodies and sCD4 [12, 266].  Overall, the current 
work reinforces the feasibility of novel pharmacologic approaches that can be 
applied to specifically disrupt viral particles (Figure 23).  Furthermore, peptide 
triazoles can be useful probes to explore poorly understood events, at the viral 
envelope following CD4 and coreceptor engagement, that lead to alterations of 
the viral membrane and its fusion to the cell membrane during entry. 
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Figure 23: Scheme comparing the HIV-1 deformation steps induced by peptide 
triazole (PT) and peptide triazole thiol (PT-SH) with gp120 shedding and gp41 trimer 
prehairpin formation that occurs during cell entry and infection. 
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2.4 Comparing the peptide triazole thiol virolysis to HIV-1 fusion with the host 
cell 
 
I showed in this thesis that KR13, a sulfhydryl-containing peptide triazole, can bind to 
gp120, block CD4 and co-receptor binding, inhibit viral infectivity, and physically 
disrupt viral particles.  Further preliminary studies was conducted in order to characterize 
the mechanism by which these transformations occur. These results showed that KR13 
peptide triazole initially causes viral inactivation through the release of gp120 followed 
by subsequent interactions with its free sulfhydryl leading to 6-helix bundle formation, 
viral membrane disruption, and p24 release.  Our data are consistent with the conclusion 
that KR13 triggers structural changes in the HIV-1 trimer typically associated with viral 
entry and membrane fusion and that, in the absence of target cells, these changes result in 
irreversible viral inactivation and lysis. Hence it was important to further analyze this 
relationship between KR13 dependent virolysis and HIV-1 – cell fusion.  
 
Previous studies have showed that the fusion inhibitor, T20, has developed resistant 
mutants that are no longer sensitive to T20 inhibition of HIV-1 fusion with the host cell. 
These mutants are mostly on the NHR of gp41, and stops T20 from interacting with the 
gp41 protein and stopping the 6 helix bundle formation. In this study these mutants were 
incorporated into the BAL-01 pseudotyped HIV-1 virion and tested to see their effects on 
T20 inhibition of KR13 induced virolysis. The results showed that these T20 mutants had 
differential levels of desensitization of the T20 inhibition of the KR13 induced virolysis. 
The next step to understanding this relationship was to study the differential inhibitory 
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effects of different already known fusion inhibitors such as 5 helix, N36, C34 and C36 
which either bind to the CHR or the NHR of gp41 respectively. The time dependent and 
concentration dependent inhibition of the fusion inhibitors of KR13 induced virolysis. 
There were very interesting observations which gave insights into the way in which the 6 
helix bundle might be folded post virolysis. Therefore, next the structural confirmation of 
gp41 on the residual virus post peptide triazole induced virolysis was tested. This led to 
the speculated model of the gp41 folded to a 6 helix bundle post virolysis as shown in 
this section. By studying the mechanism of pore formation, 6 helix bundle formation and 
lysis by KR13 on HIV-1 will provide deep insight into the way an HIV-1 cell fusion 
occurs. The potent and specific activity of this novel compound and its ability to 
inactivate virions prior to target cell engagement suggest that KR13 could be highly 
effective as a microbicide in inhibiting HIV transmission across mucosal barriers as well 
as a probe to understand biochemical signals required for membrane fusion.    
 
2.4.1 Testing the effects of several T20/enfurvitide mutants on HIV-1 virolysis 
 
Previous studies have shown that there are several resistant mutants have 
developed over the years for T20 [142]. In this study we will be using the most 
common and most effective resistant mutants of T20 which are V38A, N43D 
and I37K. V38A has been shown to have the highest potency, following N43D 
and I37K [268]. V38A and N43D were obtained from mutations that arose from 
clinical studies using T20, while I37K was a resistant mutant of C34 peptide but 
was also tested for T20 [269, 270]. The plasmids of the envelope with the mutant 
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gp41 regions were obtained as a gift from James Hoxie. The viruses with the 
mutant gp41 envelopes were synthesized as explained in section 2.2.2.1 using 
293T (HEK) cells. The backbone DNA used was the pNL4-3-Fluc+env– 
provirus developed by N. Landau[252]. Serial dilutions of KR13 starting at 
50µM were co-incubated with pseudotyped HIV-1 BaL (WT), V38A, N43D and 
I37K for 30 min at 37°C. Treated virion samples were fractionated on a 6-20% 
iodixanol gradient (above). Gradient fractions were quantified for p24 using 
ELISA, and relative p24 release was quantified and plotted using the Origin 
Pro.8 (Origin Lab).  Also the viral infection inhibition by KR13 and T20 on 
these HIV-1 mutants was compared by conducting the viral infection inhibition 
assay as explained in section 2.2.2.2. The starting concentration of T20 and 
KR13 used was 5 µM and 50 µM respectively.  Following, KR13 at 1 µM and 
serial dilutions of T20 starting at 1 µM were co-incubated with pseudotyped 
HIV-1 BaL (WT), and the resistant mutant viruses V38A, N43D and I37K for 30 
min at 37°C. The samples were then purified in order to separate the residual 
viruses from the released proteins by spinning at 15,300 rpm for 2 hours at 4°C. 
The released p24 was assayed by ELISA and quantified compared to positive 
and negative controls which were the released p24 from viruses treated with 1% 
triton X and PBS respectively.  
 
Just to confirm the mutant HIV-1 pseudotyped virions were resistant to T20, 
control viral infection inhibition studies were conducted. The results are 
summarized in Appendix Fig. 7. The results showed that T20 was most resistant 
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to I37K and it still showed infection inhibition for V38A and N43D. For KR13, 
the HIV-1 mutant that was inhibited the least for its viral infection was I37K but 
V38A and N43D both were not that different for the viral infection inhibition 
(Appendix Fig. 7). Figure 24 summarizes the anti-viral effects of KR13 on 
these mutant viruses compared to BAL-01 WT virus. From the figure it clearly 
shows that the p24 release is not that different for V38A compared to WT HIV 
for KR13 while N43D and I37K were much weaker at releasing. Further, the 
T20 inhibition of KR13 induced lysis on the mutant viruses was much weaker 
and there was a differential effect.   
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Figure 24: Effects of KR13-induced virus breakdown by the gp41-binding fusion inhibitor T20 
on the T20 resistant mutant viruses.  (A) P24 release profile induced by KR13 on the T20 resistant 
viruses versus the Bal-01 virus WT. Relative p24 release was measured using p24 ELISA by 
comparing the residual virion (18.2 - 19% Optiprep) and soluble protein (6-8% Optiprep) 
fractions.  Error bars represent the standard deviation of the mean, n = 3.  (B) Inhibition of p24 
release induced by KR13 on the mutant viruses, V38A, N43D and I37K compared to the wildtype 
control by T20.  The IC50 of T20 inhibition of peptide induced p24 release from the virus BAL-
WT was calculated to be 43.3 ± 5.9 nM.  The T20 inhibitory effect of KR13 induced virolysis was 
desensitized by mutant viruses V38A and I37K while N43D did not affect this inhibitory effect as 
much compared to BAL-WT. Sigmoidal fits were obtained using Origin Pro .8 (Origin Lab). Error 
bars represent the standard deviation of the mean, n = 3. 
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2.4.2 Comparing the effects of different fusion inhibitors that target the virus 
protein gp41 on the inhibition of peptide triazole thiol virolysis and HIV-
1- host cell fusion 
 
In order to biochemically understand the transitions of gp41 during virolysis the 
inhibitory actions of this effect by fusion inhibitors, which have established 
binding sites on gp41, were tested. This method therefore helped to breakdown 
the virolytic process and understand better the conformational changes that gp41 
goes through. To achieve this, the most studied and well understood fusion 
inhibitors which include the CHR inhibitors, 5 Helix and N36, and the NHR 
inhibitors, T20, C34 and C36 [116, 170, 239, 271]. The NHR inhibitors are 
shown to bind to the CHR of gp41 and inhibit the 6 helix bundle (6HB) 
formation at nM affinities [170, 271].  The CHR inhibitors however are shown 
to be blockers of the 6HB formation and also is involved with inhibition of 
forming a stable fuseogenic core and the stability of the 6HB [3, 272]. The 
Figure 25 shows a summary of the peptides used in this study and also the site 
on gp41 where they bind. This figure is adapted from the paper by Baldwin and 
Berkhout, 2008 [3].  
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Figure 25: Schematic representation of the gp41 inhibitors and site of action on gp41. (A) The 
sequences of the CHR  (HR2) and NHR (HR1) inhibitors and the regions on the gp41 sequence 
from which they were derived. This is shown on a gp41 sequence of the HXB2 strain. Further this 
also shows the gp41 antibodies and the sequence on gp41 that it binds to[3]. (B) Target sites of the 
different peptide fusion inhibitors and antibodies tested (drawing not to scale). For simplicity, we 
show only one gp41 molecule instead of the gp41 trimer. 
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2.1.8.1 Concentration dependent effect of the fusion inhibitors on 
virolysis 
 
In order to test the effects of these fusion inhibitors on KR13 induced 
virolysis, KR13 at 1 µM and serial dilutions of the inhibitors starting at 1 
µM were co-incubated with pseudotyped HIV-1 BaL (WT) for 30 minutes 
at 37°C. The samples were then spun on at 15,300 rpm for 2 hours at 4 ºC 
(Eppendorf Centrifuge 5415R). The supernatant was collected and the p24 
content was quantified by p24 ELISA as described in section 2.2.2.3. The 
relative p24 release was quantified and plotted using the Origin Pro.8 
(Origin Lab) compared to the positive and negative controls which were the 
virus incubated with KR13 alone and the virus incubated with no inhibitor 
but PBS alone instead. Prior to calculations the background p24 leakage for 
the inhibitors alone with no KR13 added were tested and validated to be 
<2% compared to the negative control. The controls were also tested for 
viral infection inhibition in order to compare their anti-viral effects. In order 
to test the effects of KR13 on the inhibitory effect of the fusion inhibitors, a 
serial dilution of the inhibitors starting at 5 µM was incubated with 
pseudotyped HIV-1 BaL-01 virus in the presence of 500 nM KR13 for 30 
minutes at 37°C. The samples were then added to HOS-CD4+ve CCR5+ve 
cells and the steps for a viral infection inhibition assay were followed as 
described in section 2.2.2.2. The samples were tested for viral infection 
using the reported gene assay as described above.  
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The results are summarized in Figure 26. Figure 26A shows that in general 
all these fusion inhibitors also lead to inhibition of KR13 induced virolysis 
to different degrees. The 5 helix and T20 showing the best inhibition, 
followed by N36 being an intermediate inhibitor and C37 and C34 affecting 
virolysis the least. The Figure 26B shows that these fusion inhibitors have 
no non-specific p24 release on its own. The viral infection inhibition assays 
conducted are summarized in Figure 26C and 26D. Compared to Figure 
26D, in which the viral infection inhibition of the fusion inhibitors alone is 
shown, the infection inhibition is greatly enhanced for all the 4 inhibitors in 
the presence of KR13. This therefore shows that KR13 has a synergistic 
effect with the fusion inhibitors when it comes to HIV-1 BaL pseudotyped 
infection inhibition. The IC50 values are summarized in table 2.  
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Figure 26: The effects of fusion inhibitors on KR13 induced virolysis. (A) The inhibition of p24 release 
induced by KR13 (1µM) using fusion inhibitors starting at 5 µM concentration. The IC50 values of the 
fusion inhibitors’ inhibition of KR13-induced p24 release was calculated using Origin Pro .8 (Origin 
Lab) and summarized in table 2. (B) p24 release from HIV-1 BaL pseudotyped by the fusion inhibitors. 
(C) Inhibition HIV-1 BaL pseudotyped infection in HOS CD4+veCCR5+ve cells by fusion inhibitors T20, 
C37, N36 and 5 Helix in the presence of KR13 (500 nM). (D) Inhibition HIV-1 BaL pseudotyped 
infection in HOS CD4+veCCR5+ve cells by fusion inhibitors T20, C37, N36 and 5 Helix.  Error bars 
represent the standard deviation of the mean, n = 3.    
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2.1.8.2 Time-dependent effect of the fusion inhibitors on KR13 
induced virolysis 
 
The time course of peptide triazole dependent HIV-1 breakdown inhibition 
by the fusion inhibitors T20, C37, N36 and 5 Helix was evaluated.  This was 
a time of addition experiment in order to test upto to what time is the 
prefusion intermediate exposed on a KR13 treated virion for the fusion 
inhibitor to bind. Therefore the fusion inhibitor was added either before 
addition of KR13 to HIV-1 BaL pseudotyped or 0 – 60 minutes after 
addition of KR13. The samples were then incubated for an additional 30 
minutes at 37°C and then spun on a table top centrifuge for 2 hours at 
15,300 rpm at 4°C. For each time point, purified virions incubated with PBS 
at 37°C and alternatively with 1% Triton-X 100 was used as negative and 
positive controls, respectively. The supernatant was collected and quantified 
for p24 (capsid protein) using the ELISA described above. 
 
Figure 27 summarizes the results that were observed from the time of 
addition experiment. Both the 5 helix and N36 surprisingly showed nearly 
75% inhibition of the p24 release by KR13 even when added 60 minutes 
post peptide addition. The C37 and T20 effects reduced from 80% to 20% 
inhibition when the time of addition was after 10 minutes post peptide 
addition. This shows evidence that the CHR is much more accessible to the 
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fusion inhibitors even 60 minutes post KR13 treatment which gives us 
evidence that the NHR is not as accessible.  
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Figure 27: p24 release of the inhibition by fusion peptides T20, C37, N36 and 5 
helix. The fusion peptides were added at different times either before addition or 
after addition of KR13. The relative p24 release measured subtracted from the 
negative control at each time point with viruses incubated with PBS. The p24 release 
was quantified using ELISA and the results are averaged from n=3.  
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2.4.3 Antibody mapping of the residual virion post KR13 virolysis 
 
The gp41 on the residual virion as well as the gp120 that was shed off during 
virolysis by KR13 was antibody mapped using antibodies with known binding 
sites on the respective proteins. This analysis would give very specific insights 
about the confirmation of the gp41 as well as the gp120 post virolysis and hence 
would give us better understanding about the mechanism of this action. The 
antibodies used for the gp41 antibody mapping and the gp120 antibody mapping 
are summarized in table 3 and 4 respectively.  
 
The HIV-1 BaL Pseudovirions were treated for 30 min at 37°C with KR13, 
HNG156 (1 µM) or PBS as negative control, and samples spun on a 6-20% 
iodixanol gradient. The released proteins were collected in the 6-8% fractions and 
pooled together. This released protein fraction was then fixed using equal volume 
of 0.1% paraformaldehyde and purified on a sephadex G-25 column. The purified 
protein was then loaded onto an ELISA plate at 100 µl per well and incubated 
overnight at 4°C. The plate was blocked with 3% BSA, and ELISA was used to 
detect gp120 epitopes with human gp120 antibodies from table 3 and followed by 
addition of anti-human IgG HRP secondary antibody.  The virus fractions from 
the iodixanol gradient were collected and fixed with equal volume of 0.1% 
paraformaldehyde for 30 minutes at 4°C. The treated virus fractions were spun at 
16,000 X g for 2 hours at 4°C in an Eppendorf table top centrifuge. Following 
PBS wash, fixed virions were coated on an ELISA plate at 50 µl per well and 
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incubated overnight at 4°C. The plate was blocked with 3% BSA, and ELISA was 
used to detect gp41 epitopes with human gp41 antibodies from table 4 followed 
by addition of anti-human IgG HRP secondary antibody. This method was used to 
assess time-dependent exposure of gp41 epitopes on the pseudotyped HIV-1 BaL 
virions induced by KR13 and HNG156 treatment at 1 µM constant concentration.  
 
Figure 28 shows the results from the antibody mapping studies. Figure 28A 
shows the antibody mapping of the gp120 protein released from the virion post 
KR13 addition. The CD4 binding antibodies shows reduced binding as expected 
due to both the peptides, KR13 and HNG156, altering the gp120 confirmation to 
reduce CD4 and 17b binding as previously shown (Figure 13 and 14). F105 
however showed good binding to the gp120 post KR13 and HNG156 treatment. 
However there were clear changes observed in gp120 treated with KR13 
compared to HNG156 post CD4 binding site. This is shown especially with 2G12 
which showed no binding to gp120 post KR13 treatment while HNG156 had good 
binding. Figure 28B shows the gp41 epitopes exposed on the residual virion post 
HNG156 treatment or KR13 treatment using antibody mapping. This shows that 
the HNG156 treated residual virion resembled the untreated virion based on the 
antibody binding, with increased binding to the HR2 region but mostly linear 
epitopes. But the KR13 treated residual virion gp41 had very distinctly increased 
binding to the MPER (membrane proximal external region). This is consistent 
with the data observed in Figure 21, which shows that there is increased MPER 
exposure with increasing concentration of KR13.  
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Figure 28: Antibody mapping of the gp120 and gp41 post KR13 and HNG156 treatment 
on HIV-1 BaL pseudotyped. (A) Antibody mapping of gp120 post KR13 (1 µM) and 
HNG156 (1 µM) using ELISA analysis. The region where the antibodies are directed to is 
shown in the bottom of the x-axis. The % binding is compared to the antibody binding to 
100 ng/ml monomeric gp120 which is shown as a dotted green line. (B) Antibody mapping 
of gp41 on the residual virion post KR13 (1 µM) and HNG156 (1 µM) using ELISA 
analysis. The gp41 concentration on the y-axis is calculated from a standard curve of the 
antibody binding to soluble gp41 for each antibody. Error bars represent the standard 
deviation of the mean, n = 3. 
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2.5 Model of the residual virion post peptide triazole thiol virolysis 
 
This study was conducted to focus on what are the conformational changes elicited 
on the virion during KR13 treatment that leads to virolysis of HIV-1. Previously we 
have shown that this lytic action follows a time dependent pathway that is similar to 
HIV-1 fusion, with the rate limiting step being the 6 helix bundle formation and 
poration action (Figure 20) [6]. The first steps of binding and gp120 shedding occur 
within the first 10 minutes just like in HIV-1 fusion [6, 85, 138, 273]. Following that 
there was a concentration dependent and time dependent exposure of MPER with 
KR13 treatment (Figure 21). For a typical virus-cell fusion reaction, the MPER site 
is also exposed during 6 helix bundle formation as shown by several studies both 
antibody binding and mutational studies [274, 275]. This along with the antibody 
mapping studies has given me a much better understanding of the conformational 
changes of gp41 in the virus membrane during the virolytic poration action.  
 
The T20 resistant mutant studies were the first lead on into understanding the 
conformational alterations in gp41. From this mutant study what we saw is that the 
KR13 p24 release was least inhibited by T20 in the virus that had the I37K mutation. 
This mutation was originally discovered as a C34 peptide resistant mutation and was 
also tested for T20 resistance later on [3, 270]. The I37K mutation is in the 
hydrophobic pocket in the NHR of gp41 and showed the largest change in the 
binding energy and led to the collapse of the coiled coil structure 6 helix 
bundle[14].Following I37K were V38A and N43D that resulted in electrostatic 
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repulsion also stopping the 6 helix bundle formation and resistance to T20 binding. 
This was clearly evident in the T20 viral infection inhibition of these mutated virions 
as seen in Appendix Fig. 7. This was also followed through to the inhibition of the 
peptide dependent virolytic effect by T20 in which the mutant virions followed a 
desensitization of I37K >> V38A >> N34D. Therefore this also indicates that the 
T20 inhibitory effect on HIV-1 fusion also had the same effect on KR13 dependent 
HIV lysis.  
 
Not only did T20 lead to inhibition of the KR13 dependent virolytic effect, but other 
fusion inhibitors that targeted the 6 helix bundle formation of gp41 also led to 
inhibition of KR13 induced virolysis. The results summarized in Figure 26 
demonstrated differential effects of the fusion inhibitors effects. The inhibitors that 
target the CHR had a much more long term effect as demonstrated in Figure 27. 
Although T20 had a better potency of p24 release inhibition compared to N36, this 
T20 site was no longer available completely post 10-20 minutes of KR13 exposure to 
the virion. Further it was also observed that KR13 treatment led to the exposure of 
the fusion inhibitor binding site because the fusion inhibitors had a much better 
inhibitory effect on HIV-1 infection on HOS CD4+veCCR5+ve (Figure 26). From the 
time dependent addition experiment we observe that the NHR is hidden post 10 
minutes of KR13 treatment on the virus compared to the CHR which is more 
available even post 60 minutes of KR13 treatment. The results showing that the CHR 
fusion inhibitors N36 and 5 Helix still have nearly 80% inhibition of p24 release 
even after 60 minutes of KR13 treatment shows that the 6 helix bundle formed 
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during virolysis is very similar to the 6HB during fusion. This is shown in literature 
as the asymmetric deactivation of gp41 which shows  exposure of the CHR even post 
6HB formation [276].   
 
In order to construct a model of the virion post virolysis the antibody mapping of the 
residual virion was necessary. From the results summarized in Figure 28 we observe 
that the KR13 treated virus has MPER exposed. The binding shows that even the 
MPER region that is very close to the TMD is also exposed due to the binding of 
4E10. The gp120 mapping shows that the 2G12 binding is also lost in the KR13 
treated virus gp120, showing that KR13 in addition to the CD4 and coreceptor 
binding regions also has binding or affects binding near the V3 loop region. From all 
the data obtained from above and also from the results observed previously the 
mechanism of KR13 induced virolysis is much more well-defined and shown 
schematically in Figure 29. This figure shows the time dependent virolytic events in 
part B and the rate limiting step, which is the gp41 conformational changes during 
the collapse and pore formation, is shown in Figure 29A much more in detail. The 
coiled HR’s of gp41 are not to scale but are shown to get a much more realistic 
visual representation.  
 
The study above shows that there is a very close correlation between HIV-1 cell 
fusion and KR13 induced HIV-1 irreversible breakdown. Table 5 summarizes the 
effects of peptide triazole thiol (KR13) induced virolysis and its similarity to virus-
cell fusion. This therefore shows that the peptide hijacks the fusion mechanism and 
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mocks the virus to think its fusing with a cell. This therefore leads to the cascade 
action of HIV-1 fusion without a cell present. The 6 helix bundle is formed during 
virolysis but might not be folded symmetrically which is also possible in regular 
virus-cell fusion[276]. In order to better define this virolytic mechanism it is 
important to understand what are the other steps in this cascade therefore future 
studies will be looking at the effects on the viral  
membrane and further how the cytoplasmic tail of gp41 also is involved in lysis and 
the energy required for poration. The potent and specific activity of this virolytic 
peptide and its ability to inactivate virions prior to target cell engagement by 
hijacking the viral fusion mechanism will provide insight to the virus-cell fusion. 
Further this agent will be highly effective as a microbicide in inhibiting HIV 
transmission across mucosal barriers as well as a probe to understand biochemical 
signals required for membrane fusion.    
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Figure 29: Schematic representation of the KR13 induced virolytic cascade. (A) Kinetic 
breakdown of the virolytic process, first showing the peptide binding following which the gp120 is 
shed off and the gp41 is exposed within the first 10 minutes. Following this is the rate limiting 
step of the pore formation caused by conformational changes in gp41 and eventually p24 release 
from the viral core. (B) Detailed schematic of the conformational changes of gp41 during 
virolysis, the loops reach a pre-lysis intermediate following which it is collapsed into a 6 helix 
bundle with the loop region on gp41 hidden into the viral membrane and MPER region exposed 
out of the membrane, (C) The zoomed in version of the 6 helix bundle formation schematic drawn 
based on the experimental results.  
114 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3: MECHANISM OF MULTIVALENT ENCOUNTER FOR 
POTENCY ENHANCEMENT OF PEPTIDE TRIAZOLE INACTIVATORS OF 
HIV-1 
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3 Introduction 
There is an urgent need for new antiretroviral agents for the prevention and 
treatment of HIV-1 infection.  Current inhibitors used in most combination 
antiretroviral therapies target viral enzymes reverse transcriptase, integrase and 
protease.  Although the use of combination antiretroviral therapy has resulted in 
reducing viremia and HIV related morbidity and mortality, these drugs target the 
later stages of HIV-1 infection and have significant challenges such as complex 
regimens and treatment-resistant variants of HIV-1. Currently, there are only two 
FDA approved antiretroviral drugs targeting the initial entry of the virus into host 
cells, namely T20 (enfurvitide) and maraviroc, but these are used mainly in salvage 
therapy due to risks concerning their usage. T20, a fusion inhibitor, targets transient 
conformations of the virus Env protein, gp41, and hence has a relatively short time 
window to act during HIV-1 host  cell fusion event. Maraviroc, on the other hand, 
targets the host cell co-receptor, CCR5 and can only block R5-tropic HIV-1 virions 
from infecting the cell.  Hence, this will result in the prevelance of the X4-tropic 
HIV-1 virus.  
Host cell infection by HIV-1 is mediated by cell receptor interactions with trimeric 
envelope glycoprotein (Env) spikes that are exposed on the virus membrane surface.  
Env protein is the only virus-specific protein on the virion surface.  The external 
gp120 component of Env is essential for cell receptor (CD4) and coreceptor (usually 
CCR5 or CXCR4) interactions and subsequent virus-cell fusion.  Hence, Env gp120 
presents an obvious target to attack the virus directly in order to block the cascade of 
integrated binding and conformational change steps that lead to host cell infection.  
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Env-specific inhibitors that could inactivate the virus before receptor encounter 
would hold great promise in preventing AIDS transmission and progression. In spite 
of the potential of gp120 antagonists as microbicides, progress has been limited for 
such agents, due to such factors as, high rate of mutation of gp120 protein leading to 
development of inhibitor resistance[277-279], low potency of small molecule 
inhibitors [18, 170, 187], the high cost and potential toxicity of protein 
inhibitors[159, 194, 280], and the potential risk of infection enhancement with CD4-
mimicking ligands[187, 243].   
Previously we showed that a family of entry inhibitors, peptide triazoles, bind 
specifically and with high affinity to HIV-1 Env gp120, antagonize the interactions 
of Env binding sites for both host cell receptors CD4 and CCR5/CXCR4 and cause 
gp120 shedding from the virus surface, leading to HIV-1 inactivation before host 
cell encounter[9, 10, 22, 24, 25, 32].  The most potent compositions of peptide 
triazole inactivators discovered so far are multivalent forms conjugated to 
monodisperse gold nanoparticles.  The conjugates initially derived were found to 
have low nanomolar inhibitory values and to act as virucidal agents leading to the  
irreversible breakdown of the virus before the virus has a chance to engage the host 
cell[8].   
The functional properties of virolytic gold nanoparticle-peptide triazole (AuNP-PT) 
conjugates make it feasible long term to use this type of agent to inactivate HIV-1 
before host cell encounter.  In the current work, we sought to investigate the 
mechanism of cell-free HIV-1 inactivation using the AuNP-PT multivalent 
nanostructures. Previous literature has shown that using nanoparticles ehanced 
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antiviral activity of an inhibitor[281, 282]. We evaluated the impact of altering the 
properties of both the AuNP-PT constructs, by increasing size of the AuNP core and 
density of the PT coverage, and the HIV-1 virus spike density.  The results 
demonstrate the importance of multivalent contact between nanoparticle and virus 
surface interaction partners.  The results lead to Env-targeting NP designs that take 
advantage of HIV-1 Env metastability and cause specific and irreversible HIV-1 
inactivation.  Overall, the investigation demonstrates that the multivalent physical  
contact approach  can be used as a general strategy for antagonizing HIV-1 
transmission and proliferation. 
 
3.1 Materials and Methods: 
 
3.1.1 Materials 
 
For peptide triazole synthesis, all fmoc-protected α- and β-amino acids, O-
Benzotriazole-N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate (HBTU), 1-
Hydroxybenzotriazole (HOBt), Rink amide resin  (4-(2',4'-Dimethoxyphenyl-
Fmoc-aminomethyl)phenoxy resin) with a 0.55 mmol/g substitution, N,N- 
dimethylformamide (DMF), Pyridine and N,N-di-isopropylethylamine (DIPEA) 
were purchased from Chem-Impex International Inc, Ethynylferrocene and Cu(I)I 
was purchased from Sigma-Aldrich and used without further purification. Fmoc-
cis-4-azidoproline was synthesized starting with commercially available trans-
Hydroxyproline-OH[22].  Gold (III) chloride hydrate and citric acid were 
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obtained from Sigma-Aldrich, Bis (p-sulfonatophenyl) phenylphosphine 
dehydrate dipotassium salt (BSPP) from Strem Chemicals. Citric acid and 
cysteine used in the conjugation were from Sigma Aldrich. Modified human 
osteosarcoma cells (HOS.T4.R5) engineered to express CD4 and CCR5, receptor 
and co-receptor respectively, as well as pNL4-3.Luc R-E- backbone DNA, were 
obtained from Dr. Nathaniel Landau.  The HOS.T4.R5 cells were grown in 
DMEM supplemented with 10% FBS, 2.5% HEPES, 1% Penicillin- 
Streptomycin, 2% L-Glutamine and 1 mg of puromycin.  293T cells were 
obtained from American Type Culture Collection and grown in the same culture 
medium as the HOS.T4.R5 cells except without puromycin.  The plasmids for 
HIV-1 BaL-01 gp160 and VSV-G Env DNA were from the AIDS Research and 
Reference Reagent Program (ARRRP).   Replication competent HIV-1 BaL-01 
virions were obtained from the University of Pennsylvania Center for AIDS 
Research (Penn CFAR). Mouse anti-p24, rabbit anti-p24 and p24 protein were 
from Abcam. Fully Infectious HIV-1 (BaL) was a gift from Dr. Michele Kutzler 
and obtained from the Penn CFAR.   The gp120 monomer protein was produced 
using an already-established protocol[25], anti-gp120 D7324 was purchased from 
Alto chemicals. Gp41 protein, Enfurvirtide (T20) and anti-gp41 antibodies 4E10 
and 2F5 were obtained from from NIH AIDS Research and Reference Reagent 
Program (ARRRP). Enhanced Chemiluminescence western blot detection system 
was from Amersham. O-phenylenediamine (OPD) was from Sigma Aldrich.  All 
other materials were from Fisher Scientific. 
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3.1.2 Peptide Triazoles 
 
To conjugate peptide triazoles on nanoparticles, the peptide triazole KR13 
(RINNIXWSEAMMβAQβAC, X=ferrocenyltriazolePro) was synthesized to 
contain the 12-residue N-terminal sequence of HNG-156 with a C-terminal 
extension containing a free thiol group.  KR13 itself contained the essential 
peptide triazole pharmacophore, Ile-triazole-Pro-Trp, and not surprisingly was 
functionally active [6].  The free sulfhydryl group was incorporated to enable 
direct thiol conjugation to the gold surface of AuNP[8].  
 
3.1.3 Gold nanoparticles 
 
The citrate reduction method developed by Frens et al. [283] was modified in 
order to synthesize size-controlled, stable and monodisperse AuNPs.  The citrate 
acid concentration was varied to obtain AuNP with various sizes ranging from 
13 nm – 123 nm. The citrate reaction solution, initially at 100˚C, was cooled to 
room temperature and BSPP (18 mg/ml for 20 nm AuNP) was added to the 
synthesized particles and stirred overnight at room temperature. The resulting 
particles were further washed with phosphate buffer at pH 7.2 and concentrated 
using a Millipore 100,000 kDa filter. The particle size was determined by 
Dynamic Light Scattering (DLS) in the Zetasizer NS90 (Malvern Instruments), 
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and the particle concentration was calculated using the absorbance at 450 nm 
and the peak absorbance of the UV spectrum[284]. The AuNP particle 
morphology was characterized using Transmission Electron Microscopy. 
Samples were prepared by adding a drop of the AuNP solution onto a lacey 
carbon grid film and then allowing evaporation.  Bright field images were taken 
with a JEM 2100 camera operated at 200 kV. Further the samples were validated 
for cell cytotoxicity and stability in physiological conditions prior to cellular 
assays, the methods and results are elaborated in appendix Fig. 8A and B.  
 
3.1.4 Gold nanoparticle-peptide triazole conjugates 
 
Peptide conjugation to the AuNPs was achieved via covalent linkage between the 
thiol moiety (-SH) on C-terminal cysteine residue and the gold surface of 
AuNP[8]. A flocculation assay[285] was conducted to determine the ratio of 
AuNP to KR13 to use for complete peptide conjugation without peptide 
aggregation following the protocol developed by Xie et al. 2003 (Appendix Fig. 
9). The BSPP-stabilized AuNP:PT mixtures in phosphate buffer were stirred 
vigorously for 30 minutes at 25ºC. Excess peptide was removed from the 
nanoparticle fraction using a 10,000 MW cut-off centrifugation filter. PT content 
of AuNP-PT preparation was determined using amino acid analysis after acid 
hydrolysis (Keck Institute, Yale University). To prepare AuNP-PT particles with 
varying density of KR13, we used 20 nm AuNPs. We mixed different molar ratios 
of KR13 and L-cysteine during the step of peptide conjugation to AuNP. Both 
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molecules present a single reactive thiol for covalent attachment to the BSSP-
stabilized nanoparticle. However, AuNP-Cys has no virolytic activity (Table 2), 
and only the KR13 component will bind to HIV Env on the virion surface.  
Incorporation of KR13 was measured directly by amino acid analysis.  We 
calculated the average density of peptide coverage (ρcoverage) by the relationship,  
𝜌𝑐𝑜𝑣𝑒𝑟𝑎𝑔𝑒  =  
[
𝐶𝑝𝑒𝑝𝑡𝑖𝑑𝑒
𝐶𝐴𝑢𝑁𝑃
]
 𝜋𝑑2 
 
where πd2 is surface area of nanoparticle and Cpeptide/CAuNP is molar ratio of 
peptides per nanoparticle. The conjugates were validated for peptide conjugation 
by testing their change in zeta potential, which was measured by the Zetasizer 
NS90 (Malvern Instruments) (Appendix Fig. 10). Further their monodispersity 
was assessed using both the DLS (Figure 29B) as well as TEM imaging (Figure 
29C).  
 
3.1.5 HIV-1 Pseudotyped Virions 
 
The recombinant virus consisted of the pro-viral envelope plasmid sequence 
corresponding to the CCR5 targeting HIV-1BaL strain or a VSV (Vesicular 
Stomatitis Virus) pseudotype, and the backbone sequence corresponded to an 
envelope-deficient pNL4-3 luc+, env– provirus developed by N. Landau[251, 
286]. Four µg of envelope DNA and eight µg of backbone DNA were co-
transfected into 293T cells using FuGene 6 as the transfection reagent 
(Promega).  Fourteen hours post-transfection, the medium was changed, and the 
VLP containing supernatants were collected at 48 hours post transfection.  
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Protease digestion of pseudovirus was conducted by treating the culture 
supernatants with a protease cocktail of 1 μg of trypsin, chymotrypsin, subtilisin, 
and/or proteinase K (Sigma) at 37°C as described by Crooks et al. [287]. 
Following the enzyme digest, soluble proteins (including Env gp120 and p24) 
were removed via fractionation on 6-20% iodixanol gradient for 2 hours at 
30,000 rpm. The collected fractions were validated for p24 content using capture 
ELISA as well as gp120 content using the western blot detection. Virions 
purified on the 6-20% iodixanol gradient exhibited a characteristic distribution 
profile of p24 and gp120 content, enabling viral fractions (18-19.2% iodixanol) 
and soluble protein fractions (6-8% iodixanol) to be isolated. The gradient-
purified virus samples were collected, aliquoted and stored at -80°C until further 
use.   
 
3.1.6 Env Spike Presentation on the Virus Surface  
 
To make viruses with varying spike density, HEK293T cells were transfected 
with backbone vector, pNL4-3.Luc R-E-, and a mixture of active env plasmid 
(HIV-1 BaL - WT) with a plasmid encoding inactive env gp120 S375W BaL; 
the S375W mutation has been found previously to cause suppression of PT 
binding to gp120[222],[24]. Of note, varying density does not in itself eliminate 
the potential for local clustering, and indeed evidence has been obtained showing 
that HIV-1 Env spike has the tendency to cluster[288, 289].  Control virions 
included those with all-active Env (BaL- WT) and all-inactive Env (S375W 
BaL).  Protease digestion of spike-varying viruses was conducted as described 
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above.  Spike density was quantified using western blot analysis of gp120, viral 
infection and p24 content (ELISA) as explained above (Appendix Fig. 11). 
 
 
3.1.7 Anti-viral functions of AuNP-KR13 conjugates  
 
Dependence of anti-viral effects on the size of AuNP-KR13:  
To test the effects of nanoparticle size on viral inhibition and virolytic activity, we 
synthesized gold nanoparticles (AuNP) with diameters ranging from 10-200 nm 
as previously described. After AuNP functionalization with the KR13 peptide, we 
utilized assays for HIV cell infectivity and cell-free leakage of virus contents, p24 
and gp41, to correlate nanoparticle diameter and surface area of the AuNP-
KR13’s with antiviral effects.  Purified virus was treated with AuNP-KR13 
constructions for thirty minutes at 37°C and spun on a 6-20% iodixanol gradient 
for 2 hours at 30,000 rpm. The collected virus fraction and the supernatant 
fraction were tested for infectivity, p24 and g120 content from the virus post 
treatment. Virus treated with PBS for 30 minutes at 37°C was used as negative 
control for background signal, and virus incubated for 5 minutes with 2% Triton-
X at 98°C was the positive control for p24 and gp120 content.  
 
Modulating nanoparticle surface density of peptide triazoles on AuNP: 
Peptide triazole inhibitor coverage on 20 nm diameter Au nanoparticles was 
varied by mixing different molar ratios of KR13 and L-cysteine during the step of 
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peptide conjugation to AuNP.  Both molecules present a single reactive thiol for 
covalent attachment to the BSSP-stabilized nanoparticle.  However, only the 
KR13 were expected to bind to HIV envelope glycoproteins on the surface of the 
virion. AuNP and KR13 were synthesized and functionalized as described above.   
Cysteine/KR13 molar ratios were varied from 0:1000 to 1000:0 in increments of 
50.  We calculated the density of peptide coverage (ρ coverage) by the 
relationship: 
 ρcoverage = [Cpeptide/CAuNP] / 4π(d/2)2 
where 4π(d/2)2 is surface area of nanoparticle and Cpeptide/CAuNP is the molar ratio 
of peptides per nanoparticle.  Purified virus was treated with AuNP-KR13 
constructions for thirty minutes at 37°C and spun on a 6-20% iodixanol gradient 
for 2 hours at 30,000 rpm. The collected virus fraction and the supernatant 
fraction were tested for infectivity and both p24 and g120 contents post treatment.  
 
AuNP-KR13 effects on replication competent HIV-1:  
Replication competent HIV-1 BaL virions were obtained from the Penn CFAR, 
purified using 6-20% iodixanol gradient and p24 content measured using ELISA. 
The inhibitor concentration that gives 50% reduction of the viral titer in tissue 
culture (IC50) was determined using Origin V.8.1 (Origin Lab). The working 
dilution of virus was pre-treated with a serial dilution of AuNP-KR13 (20 nm and 
80 nm), starting from 50 µM and 10 µM respectively, for 30 min at 37 °C. 
HOS.T4.R5 cells, seeded at 8,000 cells per well, were incubated for 24 hours 
followed by addition of pre-incubated inhibitor-virus mixtures.  After 48 hours 
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infection, p24 content of virions in the supernatant was measured in order to 
determine the IC50 value of inhibition of virus infection. For the latter, the peptide 
triazole and cell-free replication competent HIV-1 BaL virus were pre-incubated 
for 30 min at 37°C followed by spinning for 2 hours at 13,600 rpm in a table top 
centrifuge (Eppendorf) at 4°C. Supernatant was separated and p24 content 
determined using the p24 capture ELISA as described above. The extents of viral 
inhibition of, and p24 release from, fully infectious HIV-1 BaL were also 
evaluated for control peptide KR13 (data shown in Bastian et al. 2013) [6].   
 
3.1.8 Comparisons of anti-viral functions of AuNP-KR13 to KR13 alone  
 
Exposure of gp41 in viruses treated with AuNP-KR13 and KR13:  
The HIV-1 BaL pseudotype was incubated with increasing concentration of either 
KR13 starting at 50µM or AuNP-KR13 starting at 1 µM (KR13 concentration) for 
30 minutes at 37°C. The samples were spun at 16,000 rpm for 2 hours at 4°C, and 
the virion fraction for each sample was collected and fixed using a homemade 
fixative with 0.1% formaldehyde and 4% gluteraldehyde in PBS. Glycine (0.1 M) 
was added to stop the crosslinking reaction by the fixative. The virions then were 
loaded onto an ELISA plate (high protein binding) and incubated overnight on a 
shaker at 4°C. The plate was blocked with 3% BSA, and ELISA was used to 
detect gp41 epitopes with human gp41 antibodies 2F5 and 4E10 followed by 
addition of anti-human IgG HRP secondary antibody. 
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Effect of fusion inhibitor enfurvirtide (T20) on virolysis induced by AuNP-KR13 
and KR13:  
T20 was shown previously to effect the 6-helix bundle formation of the HIV-1 
virion during fusion with the host cell[14, 239].  Further, T20 was found to 
specifically inhibit KR13-induced HIV-1 cell-free virolysis [6].  A corresponding 
experiment was conducted to test whether T20 inhibited virolysis of pseudotyped 
HIV-1 BaL induced by AuNP-KR13. The AuNP-KR13 was kept at an IC80 
concentration of 25 nM, and serial dilutions of T20 starting at 1 µM were co-
incubated with pseudotyped HIV-1 BaL for 30 min at 37°C. Treated virion 
samples were fractionated on a 6-20% iodixanol gradient (above). Gradient 
fractions were quantified for p24 using ELISA, and relative p24 release was 
quantified and plotted using Origin V.8.1 (Origin Lab).  
 
Time dependence of AuNP-KR13 induced HIV-1 breakdown:  
The time dependence of gp120 shedding, p24 release and inhibition of 
pseudotyped HIV-1 BaL by an IC80 concentration of AuNP-KR13 (25 nM) was 
measured. The AuNP-KR13 was incubated with the virus for different times 
ranging from 1 min to 24 hours at 37°C, the samples were spun on a 6-20% 
iodixanol gradient and the gradient fractions were tested for gp120 shedding, p24 
release and inhibition of viral infection. For gp120 shedding, the fractions were 
tested using a western blot analysis with primary anti-gp120 antibody, D7324, 
and secondary antibody, anti-sheep HRP. For p24 release, the ELISA explained 
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above was used.  For inhibition of viral infection, the luciferase reporter assay 
was used as explained above[6].   
 
 
Anti-viral effects of AuNP-KR13 vs. KR13 on HIV-1 pseudovirions with modified 
env spike presentation on the virus surface:  
Comparisons were made of the lytic deformation of viruses by KR13 and AuNP-
KR13 with viruses containing a varying proportion of PT-resistant mutant Env 
spike vs. WT spike density. In the western blot analysis, the amount of loaded 
virions was normalized using both p24 content from ELISA and total protein 
content measured using Bradford assay. Antiviral assays included inhibition of 
infection by KR13 compared to AuNP-KR13 on HOS.T4.R5 cells, and cell-free 
HIV-1 p24 release.  
 
3.1.9 Morphological Analysis of HIV-1 after AuNP-KR13 conjugate treatments  
 
Transmission Electron Microscopy (TEM) was conducted to visualize the 
morphology of the virions treated with AuNP-KR13. Purified pseudotyped HIV-1 
BaL virus and AuNP-KR13 were pre-incubated from 5-1440 min at 37°C. 
Following incubation, samples were fixed with 2% glutaraldehyde for 30 minutes 
at room temperature, and then embedded in Spurr’s low viscosity epoxy medium 
after acetone washes to dry the virions.  Slices (100 nm thick) were prepared 
using an ultra-microtome (Leica EM UC6), loaded onto a holey carbon TEM 200 
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mesh grid (Electron Microscopy Science) and imaged using the JEM 2100 camera 
operated at 120 kV (JEOL, Japan).  Sixteen images were taken per sample, and 
the sizes of observed particles were determined, using Image J software to derive 
average diameters of the virion particles from TEM images measured from 5 
angles. 
 
3.2 Results 
 
3.2.1 Monodispersity of Gold Nanoparticle-Peptide Triazole Conjugates  
 
The physical characteristics of gold nanoparticle-peptide triazole conjugates were 
validated by DLS, TEM and U.V. absorbance. The particle size was obtained by 
DLS using the Zetasizer NS90 (Malvern Instruments), while the particle 
concentration was calculated using the UV spectrum as described in the methods 
section[284]. The DLS data are shown in Figure 30, along with representative 
TEM images of AuNP-KR13 conjugates of various AuNP sizes. Figure 30A also 
shows the comparison between the expected sizes of AuNP using varying 
concentrations of citric acid as well as the experimentally obtained diameters 
(DLS). The AuNP-PT conjugates showed good monodispersity as observed by 
the TEM images in Figure 30C. Further, as shown in Appendix Fig. 10, zeta 
potential values for AuNP-KR13 conjugates compared to the AuNP alone verified 
the successful peptide conjugation to AuNP [290].  
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Figure 30: Characterization of the AuNP-KR13 conjugates. (A) Compares the theoretical 
AuNP diameters, that were expected with increasing concentration of citric acid in the 
reaction as represented in Frens et al. 1973, to the diameters of the AuNP that were 
syntehsized as measured using dynamic light scattering (DLS) (n=25). (B) The % 
intensity of the different diametes of the AuNP-KR13 conjugates as measured on the 
zetasizer using the dynamic light scattering methodology (n=3). (C) Shows the 
representative TEM images of the AuNP-KR13 conjugates with diameters 13.3 nm, 19.9 
nm, 42.8 nm and 92.6 nm. Error bars represent the standard deviation of the mean, n > 3. 
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3.2.2 Anti-viral effects of AuNP-KR13 conjugates 
 
Size dependence of the anti-viral functions of AuNP-KR13:  
 
AuNP-KR13 conjugates were tested for both inhibition of HIV-1 BaL pseudotype 
infection of HOS.T4.R5 cells as well as the cell-free p24 release, in both cases 
after 30 min exposure of viruses to AuNP-KR13 conjugates.  Figure 31 shows the 
dose responses of the effects, and IC50 values are summarized in Table 6.  The 
results are compared to KR13 alone.  Strikingly, the anti-viral effects are greatly 
enhanced with increasing size of the nanoparticle.  Table 6 also shows the 
number of peptides per nanoparticle calculated from amino acid analysis and the 
amount of peptide per square nanometer on the AuNP surface.  The latter assumes 
that AuNP is a perfect sphere and that individual molecules of KR13 are 
equidistant from each other on the NP surface.  
To further probe the size dependence of AuNP antiviral effects and to 
mathematically model the AuNP-PT and virus interface, we prepared 
nanoparticles in which the number of PT per unit area (PT density) of AuNP 
surface was kept as similar as possible, by adding sufficient peptide to ensure 
stability monitored by flocculation assay (Methods) and then adding further 
peptide determined empirically to equalize density. The antiviral effects of 
increasing size of AuNP with equal PT density in AuNP-KR13 conjugates are 
shown in Figure 32, and the IC50 values obtained from these are summarized in 
131 
 
Table 8.  Here, a clear correlation was observed between the effects of AuNP size 
on inhibition of viral infection and p24 release.  
 
 
 
 
 
 
 
Figure 31: Size dependent anti-viral effects of the AuNP-KR13 conjugates on the HIV-1 
BaL pseudovirions. (A) Inhibition of cell infection was measured using a single round 
infection assay as explained in methods.  The IC50 values are reported in Table 1. (B) 
Relative p24 release from the cell-free HIV-1 BaL pseudovirions with increasing 
concentration of the different diameter AuNP-KR13 conjugates. The EC50 values are 
reported in Table 1. Error bars represent the standard deviation of the mean, n = 3. 
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Compared to Figure 31, Figure 32 shows a better correlation between the effect 
of the viral infection inhibition and p24 release. This might be due to the 
approximately equal number of peptide coverage per square nanometer and 
which can be used further for AuNP-KR13 and HIV-1 BaL pseudotype spike 
interface modelling.  
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Figure 32: Anti-viral effects of AuNP-KR13 conjugates with increasing diameter of the 
AuNP with equal density of KR13 coverage per square are on the surface of the AuNP. 
(A) Inhibition of HIV-1 infection by the AuNP-KR13 conjugates were measured using a 
single round infection assay as explained in methods.  The IC50 values are reported in Table 
3. (B) Relative p24 release from the cell-free HIV-1 BaL pseudovirions with increasing 
concentration of the different diameter AuNP-KR13 conjugates. The EC50 values are 
reported in Table 3. Error bars represent the standard deviation of the mean, n = 3. 
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Impact of density variation of peptide triazoles conjugated on AuNP on anti-viral 
functions: 
 
AuNP-KR13 conjugates were prepared with varying KR13 densities on 20 nm 
nanoparticles and tested for both inhibition of HIV-1 BaL pseudotype cell 
infection with HOS.T4.R5 cells and cell-free p24 release after 30 min of exposure 
of virus with AuNP-KR13 conjugates. The values computed for KR13 coverage 
per square nanometer of the AuNP surface assumed that AuNP is a perfect sphere 
and that individual KR13’s are equidistant from each other on the NP surface. As 
shown in Figure 33 and Table 8, inhibition of both viral infection and p24 release 
activities were greater with increasing density of KR13 on the AuNP surface. The 
total number of peptide molecules per AuNP was obtained by amino acid 
analysis.  The AuNP with 0 moles of KR13 have 100% cysteine coverage.  As 
shown in Table 3, the latter non-peptide AuNP exhibited no non-specific anti-
viral effects.  
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Figure 33: Anti-viral effects of AuNP-KR13 (19.9 nm diameter) with increasing surface 
desnity coverage of KR13 with 100% being 73 peptides per AuNP as represented in 
Table 2. (A) Inhibition of cell infection was measured using a single round infection assay as 
explained in methods.  The IC50 values are reported in Table 2. (B) Relative p24 release from 
the cell-free HIV-1 BaL pseudovirions with increasing concentration of the AuNP-KR13 
conjugates with decreasing KR13 density coverage. The EC50 values are reported in Table 2. 
Error bars represent the standard deviation of the mean, n = 3. 
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AuNP-KR13 potencies with replication competent HIV-1: 
 
The anti-viral effects of 20 and 80 nm AuNP-KR13 particles were tested with 
replication-competent Bal-01 HIV-1, as shown in Figure 34. The results 
demonstrate that the AuNP-KR13 is effective and has a greater potency than 
KR13 alone (approximately 300 fold greater for the 20 nm AuNP-KR13 and 1400 
fold greater for the 80 nm AuNP-KR13 more potent, compared to KR13).  
 
3.2.3 Comparison of the anti-viral functions between AuNP-KR13 and KR13 
 
We previously observed that KR13-induced lysis of HIV-1 embodies virus 
breakdown properties reminiscent of those occurring during virus-cell fusion.  
These include exposure of the membrane proximal external region (MPER) of 
gp41 and inhibition by fusion inhibitor T20.  In the current work, we sought to 
compare AuNP-KR13 lysis for these properties.  As shown in Figure 35A, 
AuNP-KR13 treatment does not induce a concentration-dependent exposure of 
MPER on the residual virion, while treatment with KR13 does.  In addition, as 
seen in Figure 35B, the fusion inhibitor, T20, does not lead to the inhibition of 
AuNP-KR13 induced p24 release, in contrast to the inhibition seen with KR13.  
Figure 35C shows that, like KR13, AuNP-KR13 induced virolysis is 
accompanied by gp120 shedding.  However, for AuNP-KR13, gp120 shedding, 
p24 release and viral infection inhibition occur simultaneously, all starting within 
10 min of incubation with the virus.  By comparison, in KR13 virolysis, p24 
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release occurred with a time lag compared to the gp120 shedding and virus 
infection inhibition[6]. Hence, from the data shown above, the AuNP-KR13 
induced virolysis process appears to be controlled differently than for KR13. 
 
 
 
 
Figure 34: Plots ofAuN: KR13 (20 nm and 80 nm) induced infection inhibition and virus 
breakdown of replication competent HIV-1 BaL virus.  (A)  Inhibition of cell infection was 
measured using a p24 ELISA of the produced virions in the presence of the inhibitor.  The IC50 values 
of AuNP:KR13 (20 nm) and AuNP:KR13 (80 nm) to inhibit HIV-1 BaL infection being 3.16 nM and 
0.73 nM respectively. (B) Relative p24 release from the cell-free HIV-1 BaL (replication competent) 
with increasing concentration of the 20 nm and 80 nm diameter AuNP-KR13 conjugates. The EC50 
values of AuNP:KR13 (20 nm) and AuNP:KR13 (80 nm) to inhibit HIV-1 BaL infection being 8.19 
nM and 0.49 nM respectively. Error bars represent the standard deviation of the mean, n = 3. 
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3.2.4 Impact of Env Spike Presentation on the Virus Surface 
 
We sought to evaluate the importance of simultaneous multi inhibitor-gp120 
interactions in AuNP-KR13 induced virolysis.  Such encounter could occur by 
such mechanisms as localized Env spike clustering or multivalent attachment at 
single spikes.  If the AuNP-PT effect were multivalent and required encounter 
with multiple fully active Env spikes, we expected to observe that reducing active 
Env density would cause more reduced anti-viral activity with AuNP-KR13 than 
KR13 alone.  To examine this prediction, we compared lytic processes using 
HIV-1 BaL pseudotype viruses containing different ratios of functional and non-
functional gp120.   The viruses were produced (see section 4.2) with varying 
relative amounts of WT and S375W gp120, the latter of which has been found to 
be ineffective in binding the peptides [25]. Spike variations on the virus, provided 
by altering the relative abundance of WT vs. mutant S375W gp160 DNA during 
virus production, led to virions with varying density of WT gp160’s on the virion 
surface. In order to model whether the AuNP-KR13 conjugates work by a 
multivalent contact mechanism, it was important to know how the mutant (M) and 
WT (W) monomers were arranged on the spikes (each of which has three 
monomers[105]) of the virions containing various amounts of mutant DNA. By 
assuming random protomer assortment, and using i = number of WT protomers, 
{𝑊3  , 𝑊2𝑀1,  𝑊1𝑀2, 𝑀3 } =  {𝑊𝑖𝑀3−𝑖}           𝑖 𝜖 [0,3] 
∝𝑖=
3!
𝑖! (3 − 𝑖)!
  𝑓𝑖(1 − 𝑓)3−𝑖 
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where 𝑓 = 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑜𝑓 𝑊𝑇 𝐷𝑁𝐴 −
𝑝𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛𝑎𝑙 𝑡𝑜 𝑡ℎ𝑒 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑜𝑓 𝐸𝑛𝑣 (𝑊𝑇)𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 
The values for α0, α1, α2 and α3 for each ratio of WT: S375W DNA were calculated from 
the formula above, and these values are given in Figure 38.   The AuNP-KR13 and KR13 
effects on these mutated viruses are shown in Figure 36 and Table 9.   
Analysis of virus infection inhibition by both KR13 and AuNP-KR13 revealed that, with 
for total of 4 
However, some significant differences were observed in the response patterns.  AuNP-
KR13 retained activity even with small abundance of fully active spikes e.g. WT-S375W 
ratios of 1-3 and 0.5-3.5.  In contrast, KR13 activity falls off more dramatically at those 
conditions (Figure 36).  This could reflect fundamental differences in how AuNP-KR13 
and KR13 encounter the virus to cause lysis.   
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Figure 35: Comparing the anti-viral effects of AuNP-KR13 and KR13 on the HIV-1 BaL 
pseudotyped virus. (A) Shows the MPER (membrane proximal external region) specific gp41 
epitope exposure on the AuNP-KR13 and KR13 alone treated virus by testing MPER specific 
antibodies (2F5 and 4E10) anbitody binding to HIV-1 BaL pseudotyped virion after 30 minutes of 
AuNP-KR13 (20 nm diameter) and KR13 repectively. (B) T20 (Fusion Inhibitor) inhibition of 
AuNP-KR13 (50 nM) and KR13 (1 µM) induced p24 release of HIV-1 BaL pseudotyped, with The 
IC50 value T20 inhibition of KR13-induced p24 release being 15.9 ± 4.9 nM using Origin V.8.1 
(Origin Lab). No significant effect on the AuNP-KR13 induced p24 release in the presence of T20. 
(C) Time dependent anti-viral effects of AuNP-KR13 (20 nm) on the viral infection inhibition p24 
and gp120 release. . Time-dependence of viral breakdown by HNG156 (a) and KR13 (b) 
treatments of HIV-1 BaL pseudovirus. The % of cell infection retained after peptide treatment is 
shown on the left y-axes, and the viral protein gp120 and p24 retained in the virus fraction is 
shown on the right y-axes. All samples were adjusted to the untreated virus as 100% infection and 
100% viral protein retention . Each time point had controls of untreated virus which was used for 
normalizing relatively for the each time point peptide treatment. Error bars represent the standard 
deviation of the mean, n = 3. 
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Figure 36: Comparing the antiviral effects which include virus infection inhibiton (A) and 
p24 release (B) of AuNP-KR13 (20 nm) compared to the virus infection inhibiton (C) and p24 
release (D) of KR13 on the HIV-1 BaL pseudovirions with varying concentrations of S375W 
mutant spikes incorporated. Inhibition of HIV-1 infection was measured using a single round 
infection assay as explained in methods.  The cell-free KR13 and AuNP-KR13 (20 nm) induced 
p24 release from these virions were measured using the p24 ELISA of the released protein as 
explained in the methods section.  The EC50 values are reported in Table 8. Error bars represent 
the standard deviation of the mean, n = 3. 
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3.2.5 A continuum mechanics model of the virion-nanoparticle complex 
 
In order to better understand how the AuNP-KR13 conjugates interact with the 
spikes on the virions, we sought to construct a mathematical model. The surface 
of AuNP-KR13 particles with varying peptide densities and sizes were modeled 
as shown in Figure 37. The spike dimensions of gp160 were obtained from Mao 
et al.[106] ,wherein the calculated height and width of the spike was found to be 
12 nm and 15.5 nm, respectively, from single particle cryo-electron microscopy.  
The contact area between the AuNP and virus was modeled by the Hertz contact 
radius (α) formula using an elastic infinite half space analysis[291], 
𝛼 =  [
3𝐿𝑅
4𝐸∗
]
1/3
 
where L is the applied normal force (load), and the combined Young’s modulus 
and radius of curvature of the two materials 1 and 2 are E* and R, i.e., 
𝐸∗ =  (
1−𝑣1
2
𝐸1
+
1−𝑣2
2
𝐸2
)
−1
   , and  𝑅 =  (
1
𝑅1
+  
1
𝑅2
)
−1
  
In the equation above, material 1 is AuNP and the material 2 is the HIV 
pseudovirus; v1 and v2 are the poisson ratios of materials 1 and 2, respectively. 
The poisson ratio, v1, and the elastic modulus, E1, for gold nanoparticle used for 
the calculation were 0.32 and 100 GPa, respectively[292, 293].  The poisson ratio, 
v2, and the elastic modulus, E2, for the HIV pseudovirus used for the calculation 
were 0.44 and 440 MPa respectively[294-297]. The load force used was 130 pN, 
which is the maximum force that can be exerted on the viral membrane that does 
not fracture the surface[294, 297].  Several assumptions were taken into account 
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in order to resolve a simplified mathematical model for the contact interface 
between virion and nanoparticle. These assumptions include: (a) the virus and the 
AuNP are perfect spheres and (b) the peptides on the AuNP surface have an 
isotropic arrangement. Figure 38 depicts the interface of the AuNP and virion 
surfaces resulting from the above calculations.  
 
3.2.6 Morphological analysis of AuNP-KR13 effects on HIV-1  
We sought to image the virus-nanoparticle interface and consequent virus lysis 
using transmission electron microscopy.  Viruses were treated with the AuNP-
KR13 (20 nm and 80 nm) conjugates for 10 minutes, and then fixed and loaded on 
a TEM grid.  Uranyl acetate was used as a contrast agent to stain the lipids in 
order to visualize the virion.  Representative images obtained are shown in 
Appendix Fig 13.  In the images for both the 20 nm and 80 nm AuNP-KR13, a 
limited number of AuNP-KR13 particles (average 1-3) were found associated 
with individual virions, suggesting that a small number of NP’s is sufficient to 
induce virus lysis. The 80 nm AuNP-KR13 appeared to cause a more drastic 
disruption of the virion compared to the 20 nm AuNP-KR13.  
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Figure 37: A representative model of the AuNP-KR13 and HIV-1 virus interface. The diameters 
of the HIV-1 virus as well as the AuNP-KR13 conjugates are taken from the measured values by 
DLS and TEM respectively. The width and height of a spike was taken from the cryo-TEM 
modeling from Mao et al. 2012. (A) Shows the interface of the AuNP and virion interface for the 
size variation of AuNP from figure 30 viewed from a perspective parallel to the viral membrane 
(top) and viewed from the perspective of the AuNP, at the same contour level (bottom). (B) 
Shows the interface of the AuNP and virion interface for the density variation of AuNP from 
figure 31 viewed from a perspective parallel to the viral membrane (top) and viewed from the 
perspective of the AuNP, at the same contour level (bottom). The contact radius, α, calculated 
between the AuNP and HIV virion are shown in the bottom images. The model is just 
representative and has assumptions, one being that the peptides around the AuNP have an 
isotropic arrangement, two , both the AuNP and HIV-1 virion are perfect spheres and three that 
the peptide on the AuNP and the spike on the virion are stagnant. 
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Figure 38: A presentation of how the WT: mutant (S375W) monomers are arranged on 
the virus spike with different ratios of the WT: mutant DNA concentrations used for virus 
production. These % of spikes are calculated using the formula which is elaborated in the 
results section. 
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3.3 Discussion 
 
This study demonstrated the ability to enhance the anti-HIV-1 potency of peptide 
triazoles dramatically by gold nanoparticle display and at the same time derived a 
conceptual model of nanoparticle-virus encounter to account for this enhancement.  
Previously, we demonstrated that conjugating peptide triazole thiol on AuNP (20 nm) 
enhanced potency of its anti-viral function[8]. To investigate the limits of this 
enhancement effect and provide a mechanistic explanation, we altered the size of the 
AuNP as well as the density of the peptide coverage on the AuNP. Increasing both the 
size and PT coverage density led to an enhancement in potency of both the viral infection 
inhibition as well as the cell-free virolysis (Figures 31, 32 and 33). Potency 
enhancement was also observed in replication competent HIV-1 (Figure 34).  
While prior work had shown that the peptide triazole KR13 alone can causes HIV-1 
inactivation and lysis, in this study we show that these antiviral effects are enhanced by 
AuNP-KR13 conjugates. But there are several observations made in this study (Figure 6) 
demonstrated that the mechanism by which AuNP-KR13 induces inactivation and lysis is 
different from KR13 alone.  The membrane proximal external region of gp41 on the HIV 
Env is known to be exposed during the HIV-1 and host cell fusion process, but to be 
unexposed in the ground (unliganded) state of the virus[274].  For KR13, we previously 
observed both concentration dependent and time dependent exposure of the MPER 
epitope on the HIV-1 virion when viruses were treated with KR13[6].  However, in the 
case of AuNP-KR13, we did not observe MPER epitope exposure (Figure 35A). In 
addition, the data in Figure 6B show that T20, which is a fusion inhibitor that targets the 
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6-helix bundle formation of gp41 during HIV- fusion with host cell, inhibits KR13-
induced p24 release (as reported previously) but does not inhibit such release by AuNP-
KR13. Further, the data of Figure 6C show that gp120 shedding, infection inhibition and 
virolysis induced by p24-release of the HIV-1 BaL pseudotype all had a similar time-
dependence for the AuNP-KR13 exposure, versus unequal kinetics for KR13 (for which 
p24 release lagged compared to gp120 shedding and infection inhibition[6]).  
Collectively, the characteristics of MPER exposure, T20 sensitivity and time-dependence 
of antiviral effects observed for KR13 all argue that KR13-induced lysis bore a 
relationship to the physiological events of virus-cell fusion.  In contrast, the lack of these 
phenotypes (or a similar word) with AuNP-KR13 suggests that the latter responds to 
different forces (Figure 35).  Table 9 summarizes the differences between KR13 induced 
virolysis and AuNP-KR13 induced HIV-1 virolysis.  
Several other differences between KR13 and AuNP-KR13 have emerged during ongoing 
investigations of KR13-induced lysis (Lauren Bailey, manuscript in preparation). A 
gp120 antibody, 2G12, that binds to the V3 loop and inhibits KR13 induced virolysis, 
was found not to inhibit AuNP-KR13 induced virolysis (data not shown) We have also 
found that DTNB (dithionitrobenzene), a thiol blocking agent that inhibits KR13 induced 
virolysis, did not affect AuNP-KR13 mediated virolysis (data not shown). These data 
reinforce the need to consider gold nanoparticle specific mechanisms to explain the 
virolytic activity of AuNP-KR13.   
The responses of potency enhancement to nanoparticle and virus surface properties are 
consistent with multivalent contact between virus and nanoparticle surfaces as a major 
driving force for the antiviral effects of AuNP-KR13.   A key aspect for multivalent spike 
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engagement at the virus-nanoparticle interface is the importance of density of both 
components.  As noted above, we observed that the density of peptide on the AuNP 
surface has a high impact on its anti-viral potency (Figure 32 and Tables 5 and 7).  In 
addition, varying the amount of wildtype (active) spikes on the HIV-1 virion surface by 
replacing the active spikes with the peptide-insensitive mutant spikes, S375W, also had 
an impact on antiviral activities for AuNP-KR13 and with KR13 alone.   By 
incorporating progressively more mutant vs. peptide-sensitive WT gp120 in the HIV-1 
virions, we observed reduced sensitivity to HIV-1 infection inhibition by both KR13 and 
AuNP-KR13.  However, the effect of reduced WT gp120 abundance on p24 release was 
greater for KR13 than for AuNP-KR13.  Correlating with the relative numbers of 
heterogeneous and homogenous spikes with mutant-WT mixtures (Figure 38), we found 
that, while KR13 induced p24 release required an average of ≥1 fully active spike 
(containing 3 active WT monomers in individual spikes) per virion, the AuNP-KR13 (20 
nm) induced up to 50% p24 release even with an average of 0 fully active spikes.  
Based on the above results, we configured a multivalent encounter model based on the 
previously known dimensions of the virus[61, 106] and the following assumptions: (a) 
the KR13 on the AuNP are isotropic and equidistant from each other, (b) the virus and 
AuNP are perfect spheres; and (c) the spikes on the HIV-1 virion are stationary and do 
not cluster prior to nanoparticle encounter (Figure 37). While we recognize that these 
assumptions are idealized descriptors, they account for the general trends of increased 
interactions of AuNP-immobilized ligands with multiple spikes and the relative 
insensitivity of the encounter to the need for fully active spikes.   
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We speculate that multivalent contact could lead to an elevated stress on the HIV 
membrane and eventually cause irreversible collapse of the virion particle (Appendix 
Fig. 13). Further investigation is needed to better understand the nature of the virus 
membrane transformation caused by AuNP-KR13 and how this type of effect compares 
to membrane transformations triggered by other types of virus-lysing agents [298-300].  
Nonetheless, the nanoparticle-virus encounter model could provide a guide to further 
design inhibitor-NP complexes for HIV-1 and potentially other similar viruses such as 
influenza virus, sarcoma virus and more.  
The work presented here reinforces the potential usefulness of inhibitor display on 
nanoparticles to improve potency for disease prevention and intervention. While 
nanocarriers have been used as vehicles for drug delivery, their use for forming 
therapeutic agents has been more limited[228, 301-303]. Jiang et al. have shown that gold 
nanoparticles ranging from 2-100 nm in diameter conjugated to multiple trastuzumab 
antibodies enable targeting and cross-linking of human epidermal growth factor receptor 
(HER)-2 in human SK-BR-3 breast cancer cells, by causing reduced (HER)-2 receptor 
expression and inducing receptor mediated endocytosis[304]. Jiang also showed that the 
anti-cancer potencies were altered by variations of the diameter of the gold nanoparticles, 
with the larger particles having more protein on its surface and increased avidity, while 
the smaller particles exhibited greater receptor mediated endocytosis[304].   
Nanomedicine design for HIV-1 infection inhibition also has been limited[305].  Gold 
nanoparticle display has been shown previously to increase the antiviral potency of the 
HIV-1 inhibitor SDC-1721, a derivative of TAK-779, that targets the cellular coreceptor, 
CCR5[235, 306].  However, such studies have used very small (2 nm) AuNP that could 
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be taken up by cells non-specifically[236].  Heterogeneity of the HIV-1 also has been a 
problem limiting antibody and drug targeting[307].  The current work argues that gold 
nanoparticle display could help overcome the heterogeneity of Env spikes by enabling 
multivalent attachment of neighboring partially defective spikes.  The current work 
provides a generalizable approach for nanoparticle drug design not only for HIV-1 but 
also for other infectious enveloped viruses such as influenza and hepatitis B virus.  
 
 
 
‘ 
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CHAPTER 4: USING THE VIRUCIDAL AGENTS TO TARGET OTHER 
STAGES OF THE HIV-1 LIFECYCLE 
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4 Introduction 
HAART therapy used 2 or more antiretrovirals currently to treat patients with HIV. 
This form of therapy was chosen so that one can target different stages of the HIV 
life cycle and hence lead to enhanced inhibitory effect [126]. However, treatment 
efficacy relies on access to treatment and excellent adherence, which has proven to 
be a serious challenge to those receiving highly active antiretroviral therapy 
(HAART) [308]. There is a lot of resistance to most of the drugs used in HAART as 
well as there is a lot of non-adherence developing in adult populations [309].  Hence 
it is important to develop new inhibitors that are broadly acting and can target 
multiple stages of the virus.  
 
Since the over 20 years ago after the discovery of HIV-1, this virus has cause an 
epidemic disease called AIDS. There have been many attempts to eradicate the 
disease but somehow the virus finds a way to mutate and protect itself [89, 310]. 
There have been many attempts made in order to create immunogens that can serve 
as vaccines against this virus and there have been very few successes[182]. 
Therefore another venue which needs a lot of research and novel interventions is the 
vaccine development field.   
 
Hence this study will focus on a novel discovery that the virolytic peptide triazole 
and its multivalent conjugate to target not only the entry and fusion stage of the 
lifecycle but also lead to inhibition of new virus production or also known as 
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vironeogenesis. Further we will elaborate on how the residual virus post KR13 
treatment can be the perfect custom made immunogen using the virus that infected 
the host cell to create neutralizing antibodies against new infections.  These novel 
discoveries will open the phase on multifaceted therapy targeting different stages of 
the HIV-1 lifecycle using just one agent, making it much more reliable convenient 
as well as efficient.  
 
 
4.1 New virus production inhibition by peptide triazoles and gold nanoparticle 
peptide triazole thiol conjugates  
 
4.1.1 Introduction 
 
HAART therapy has led to a substantial decrease in deaths caused by AIDS, 
prolonging the life of the infected individual [126]. However, there is a gap in 
research knowledge in developing singular novel inhibitors that target multiple 
stages of the virus life cycle as opposed to combination therapy like HAART. 
Microbicides developed to target viral entry may also be able to target newly 
produced viruses[311], but unfortunately the bioavailability and stability of these 
inhibitors are very low, making targeting newly produced virions very difficult, 
and relegating such drugs to preventative treatments[312]. 
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As the precursor to its presence on newly budded virions, HIV Env glycoprotein 
must first be constructed and trafficked to the surface of the membrane by 
standard transcription, translation, and modification cellular machinery, which 
provides a potential shared target between an infected cell and its daughter 
virions [313]. Indeed, this has provided other studies with a method of efficiently 
and specifically killing HIV-infected cells, by conjugating cytotoxic agents to 
anti-Env antibodies [314, 315].  Furthermore, since the latent population of HIV 
infected cells has proven to be one of the most difficult stages of the HIV 
lifecycle to attack [316], and because this latent population is known to express 
gp120 on their cell membranes when stimulated [317, 318], the strategy of anti-
Env immunotoxins has also been shown to kill reactivated modeled latently 
infected cells (Brooks 2003).  However, the risks of broadly cytotoxic agents, 
combined with Env's variability, and complications with latent reactivation may 
limit the scope of such approaches. 
 
A peptide triazole (PT) class of entry inhibitors has been identified by our group 
in prior work and found to be able to bind to HIV-1 Env gp120 with nanomolar 
affinity, to suppress protein-ligand interactions of the Env protein at both its 
CD4 and co-receptor binding sites, and to inhibit cell infection by a broad range 
of virus subtypes[6, 10, 23].  Strikingly, we have recently found that a 
multivalent form of the peptide triazole KR13 displayed on gold nanoparticles 
(AuNPs) is able to disrupt virus particles in the absence of host cells, causing 
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leakage of the internal protein p24 and exhibiting strong antiviral activity as 
shown in chapter 3 [8]. 
 
This study reports on the discovery of other special functions of KR13 and its 
multivalent gold nanoparticle conjugate. KR13 and AuNP-KR13 were able to 
inhibit new virus production (vironeogenesis) by HIV-1 infected cells, and 
AuNP-KR13 additionally exhibited cytotoxicity specific against infected 
producer cells. Further developments of AuNP-KR13's cytotoxic effect may lead 
to the capability to target and kill latently infected cells. 
 
4.1.2 Materials and Methods 
 
4.1.2.1 Materials 
 
Modified Human Osteosarcoma Cells (HOS.T4.R5) engineered to express 
CD4 and CCR5, receptor and co-receptor respectively, as well as pNL4-
3.Luc R-E- backbone DNA, were obtained from Dr. Nathaniel Landau.  The 
HOS.T4.R5 cells were grown in DMEM supplemented with 10% FBS, 
2.5% HEPES, 1% Penicillin- Streptomycin, 2% L-Glutamine and 1 mg of 
puromycin. 293T (Human Embryonic Kidney) cells were obtained from 
American Type Culture Collection and grown in the same culture medium 
as the HOS.T4.R5 cells except without puromycin. CHO-K1 gp160 +ve 
cells and regular CHO-K1 cells were obtained from the aids repository and 
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were grown in DMEM supplemented with 10% FBS and 1% Penicillin- 
Streptomycin. The plasmids for HIV-1 BaL gp160 and VSV-G Env DNA 
were gifts from Dr. Julio Martin-Garcia. The antibodies mouse anti-p24, 
rabbit anti-p24, and the protein p24, were from Abcam.  Fully Infectious 
HIV-1 (BaL) was a gift from Dr. Michele Kutzler and obtained from Penn 
Center For AIDS Research (CFAR). The protein gp120 monomer was 
produced using already-established protocols [25], anti-gp120 was from 
Alto chemicals. Gp41 protein, Enfurvitde (T20) and anti-gp41 antibodies 
4E10, 2F5 and 98-6 were from NIH AIDS Research and Reference Reagent 
Program (ARRRP). Enhanced Chemiluminescence western blot detection 
system was from Amersham. O-phenylenediamine (OPD) was from Sigma 
Aldrich.  All other materials were from Fisher Scientific.  
 
4.1.2.2 Production of the peptide triazoles and gold nanoparticle peptide 
triazole conjugate 
 
For this study, we synthesized the peptide triazole denoted KR13, composed 
of the 12-residue amino acid sequence of the previously identified high 
potency peptide-triazole HNG156 [319] with a C-terminal extension 
containing a Cys-SH group. This cysteine-containing derivative was 
selected because the introduced SH group facilitates conjugation to the 
AuNP carriers.   KR13 was prepared by manual solid phase synthesis using 
Fmoc chemistry on a Rink amide resin at 0.25 mmol scale [22]. The amino 
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acid sequence of KR13 is RINNIXWSEAMMβAQβAC-CONH2, where X 
is ferrocenyltriazole-Pro. As control KR13b was synthesized which is the 
KR13 amino acid sequence with an acetomethyl group at the C terminus to 
block the active cysteine (Appendix Fig. 14). The KR13 and KR13b was 
validated for function by conducting a CD4 and 17b competition assay as 
explained in bastian et al. 2011[8].  
 
The gold nanoparticle was synthesized using the Frenz method of citric acid 
reduction of HAuCl4 and for this study we produced AuNPs at 20 nm 
diameter on average . The AuNPs were then stabilized using The 
synthesized particles will be stabilized using Bis-(p-sulfonatophenyl) phenyl 
phosphine dehydrate dipotassium salt (BSPP, Strem Chemicals) and 
transferred into phosphate buffer (pH 7.2) using a Millipore 10,000 MWCO 
filter. The AuNP was validated using dynamic light scattering and the size 
was measured as previously explained in Haiss et al. [8, 284]. The KR13 
was then conjugated onto the AuNP using the cysteine residue by vigorously 
stirring a 1000:1 ratio for 30 minutes at room temperature. The conjugate 
was then stirred at 4°C overnight. The unconjugated peptide was washed off 
using a 100K filter and the sample was resuspended in phosphate buffer (pH 
7.2). AuNP-KR13 coverage density was determined using amino acid 
analysis (Keck Institute, Yale University).  
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4.1.2.3 The effect of peptide triazoles and gold nanoparticle peptide 
triazole thiol on HIV-1 producer cells 
 
The peptide triazoles KR13 and KR13b as well as the AuNP-KR13 
conjugate was validated for their antiviral effects by testing their viral 
infection inhibition  as well as their p24 release profiles as previously 
described in Bastian et al. 2013 and 2011 respectively. Following the effect 
of these inhibitors on HIV-1 BaL pseudotyped producer cells were tested.  
 
3 million human embryonic kidney cells (293T) were seeded onto a T-75 
flask until attached for producing HIV-1 BaL pseudotyped. For recombinant 
pseudovirus production the  pro-viral envelope plasmid sequence used was 
the CCR5 targeting HIV-1 BaL strain and the backbone plasmid sequence 
used was an envelope-deficient pNL4-3-Fluc+env– provirus developed by 
N. Landau [252]. 4 µg of envelope and 8 µg of backbone DNA were co-
transfected into 293T cells using FuGene 6 or polyethylenimine as the 
transfection reagent [253].  Fourteen hours post-transfection, the virus 
producer cells were washed with PBS and detached using 0.05% trypsin. 
The cells are re-seeded onto a 24 well plate at 100,000 cells/ml with 2 mls 
per well. Post 24 hours of re-seeding, the cells were washed with PBS and a 
serial dilution of the inhibitors KR13, KR13b and AuNP-KR13 were added 
1:1 ratio with cell media. The cell supernatants were collected 24 hours post 
inhibitor addition and spun on a 6-20% iodixanol gradient at 30,000 rpm for 
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2 hours at 4°C. The virus fraction (16-18%) was collected and tested for p24 
content, gp120 content as well as tested for viral infection in HOS 
CD4+veCCR5+ve as explained in section 2.2.2.2.  
 
The p24 content was measured using ELISA as explained in section 2.2.3 
and the gp120 content was measured using western blot analysis using 1:10 
dilution of the virus fraction and primary and secondary antibodies, anti-
gp120 D7324 and anti-sheep HRP respectively.  
 
4.1.2.4 Cell viability of the virus producer cells in the presence of the 
peptide triazoles and gold nanoparticle peptide triazole thiol 
 
The virus producer cells once transferred to a 24 well plate and loaded with 
inhibitors KR13, KR13b and AuNP-KR13 as explained above, the 
supernatants were collected and the remainder cells were validated for cell 
viability. The cells were washed with PBS and loaded with 250 µl of the 
Pre-mix WST-1 reagent (Takara Bio Inc.). The reagent was incubated with 
the cells at 37°C for 30 minutes. Following incubation the absorbance was 
read at 450 nm using a plate reader (Tecan Instruments). The absorbance 
value at 450 nm corresponds to the mitochondrial activity of the cell. 
Furthermore, in order to test whether the cytotoxicity observed by AuNP-
KR13 is specific to peptide triazole binding, we tested the effect of KR13 
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and AuNP-KR13 on cells transfected with the infectious, but PT-resistant, 
envelope mutation S375W [24, 25] (Appendix Fig. 17). 
 
4.1.2.5 Effect of the peptide triazoles and gold nanoparticle peptide 
triazole thiol on cells stably expressing gp160 on the surface 
 
In order to understand the mechanism of action of how these inhibitors lead 
to virions produced with no activity it was important to understand on a 
cellular level how they react. In order to test  this, CHO-K1 gp160 +ve cells 
and regular CHO-K1 cells were obtained from the NIH aids repository and 
grown in their growth media at 100,000 cells per well on a 96 well plate. 24 
hours post seeding serial dilution of KR13, KR13b and AuNP-KR13 were 
added onto the cells and incubated overnight. The cell supernatants were 
collected and tested for gp120 shedding using western blot analysis as 
described above. The controls were PBS incubated instead of the inhibitors 
and also the CHO-K1 cells that has no gp160 expression. The cell viability 
was also tested post inhibitor addition as explained above using the pre-mix 
WST-1 reagent.  
 
4.1.2.6 Breadth analysis of new virus formation inhibition by peptide 
triazoles and gold nanoparticle peptide triazole thiol on replication 
competent viruses 
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The virus DNA was obtained from the University of Pennsylvania CFAR as 
a gift from Farida Shaheen. 293T cells were transfected with the virus DNA 
in 24 well plates as described above. The variety of viral DNA used was to 
test for tropism sensitivity as well as clade breadth of this inhibitory effect 
of these peptides and conjugates which included YU2, JRCSF, NL4-3, 
HXBC2 and R3A. Three dilutions of the inhibitors KR13, KR13b and AuN-
KR13 (10 µM, 1 µM and 0.1 µM) were added to the producer cells post a 
PBS rinse. The samples were incubated for 24 hours and the cell 
supernatants were tested for infection on HOS CD4+veCCR5+ve cells. Since 
the produced virions have no luciferase reporter gene in their RNA, the 
following protocol was used for quantification of infection. HOS CD4+ve 
CCR5+ve cells seeded, at 8,000 cells per well in a 96 well plate, were 
incubated for 24 hours followed by addition of cell supernatant collected 
from the 293T cells above.  After 48 hours infection, p24 content of virions 
in the supernatant was measured in order to determine the infection of the 
produced virions. All these experiments suing replication competent virions 
were conducted in a BSL-3 facility.  
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4.1.3 Results 
 
4.1.3.1 Inhibition of vironeogenesis by peptide triazoles and gold 
nanoparticle peptide triazole thiol  
 
The effect of KR13, KR13b as well as AuNP-KR13 on virus producer cells 
was tested in order to check whether these novel inhibitors can target 
multiple stages of the HIV lifecycle. The inhibitors were added to the 
producer cells and the cell supernatants were purified and tested for p24 
content as well as viral infection and gp120 content. As control producer 
cells treated with PBS alone was used. The viral infection and gp120 content 
was tested by using normalized virus containing solution from the p24 
content analysis in order to confirm we are loading equal amount of virus. 
Although, the AuNP-KR13 treated cell supernatants had a reduction in p24 
content and hence we did not normalize the p24 content for the gp120 and 
viral infection analysis. Figure 39 shows the p24 content, viral infection and 
gp120 content on the virions collected post inhibitor treatment. From this we 
clearly see that KR13 and AuNP-KR13 lead to virions that are not infectious 
and also do not contain gp120 on their viral membrane. But the virions still 
have p24 in their viral lumen showing that the mechanism is not the same as 
how the KR13 and AuNP-KR13 target produced viruses (Appendix Fig. 
14). Further even though KR13b does not lead to virions that are non-
infectious, it still has reduction of gp120 on the viral surface (Figure 39C).  
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Figure 39: Anti-viral effects by KR13, KR13b and AuNP-KR13 on virus producer cells. (A) 
Total p24 content in the separated virus fraction from cell supernatants that were treated with 
KR13 (black), KR13b (blue) and AuNP-KR13 (red). (B) Viral infection  and (C) gp120 
content of the of the virus fraction collected post inhibitor treatment of the producer cells, the 
samples were normalized to p24 content prior to addition into HOS CD4+veCCR5+ve cells and 
tested for gp120 using western blot analysis respectively. The IC50 values  for viral infection 
inhibition of produced virions treated with KR13 and AuNP-KR13 are 25.6 ± 3.5 nM and 1.2 
± 0.05 nM respectively. The EC50 of gp120 shedding from the produced virions post KR13, 
KR13b and AuNP-KR13  treatment  are 25.7 ±7.2 nM, 38.7 ± 3.4 nM and  1.8 ± 2 nM 
respectively. Error bars represent the standard deviation of the mean, n = 3. 
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4.1.3.2 Cell viability of the virus producer cells in the presence of the 
peptide triazoles and gold nanoparticle peptide triazole thiol 
 
We tested to see whether the virus producer cells had any toxicity in the 
presence of the inhibitors, KR13, KR13b and AuNP-KR13. In order to test 
this we used the WST-1 pre-mix reagent that forms a formazan product 
based on the metabolic activity of the cells. The results are summarized in 
Figure 40, and show that the cells are nearly 100% viable in the presence of 
KR13 and KR13b but substantially get affected in the presence of AuNP-
KR13. This therefore validates why the p24 content of the virus produced 
from cells treated with AuNP-KR13 have relatively low amount of p24 
(Figure 39A). In order to confirm that the AuNP alone had no effects on 
cell viability, the producer cells were subjected to unconjugated AuNP as 
well as AUNP conjugated to KR13s a scrambled sequence of KR13 that has 
no antiviral activity. The results showed that these controls had no effect in 
cell viability (Appendix Fig. 15).   
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Figure 40: Cell viability of transfected 293T cells which are incubated with KR13 
(black), KR13b (blue) and AuNP-KR13 (red). The samples were tested using WST-1 
reagent and the absorbance measured at 450 nm. The samples were compared to control 
which is PBS treated virus producer 293T cells. Error bars represent the standard 
deviation of the mean, n = 3. 
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4.1.3.3 Peptide triazoles and gold nanoparticle peptide triazole thiol 
functions on cells stably expressing gp160 on the surface 
 
To better understand the mechanism of how the KR13 and AuNP-KR13 
treatment leads to virions that are non-infectious we tested their effects on 
cells expressing the HIV env (gp160). This was done with CHO-K1 cells 
that stable express gp160 trimer. With inhibitor treatment we observed that 
gp120 was shed from the cell surface in a concentration dependent manner 
(Figure 41). From this result we can confirm that the gp120 also is shed 
from virion producer cells upon peptide treatment leading to virions that 
have no gp120 on their surface and thus no infection. Further this also 
validates that the p24 is not released from the produced virions because the 
peptide acts on a cellular level. The AuNP-KR13 treatment although not 
only led to gp120 shedding from the CHO-K1 cell surface but further led to 
cell lysis and thus cell toxicity (Figure 41). The cell viability of CHO-K1 
cells –ve gp160 was also conducted in the presence of KR13, KR13b as well 
as AuNP-KR13. This was a control experiment done in order to test if this 
gp160 shedding is specific and also whether AuNP-KR13 cell lysis is 
specific to cells expressing gp160 (Appendix Fig. 16). From this 
experiment it is evident that the AuNP-KR13 induced cell toxicity is 
specific to cells expressing gp160 on their envelope (Figure 40 and Figure 
41). 
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Figure 41: Effects of KR13, AuNP-KR13 and KR13b on CHOK1 cells stably 
expressing gp160. The dotted lines show the cell viability of the cells when treated for 
24 hours with the inhibitors and post a media change. The cell viability was measured 
using WST_1 Pre-mix reagent and the absorbance read at 450 nm.  The samples were 
normalized from the negative control which was the absorbance measured of cells 
treated with PBS.  The solid lines show the gp120 shedding from the CHOK1 gp160 
+ve cells when treated with the inhibitors for 24 hours. The cell supernatants were 
collected and measured for gp120 using western blot analysis. The positive and 
negative controls include cells treated with 0.1% triton X and cell treated with PBS 
respectively. Error bars represent the standard deviation of the mean, n = 3. 
.  
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4.1.3.4 The new virus production inhibition by peptide triazoles and 
AuNP-KR13 had a broad spectrum against replication HIV-1 
competent virions   
We used a broad spectrum of HIV-1 virions which include YU2 and JRCSF 
(clade B, tier 2 and CCR5 tropic); NL4-3 (clade B, tier 1 and dual tropic); 
HXBC2 (clade B, tier 1 and CXCR4 tropic) and R3A (clade B, tier 2 and 
dual tropic). The results are summarized in Figure 42 and we observe that 
KR13, KR13b as well as AuNP-KR13 all lead to production of non-
infectious virions with all the various virions tested. The virions produced in 
the presence of AuNP-KR13 however had a reduced level of p24 in the 
supernatant showing that there were fewer virions produced compared to 
KR13 and KR13b treated virions. The effect of KR13, KR13b and AuNP-
KR13 had some very interesting differential effects observed between the 
different types of virions tested. First of all R3A which is a lab adapted 
strain had the least effect by the inhibitors compared to other strains and 
JRCSF had the highest effect by KR13 and AuNP-KR13. Further the 
inhibitory action by KR13 and AuNP-KR13 was observed with both the 
dual tropic,NL4-3 and CXCR4 tropic, HXBC2 although AuNP-KR13 action 
was limited in NL4-3.  
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Figure 42: The breadth analysis of KR13 and AuNP-KR13 inhibition of vironeogenesis. (A) Relative 
the viral content of the cell supernatant post 24 hours of treatment of producer cells measured by p24 
quantification. The % p24 was relative to the 100% control which was cells treated with 0.1% triton 
X and 0% control which was producer cells treated with PBS (B) Viral infection of the produced 
virions post 24 hours of inhibitor treatment. The p24 levels were normalized prior to addition to HOS 
CD4+ve CCR5 +ve cells. (C) Cell viability of the 293T transfected cells 24 hours post inhibitor 
addition. Measured using WST-1 Premix and normalized to the untreated cell control incubated for 
the same time. The samples were quantified using p24 content in the cell supernatant 24 hour post 
treatment to measure produced viruses. Error bars represent the standard deviation of the mean, n = 3. 
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4.1.4 Discussion 
 
Previously we have shown that KR13, KR13b and AuNP-KR13 can inhibit viral 
infection with nM potencies and further we have also shown that KR13 and 
AuNP-KR13 have an addition virolytic function [6, 8]. In this study we have 
shown for the first time a class of inhibitors that have multifaceted anti-viral 
functions that target not only inhibition of viral entry and fusion but further can 
inhibit viral propagation by targeting new virus production. We showed that 
KR13 and AuNP-KR13 can target virus producer cells and inhibit new virus 
production. Further AuNP-KR13 showed an addition effect of cell-lysis or 
toxicity of cells that are either producing active HIV-1 virions or have stable 
g160 on the cell surface. This vironeogenesis inhibitory effect of this class of 
peptide triazoles and conjugate had good breadth of action across the replication 
competent HIV-1 viruses and also was specific in action. Therefore is a novel 
inhibitor class that can target multiple stages and hence provide not only 
protection against HIV-1 initial entry but can even limit propagation of the virus.  
 
The 293T cells that were transfected to produce HIV-1 BaL pseudotyped was 
treated with KR13 and AuNP-KR13 and this lead to viruses produced that were 
non-infectious (Figure 39). Although KR13, KR13b and AuNP-KR13 treatment 
led to virions produced with no gp120 on the viral surface only KR13 and AuNP-
KR13 led to virions that were non-infectious. In order to explain this effect it is 
important to know that HIV-1 pseudovirions have nearly 80% of misfolded gp120 
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that are very weakly tethered to gp41 and can be shed off non-specifically or with 
a very slight conformational change[267, 320, 321]. From previous work we 
know that only KR13 and AuNP-KR13 induce virolysis when treated on cell-free 
HIV-1 BaL pseudotyped. Hence the treatment of virus producer cells with KR13b 
might be resulting in shedding off of the misfolded Env protein but keeping the 
functional Env intact which therefore results in infection (Figure 39B).  
 
The cell viability studies conducted show that the KR13 and KR13b treated virus 
producer cells as well as cells that stably express gp160 on their surface had no 
effect of toxicity. But from the results shown in Figure 41 we observe that the 
gp120 is shed from the surface of the CHOK1 cells that stably express gp160, 
which gives us a mechanistic insight to how these inhibitors produce virions that 
are non-infectious. The peptide treatment leads to gp120 shedding from the virus 
producer cells which therefore leads to virions that are budded with no gp120 on 
their surfaces and thus are non-infectious. But as previously explain KR13b might 
be shedding off only gp120 that are misfolded from the virus producer cells and 
thus still leads to budding of virions that are infectious. In order to further test this 
hypothesis, future studies will be focused on understanding the confirmation of 
the shed off gp120 using antibody mapping and mutational analysis.  
 
The AuNP-KR13 treatment however had some interesting observations that 
might give us a better understanding of its mechanism of action. First and 
foremost AuNP-KR13 treatment resulted in virions with much less p24 content in 
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their lumen (Figure 39A). We also observed that AuNP-KR13 treatment of the 
virus producer cells led to cell-toxicity with a CC50 of 232 ± 53 nM. Since KR13 
is decorated in a multivalent fashion around the AuNP, this will result in an 
increased local concentration of KR13 on the cell surface. Previously we have 
found that KR13 and AuNP-KR13 result in virolysis of cell free virus, and so this 
explains why the increased concentration of KR13 on the virus producer cell 
surface by AuNP conjugation might result in cell membrane stress due to poration 
and thus lead to cell lysis which will result in cell toxicity[6, 8]. This result is also 
shown in CHOK1 cells that stably express gp160 on its surface. From Figure 40 
it is evident that the cells start dying only when more than 80% of the gp120 is 
shed from its surface. Therefore the AuNP-KR13 vironeogenesis inhibition 
precedes the cell toxicity effect making this a multi-step inhibitory action. 
Previous studies have found that cells that express gp120 on their surfaces are 
either producer cells or cells that contain latent HIV-1 population [318, 322]. 
Therefore finding an inhibitor that targets this latent population is revolutionary 
and can be extremely advantageous [323].  
 
The KR13 and AuNP-KR13 activity observed in this study is specific as seen in 
appendix Fig. 15 and 16. The breadth analysis conducted showed that these 
inhibitors are broad acting against HIV-1 replication competent virions (Figure 
42). Further we also showed the AuNP-KR13 led to virions with less p24 in the 
replication competent virion lumen as observed in HIV-1 BaL pseudotyped. The 
R3A virus however was not that sensitive to the inhibitory action by KR13 and 
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AuNP-KR13 (Figure 42B). The R3A virion is a lab adapted viral strain and 
usually functions very well with lab developed inhibitors but in this study it was 
the opposite result. This might also be because the inhibitors were developed and 
tested on BaL virions and thus might be more specific to this viral strain. Studies 
will be conducted in the future to identify the genetic difference between these 
viral envelopes that might be showing these differential effects by these 
inhibitors. But all in all it is important to observe that these inhibitors are able to 
successfully lead to non-infectious virions across a panel of virions that are 
otherwise difficult to inhibit. Therefore this study exemplifies the emergence of a 
new class of inhibitors that can target multiple important stages of HIV-1 
infection including; irreversible inactivation of virus, blocking virus entry and, 
stopping new virus formation.   
 
 
4.2 Immunogen creation using the peptide triazole thiol treated residual virion 
 
4.2.1 Understanding the potential of a customizable immunogen creation on the 
HIV-1 epidemic 
 
HIV-1 has been a very difficult virus to completely eradicate due to its high 
degree of genetic diversity and antigenicity. Although there have been many 
trials that have been conducted in order to develop a successful vaccine there is 
still no progress due to the limited neutralizing antibodies developed in this 
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process[182, 324]. The field has now switched focused on controlling viral load 
after infection and reduce secondary transmission [325-328].  This is another 
difficult challenge due to the quick mutations the virus goes through in the host 
cell post infection. Hence it is very important to design vaccines that target sites 
on the virion that is highly conserved through the genetic diversity, close to 
100% [329]. There have been many recent advances in developing immunogens 
against gp120 because this is one of the first viral proteins that are encountered 
by the host immune system [51, 188, 330]. Such an advance is using the new 
gp120 glycan antibody series PGT, but this is still developing and might take a 
long time due to the irregularity of the glycans present on the gp120 protein[188, 
331]. Hence targeting this protein will lead to antibody leads that can be further 
developed. But this glycoprotein goes through several conformational changes 
once in the cell and can hence bypass the immune system attack and reach its 
target cell. And even though studies are currently being conducted with native 
gp140 trimers as the immunogen, it is still very limited in developing 
neutralizing antibodies [332-334]. 
 
Our previous studies have shown that KR13, a peptide triazole thiol lead not 
only to HIV infection inhibition but also to cell-free irreversible virolysis [6, 8]. 
Further we have also demonstrated that the KR13 treated HIV-1 BaL 
pseudotyped residual virion has gp41 still on its surface and is immunoactive 
against the MPER binding site[6]. This therefore has led us to the work in this 
section which focuses on developing the KR13 residual virion as an immunogen. 
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In the vaccine development front, MPER site on gp41 is one of the most 
immunoreactive areas of the virus that has led to several neutralizing antibody 
development such as 2F5, 4E10 and most recently 10E8 [335-339].  
 
In this study we will be focusing on developing an immunogen which can be a 
created from the virions present in an infected individual and hence can be 
tailored to specifically target that viral strain and thus make it custom made for 
each individual. This novel approach will be the start on a revolutionary 
approach for vaccine development in the HIV field due to it surpassing the 
hurdle of HIV genetic diversity by forming a custom immunogen for each 
individual. This preliminary study might also lead to development of new 
neutralizing antibodies that target gp41 and can be further developed to find 
crucial binding sites on gp41 that can be target for creating new microbicides 
and inhibitors of HIV-1.  
 
4.2.2 Antibody epitope exposure mapping of the residual virion post peptide 
triazole thiol virolysis 
 
 
The gp41 epitope exposure was further validated by conducting a gp41 antibody 
mapping experiment. The peptide treated residual virions were fixed using equal 
volume of 0.1% paraformaldehyde and loaded onto an ELISA plate. A panel of 
gp41 antibodies was used in order to test the conformation of gp41 on the 
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residual virion post KR13 treatment as shown in Figure 28B. From this it is 
clearly evident that the MPER is exposed on virions treated with KR13 
specifically. In order to confirm that the immunoactive areas of gp41 are 
exposed on the KR13 a competition experiment was conducted. HIV-1 BaL 
pseudovirions were incubated with a constant concentration of KR13 (1 µM) and 
increasing concentration of 2F5, 4E10 or 10E8 (anti-MPER antibodies) and as 
control 98-6 (anti-gp41 linear epitope) for 30 minutes at 37°C. The samples were 
then either loaded onto HOS CD4+veCCR5+ve cells to test viral infection as 
explained in section 2.2.2.2 using luciferase reporter gene assay or spun on a 
table top centrifuge at max speed (15,600 rpm) for 2 hours at 4°C for p24 release 
analysis.  The supernatants were collected and tested for p24 using a p24 capture 
ELISA as explained in Bastian et al. 2013 [6].  
 
The results are shown in Figure 43, and from this we observe that all the three 
gp41 antibodies that target MPER and are highly neutralizing are able to inhibit 
the KR13 induced p24 release from the HIV-1 BaL pseudovirions. This shows 
that the MPER exposure is important for leakage and further also validates that 
this exposure is specific to KR13 treatment.  
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Figure 43: Testing the specificity of KR13 induced MPER exposure. (A) Effect of KR13 on the 
inhibitory action of the MPER antibodies 2F5, 4E10, 10-E8 and 98-6. The IC50 values of the MPER 
antibodies 2F5, 4E10 and 10E8 are 0.42 µg/ml, 0.78 µg/ml and 0.098 µg/ml and are shown in dotted 
lines. The samples are normalized to the control 100% infection which is virions treated with PBS and 
loaded onto HOS CD4+veCCR5+ve cells. (B) Inhibition of p24 release induced by KR13 (1µM) by 
2F5, 4-E10, 10E8 and 98-6. The samples are normalized to 100% release being the p24 released by 
the HIV-1 BaL pseudotyped treated with 1 µM KR13. . Error bars represent the standard deviation of 
the mean, n = 3. 
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4.2.3 The sample preparation and validation of the immunogen for in-vivo 
studies 
 
In order to start immunogen creation it is important to understand its 
immunoreactivity in vitro. The immunogen was created as explained above by 
using KR13 (1µM) and treating with HIV-1 BaL pseudotyped virions that was 
lab synthesized as explained in section 2.2.2.1. As controls KR13b and PBS 
treated HIV-1 BaL pseudotyped virions were used to confirm the production of 
the immunogen. The virions once synthesized using a co-transfection of the 
HIV-1 BaL envelope plasmid and envelope-deficient pNL4-3-Fluc+env– 
provirus, was purified using a 6-20% iodixanol gradient as shown in Figure 16. 
The peptide and virus was incubated together for 30 minutes at 37°C and then 
purified once again in a 6-20% iodixanol gradient to separate the released viral 
proteins from the residual virion (16-18% iodixanol). The residual virion 
fraction was pooled and buffer exchanged to PBS. The samples were then fixed 
with equal volume of 0.1% paraformaldehyde for 30 minutes at 4°C. The treated 
virus fractions were spun at 16,000 X g for 2 hours at 4°C in an Eppendorf table 
top centrifuge. The resulting collected virus was loaded onto an ELISA high 
protein binding 96 well plate and coated at 4°C overnight. The plate was blocked 
with 3% BSA for 2 hours at room temperature, and then anti-g120 (D7324), 
anti-gp41 (2F5, 4E10 and 98-6), and anti-p24 (ab 93913 – abcam). The gp120 
content and p24 was tested in the residual virion in order to confirm the virus 
was completely inactive. Further the virion was also tested for viral infection in 
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HOS CD4+veCCR5+ve cells as explained above. Further the residual virions was 
tested to see the exposure of gp41 using 98-6 linear gp41 antibody and 
specifically MPER in gp41 using conformational gp41 antibodies, 2F5 and 
4E10.  
 
The results from two batches prepared are shown in appendix Fig. 17 and we 
can clearly see that the KR13 treated virions have very low levels of gp120 and 
p24 while a good amount of gp41 (~500 µg/ml). The gp41 in the KR13 treated 
virions was quantified using anti-gp41 2F5 standard curve (for binding to 
monomeric gp41 protein) and the gp41 in the IV (intact virus) and KR13b 
treated virions was quantified using anti-gp41 98-6 standard curve (for binding 
to monomeric gp41 protein). The samples were then transported for 
immunization in balb/c mice (Jackson Laboratories, Bar harbor, ME) in the 
Kutzler lab. The mice was acclimatized to the facility and stored in a 
temperature controlled, light-cycled specific pathogen free facility at Drexel 
University College of Medicine.  
 
4.2.4 First immunization trial with the peptide triazole treated virions and results  
 
For mouse immunizations, experimental groups (Figure 44) contained 100 μl of 
formulation (Freund’s) as negative control (n=3); 100 μl of PBS containing 22 
μg of either KR13-treated HIV-1 BaL pseudovirus (n=4) or KR13b-treated HIV-
1 BaL pseudovirus (n=4).  100 μl of immunogen was mixed 1:1 with incomplete 
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freunds adjuvant and injected into the right quadriceps muscle using an insulin 
syringe needle (28 g). At endpoints designated in the figure legends, animals 
were sedated using isofluorane, and 200ul of mouse serum was collected on 
awake mice using the submandibular technique as described in animal protocol 
20090.  Immunizations will be carried out separated by 2 weeks.   
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Figure 44: The schematic showing the protocol used for the HIV-1 BaL pseudotyped virions 
deactivated with KR13 or KR13b immunization in BALB/C mice. This also shows in red dots 
where the blood was collected for further analysis. The table below shows the immunological 
activities expected in the groups based of on the proteins reactivity of the residual virions. The 
gp41 used here as control is the monomeric soluble gp41 obtained from NIH aids repository. Data 
adopted from Michele Kutzler 
182 
 
 
The sera were collected as described in figure 44 and they were used to detect 
gp41, gp120 and p24 antibodies. The respective soluble proteins (gp41, p24 and 
gp120 – obtained from NIH aids repository) were coated in an ELISA high 
protein binding overnight at 4°C and the plate was blocked for 2 hours with 3% 
BSA at room temperature. Sera from immunized mice were diluted in blocking 
buffer, added to wells in duplicate, and incubated at room temperature for 2 
hours or overnight at 4°C. Bound antibodies were detected with horseradish 
peroxidase–labeled goat antimouse IgG (Santa Cruz Biotechnology) and 
developed with substrate 3,3′,5,5′-tetramethylbenzidine (TMB) H2O2 (Pierce).  
 
The results are summarized in figure 45. And this first batch shows promising 
results with KR13 residual virions generating anti-gp41 antibodies comparable 
to control gp41 protein which also generates anti-gp41 antibodies. Although this 
was promising we did observe that the formulation used did reduce the 
antigenicity of the residual virions (Appendix Fig. 18). And so for the next set 
of immunizations we switched to footpad injections with no adjuvant addition 
using PFA fixed virus particles. The sera collected from the 2nd and 3rd 
immunizations were also tested for antibodies generated for p24, gp120 and 
gp41 using the capture ELISA as described above. The results are summarized 
in Appendix Fig. 19, and we see that the sera from the mouse immunized with 
KR13 treated residual virion had binding specific to gp41 even at the 3rd 
immunization.  
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Figure 45: Delivery of KR13 treated virus generates anti-gp41 antibodies in mice post 
first immunization. The gp120, p24 and gp41 (1 µg/ml) was coated to an ELISA plate 
and coated overnight. The plate was blocked with 3% BSA and the sera were added at 
1:10 dilution. The antibody binding was detected using horseradish peroxidase–labeled 
goat anti-mouse IgG. Data obtained from Kutzler lab (Michele Kutzler).  
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4.2.5  The future directions and importance of the immunogen work 
 
The figure 45  shows promising results, and currently there is work being done 
in order to study whether the generated antibodies from the final  bleed post the 
first immunization study is MPER specific and neutralizing. In order to detect 
the MPER specific epitopes,  an assay was developed, in which MPER (2 µg/ml) 
is coated in a high-protein binding ELISA plate and incubated overnight at 4°C. 
Following this the plate was blocked for non-specific binding using 3% BSA and 
incubated for 2 hours at room temperature. Serial dilution of the sera was loaded 
for 2 hours to the plate and incubated at room temperature. The samples were 
then detected using anti-mouse HRP (Santa Cruz Biotechnology). The find out 
whether the MPER antibodies generated is neutralizing two different assays 
were designed and performed. The first assay was a competition ELISA in 
which the MPER was coated on an ELISA plate as explained above. The plate 
was blocked with 3% BSA and serial dilution of the sera was loaded with equal 
volume of anti-gp41 antibodies, 2F5, 4E10 and 10E8 (MPER specific) at 1µg/ml 
concentration. The samples were incubated for 1 hour at room temperature, 
following addition anti-human HRP (EMD Millipore) specific to the MPER 
antibodies. The preliminary results are shown in Figure 46. From this it is 
clearly evident that the KR13 treated residual HIV-1 BaL pseudotyped 
immunization in Balb/c mice is able to generate antibodies specific to MPER 
(Figure 46A). The competition assay done with MPER specific antibody 2F5 
and the sera generated from the different immunogens showed that the sera from 
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the gp41 protein and the residual virion post KR13 treatment had competition 
with 2F5 (Figure 46B).  
 
From these results it is evident that the KR13 treated residual virion is a custom 
made immunogen that leads to generation of MPER specific antibodies. 
Currently work is being conducted to test the neutralization of HIV-1 BaL 
infection of HOS CD4+veCCR5+ve cells. These astounding results can lead to the 
initiation of a study that can produce immunogens using the virions that are 
already in patients that are infected and thus stop AIDS progressing and 
eventually suppression.  
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Figure 46: Characterization of the sera obtained post immunization of formulation, gp41 protein, 
residual virion post KR13 (1 µM) and KR13b (1 µM) treatment. (A) ELISA results showing sera 
binding to MPER (n=6). (B) ELISA results showing dilution of sera competing with 2F5 anti-gp41 
antibody (1ug/ml) to MPER. The number of animals bled for formulation group (n=4), gp41 
protein (n=5), KR13 treated residual virion (n=6) and KR13b treated residual virion (n=6). Data 
obtained in collaboration with Michele Kutzler 
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4.3 Effect of virolytic agents on capsid mutants and immature virus particles 
 
4.3.1 Effect of capsid stability on the HIV-1 virolytic effect by KR13 and 
AuNP-KR13 
 
From previous studies and the studies in this thesis we have shown that a class of 
peptide triazoles known as peptide triazole thiols led to virolysis of HIV-1 which 
is measured by p24 release from the viral core[6, 8]. Further we also showed that 
the multivalent conjugate of the peptide triazole thiol, AuNP-KR13 led to the 
same HIV-1 virolysis but at a much lower concentration of the inhibitor [8]. The 
mechanism of HIV-1 virolytic activity observed by peptide triazole thiol, KR13, 
has been shown to follow a pathway in which it hijacks the viral-cell fusion 
mechanism. The mechanism of virolytic activity observed by AuNP-KR13 
however is a much more physical action on the virion that leads to complete 
obliteration of the virus.  
 
This study was conducted in order to better understand whether the p24 released 
by KR13 and AuNP-KR13 is from the intra-viral space between the membrane 
and the viral core or whether it is specifically released from the viral core. The 
average HIV-1 virion has been shown to have from 1500- 3000 molecules of p24 
[340-342]. Previous studies have shown that the viral capsid contains only 10-
20% of the total p24 content of the virion and the remaining is in the intra-viral 
space between the viral matrix and the core[343-345]. The HIV-1 capsid core 
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(CA) consists of a total of 231 residues of the hexamers of p24 and 6 pentamers 
that are connected using a flexible linker. Interactions between the N-terminal 
domains (NTDs) form hexamers through an intersubunit NTD-NTD interface, 
while the C-terminal domains (CTDs) form dimers that connect adjacent 
hexamers through a CTD-CTD interface[341, 342, 346, 347].  
 
Therefore in this study we will be using the previously known mutants of the 
capsid in between the NTD-NTD (E45A) interface and the CTD-NTD interface 
(E213A) in order to make the capsid core much more stable and thus test the 
effect of this on the release p24 by KR13 and AuNP-KR13 [343, 344, 348]. From 
this study we observed that the making the HIV capsid led to a drastic reduction 
in the p24 released by KR13. This effect however was not observed with AuNP-
KR13 which even though had a slight reduction still led to approximately 70% 
p24 release with both the core stability mutations.  
 
 
4.3.1.1 Materials and Method 
 
Materials 
 
For peptide triazole thiol preparation, the protocol was followed as 
previously explained [6, 8]and the reagents were purchased from Chem-
Impex International Inc, Ethynylferrocene and Cu(I)I was purchased from 
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Sigma-Aldrich and used without further purification. Fmoc-cis-4-
azidoproline was synthesized starting with commercially available trans-
Hyp-OH [22]. Gold (III) chloride hydrate and citric acid were procured 
obtained from Sigma-Aldrich, Bis (p-sulfonatophenyl) phenylphosphine 
dehydrate dipotassium salt (BSPP) from Strem Chemicals. Modified human 
osteosarcoma Cells (HOS CD4+ve CCR5+ve) engineered to express CD4 and 
CCR5, receptor and co-receptor respectively, as well as pNL4-3.Luc R-E- 
backbone DNA, were obtained from Dr. Nathaniel Landau.  The 
HOS.T4.R5 cells were grown in DMEM supplemented with 10% FBS, 
2.5% HEPES, 1% Penicillin- Streptomycin, 2% L-Glutamine and 1 mg of 
puromycin. 293T cells were obtained from American Type Culture 
Collection and grown in the same culture medium as the HOS.T4.R5 cells 
except without puromycin. The plasmids for HIV-1 BaL-01 gp160 and 
VSV-G Env DNA were from the AIDS Research and Reference Reagent 
Program (ARRRP). The core mutant plasmids E213A and E45A and the 
immature virion core plasmids MA/P6, MA/P6 ΔE, NL4-3 ΔPro were 
obtained from Dr. Christopher Aiken from Vanderbilt University. The 
antibodies mouse anti-p24, rabbit anti-p24, and the protein p24, were from 
Abcam. Enhanced chemiluminescence western blot detection system was 
from Amersham. O-phenylenediamine (OPD) was from Sigma Aldrich.  All 
other materials were from Fisher Scientific. 
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Methodology 
 
In order to test the effects of the capsid stability, HIV-1 BaL pseudotyped 
containing the core mutants were produced using the virus production 
protocol as mentioned above. 4 µg of envelope (BaL-01) and 8 µg of 
backbone DNA (NL4-3 WT, E213A and E45A were co-transfected into 
293T cells using FuGene 6 as the transfection reagent [253].  Fourteen hours 
post-transfection, the medium was changed, and subsequently the VLP-
containing supernatants were collected at 48 hours post transfection.  The 
VLP-containing supernatants were cleared using a 0.45 µm syringe filter and 
purified further by spinning the sample on an iodixanol gradient, using a 
Hoefer continuous gradient maker, ranging from 6 - 20 % iodixanol, at 
30,000 rpm for 2 hours at 4 °C.  
 
In order to test the effect of the core stability, serial dilution of the peptide 
KR13 and AuNP-KR13 were incubated with a known concentration of the 
virions for 30 minutes at 37°C. The samples were then spun at max speed on 
a table top centrifuge for 2 hours at 4°C. The supernatant was collected and 
quantified for p24 using a capture ELISA as explained in section 2.2.3. As 
negative and positive controls the viruses are treated with PBS alone and 
0.1% triton X respectively. In order to validate this effect is specific, the 
effect of VSV-G virions produced with the core mutants were also tested for 
p24 release with KR13 and AuNP-KR13.  
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4.3.1.2 Results 
 
The effect of the capsid mutation on the KR13 and AuNP-KR13 p24 release 
are summarized in Figure 47. From this we observe that the p24 release 
induced by KR13 on the HIV-1 virions is severely affected by both the 
E45A and the E213A. While for the p24 release by AuNP-KR13 was not 
affected as much by the E213A mutation compared to E45A. The VSV-G 
enveloped virions with the core mutants and WT had no effect and did not 
lead to p24 release with KR13 or AuNP-KR13 treatment. Further we also 
saw that the mutants had very minimal levels of viral infection which is 
concurrent with the data observed previously with these mutants due to the 
stability of the cores [343, 344].  
 
4.3.1.3 Discussion 
 
From the results we observe that the core mutants of HIV-1 which make the 
core more stable leads to reduction in levels of p24 released. The interesting 
factor is that the core is made up of only approximately 10-20% of the total 
p24 content in a virion and the core mutants E213A and E45A lead to the 
core containing 30% and 40% of the total p24 content[343, 344]. As 
observed by Figure 47A, the p24 release in the virion with the E45A mutant 
is much more stabilizing compared to E213A of the core. While the AuNP-
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Figure 47: The effects of core stability on KR13 and AuNP KR13 induced p24 release on HIV-1 
BaL pseudotyped.  The p24 release induced by KR13 (A) and AuNP-KR13 (B) on HIV-1 BaL WT 
compared to the core mutant virions E45A and E213A. The VSV-G enveloped WT virus and its 
core mutants were also tested for KR13 (C) and AuNP KR13 (D) induced p24 release. The controls 
used was 100% release which was virions treated with 1% triton X and 0% release as virions 
treated with PBS alone.  
KR13 induced p24 release is not that affected by the E213A mutant 
compared to the E45A mutant (Figure 46B).  
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The E213A mutation is in the helix 10 of the CTD of the capsid dimer and 
leads to a stronger bond between the two dimers in the hexameric lattice 
which E45A is a mutation in the helix 2 of the NTD of the capsid hexamer 
and this makes the interactions between the hexamers much more stronger 
keeping the core structure hyperstable[343, 344]. From the results it is 
clearly visible that the stability between the dimers of p24 protein in the 
hexameric lattice is much more important than the stability of the core itself. 
Further this effect is specific as seen by the VSV-G controls in which the 
KR13 and AuNP-kR13 treatment has no effect on the p24 release (Figure 
47C and D).  
 
4.3.2 Peptide triazole thiol effects on immature HIV-1pseudotyped virions 
 
In a HIV-1 virus lifecycle, post budding of new virions from the host cell, the 
virus undergoes a maturation process in order to become completely infectious. 
The immature virion is much thicker and has a hard gag shell that makes the 
virion much stiffer and will not be able to infect a new cell [295, 341, 349, 350]. 
The Figure 48 shows the structure of the immature compared to the WT and 
shows how much stronger the viral shell of the immature virus is (3.1 N/m 
stiffness) compared to the mature virus (0.2 N/m stiffness)[295].  
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Figure 48: The characteristics of immature HIV-1. (A) Schematic representation of the 
HIV gag with matrix protein (MA) in blue, capsid protein (CA) in red and nucleocapsid 
(NC) in green. (B) The model of the immature (left) and mature (right) virion and the 
location of the gag proteins in both these virions. (C) Average point stiffness of different 
variation of HIV-1. The stiffness is a mean value (~100 FD curves) of the total number of 
virions analyzed per sample (number shown in the bars).  
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In order to produce these immature particles there are two plasmids that were 
given to us as a gift from Dr. Christopher Aiken. These were the NL4-3 MA/P6 
core plasmid and the NL4-3 ΔPro. The MA/P6 contains substitutions preventing 
cleavage of the major Pr55Gag cleavage sites but encoding a wild-type PR 
sequence.  This mutation has shown to produce immature particles that are non-
infectious and have a defective gag preventing correct protease cleavage action 
[351-353]. The other plasmid NL4-3 ΔPro is the core plasmid with no protease 
gene and thus will lead to production of immature particles [354-356]. Therefore 
both these mutants lead to virions that are immature with very rigid viral shells 
and are non-infectious.  
 
In this study we will be testing whether these immature HIV-1 particles are lysed 
by KR13 or AuNP-KR13 just like the regular wild type BaL virion. This was 
conducted in order to understand whether the virus leakage induced by these 
virolytic agents depends on the stiffness of the viral membrane. The results show 
that this effect is indeed dependent on the virus stiffness for both KR13 
treatment and AuNP-KR13 treatment. Further this gives us insight on viral 
envelope incorporation on immature virus and how this affects the amount of 
leakage observed with KR13 and AuNP-KR13 treatment.   
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4.3.2.1 Materials and Methodology 
 
4.3.2.1.1 Production and validation of the immature HIV-1 virions 
 
The virions are produced as previously described by using co-transfection 
of 4 µg of HIV-1 BaL-01 envelope plasmid DNA and 8 µg of backbone 
DNA (NL4-3 WT, NL4-3 MA/P6, NL4-3 MA/P6 Δenv, NL4-3 ΔPro, NL4-
3 ΔPro ΔEnv). The cells used for virus production was the 293T cells 
seeded at 3 million cells in a T75 flask. The cell supernatant were collected 
48 hours post incubation at 37°C and purified using 6-20% iodixanol 
gradient as explained above. The viruses were collected in the virion 
fraction (16-18% iodixanol) and the buffer was transferred to DMEM. The 
virions were then validated by testing its p24 content using a capture 
ELISA as explained above, and tested for virus infection of TZMB1 cells. 
Since the backbone DNA plasmid used to produce the virions did not 
contain the luciferase reporter gene we used TZMB1 cells which contains a 
tat promoter gene that provides luminescence upon HIV-1 infection to 
quantify infection[357].  
 
4.3.2.1.2 KR13 and AuNP-KR13 treatment of immature HIV-1 virions 
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The produced virions were normalized for their p24 content and a serial 
dilution of KR13 or AuNP-KR13 were incubated with the virus for 30 
minutes at 37°C. The samples were then spun on a table top centrifuge at 
max speed (15,600 rpm) for 2 hours at 4°C. The supernatants were 
collected and tested for p24 using a capture ELISA method. The controls 
included 100% release which was virions treated with 0.1% triton X and 
0% release which was virions treated with PBS alone. The values were 
calculated and plotted using Origin Pro. 8.  
 
4.3.2.1.3 Testing the amount of Env incorporation and its dependence on 
p24 leakage induced by KR13 and AuNP-KR13 
 
From the results we observed that the p24 release induced by KR13 and 
AuNP-KR13 was reduced by the immature virions. Hence we conducted a 
western blot analysis of the amount of gp120 present in these immature 
virus particles. The virions were normalized to their p24 content and loaded 
into an SDS page gel (10%) and detected using anti-gp120 D7324 and 
secondary antibody anti-sheep HRP. Therefore we produced regular wild 
type virus particles with reduced amounts of Env incorporation by reducing 
the concentration of Env plasmid DNA used during transfection. This 
therefore resulted in virions with reduced level of spikes (Figure 50A).  
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4.3.2.2 Results 
 
4.3.2.2.1 P24 release induced by KR13 and AuNP-KR13 on immature 
HIV-1 virus particles 
 
Figure 49 shows that the p24 release induced by both KR13 and AuNP-
KR13 is completely suppressed in the both the MA/P6 and NL4-3 ΔPro 
immature HIV-1. The virions were normalized for the p24 content prior to 
the leakage assay. From this it is clearly evident that the immature virions 
are too stiff for the virolytic action of both KR13 and AuNP-KR13. AuNP-
KR13 does have a low amount of release (20%) at the highest concentration 
(5 µM KR13). Therefore this shows that the AuNP-KR13 action is much 
more vigorous that the KR13 alone leading to poration of the immature 
viral membrane which is nearly 10 times stiffer that the regular WT HIV-1 
membrane (Figure 48C).  
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Figure 49: The p24 release induced by KR13 (A) and AuNP-KR13 (B) on immature virions 
compared to BaL-01 wild type control. The p24 content of the virions are normalized prior to 
experiment. The 100% p24 release control is virions treated with 0.1% triton X and 0% 
control is virions treated with PBS alone. n=-1 
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4.3.2.2.2 HIV-1 Env incorporation in the viral membrane and its 
dependence on virolysis induced by KR13 and AuNP-KR13 
 
The gp120 content in the immature virions are quantified using western blot 
analysis and the results are summarized in figure 49A. This shows that 
there are very low levels of gp120 in the immature virions. Since KR13 and 
AuNP-KR13 binds to gp120 and then proceeds to p24 release, if the level 
of gp120 is lower this might impact the p24 release profile. In order to test 
this, we produced HIV-1 BaL WT with reduced levels of gp160 by 
reducing the Env DNA. The Figure 50B shows the characterization of the 
HIV-1 BaL WT with reduced levels of spikes. The amount of spike 
incorporation was validated from the gp120 content and compared to a 
standard curve of monomeric gp120.  The Figure 50C shows that the 
virolytic activity of the KR13 and AuNP-KR13 on the HIV-1 virion 
reduces with reducing level of with the spike incorporation.  
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Figure 50: gp120 quantification and spike density variation of BAL-01 WT HIV-1. (A) 
The gp120 quantification of the gp120 on the viral surface of BAL-WT compared to 
NL4-3 ΔPro and MA-P6 mutant. The antibody used for gp120 detection was D7324 and 
secondary antibody, anti-sheep HRP. (B) The characterization of the HIV-1 BaL virions 
with varying spike density which was quantified based on the western blot analysis from 
the inset shown. The p24 was quantified using anti-p24 (ab9313) and gp41 using anti-
gp41 (98-6) and their respective secondary antibodies using ELISA analysis. p24 release 
profiles of  KR13 (C) and AuNP-KR13 (D) treatment with HIV-1 with varying spike 
density. The values were plotted using Origin Pro 8.0 and the error bars represent 
standard deviations of n=3. 
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4.3.3 Discussion 
 
The results in this study have shown several important characteristics of the 
virloytic activity observed by KR13 and AuNP-KR13 that will give more insight 
to the mechanism of this activity. The results show that KR13 and AuNP-KR13 
p24 release is diminished with the p24 core mutants as well as immature virions. 
This shows that the p24 release by KR13 and AuNP-KR13 depends on the 
stability of the viral core and stiffness of the viral membrane. Previously we 
have shown that the KR13 induced p24 release is caused by hijacking the viral-
cell fusion mechanism, and previous studies have shown that the immature 
virions and hyper stable core mutants have no infection[6, 344, 349, 351, 357]. 
Therefore since these mutants limit viral entry to host cell and also inhibits 
KR13 dependent virolysis this confirms that both these actions are correlated.    
 
The results of the core mutants show that KR13 induced virolysis has a different 
mechanism compared to the AuNP-KR13 induced virolysis. The AuNP-KR13 
virolysis is not affected when the dimers in the capsid is mutated to have an 
electrostatic bond making it hyperstable, while when the capsid has a mutation 
to make the bond between the hexamers stronger, this led to reduction in p24 
release. But for KR13 induced virolysis both the mutants that made the capsid 
core stable reduced the p24 release dramatically. It is known that capsid core 
contains only around 20% of the total p24 content in the virus, and when the 
core is hyperstable the core contains max 40% of p24 [343-345, 351]. Therefore 
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from this we can conquer that the AuNP-KR13 poration is much larger than the 
pore formed with KR13 on the HIV-1 viral membrane. This can be further 
explored by studying mutants in the core like L203A and Q219A which are 
capsid destabilizing and L49D which disrupts the interaction between gp120 and 
gp41[343-345, 358].  
 
The stiffness of the immature HIV virions is 10-20 fold more stiff than the HIV-
1 BaL wildtype. The MA-P6 mutation still has the protease enzyme but has a 
defective gag protein and thus cannot lead to complete protease digest and hence 
will not form mature infectious virions[351-353]. The NL4-3 ΔPro virions are 
completely immature because with the protease enzyme they will not be able to 
mature [351, 354, 356]. The slight activity of AuNP-KR13 with MA-P6 shows 
that the gag deficiency is not as effective as the protease deletion to inhibit 
virolysis. Previous studies have shown that the defective gag MA-P6 mutation is 
not as stiff as the protease deleted virus but both of these mutations are much 
stiffer than the regular HIV WT [350, 359]. Hence AuNP-KR13 virolytic 
process is stronger and can induce a pore even on viral membranes that can be 
much stiffer. Future work will be focused on testing mutations that alter the viral 
membrane rigidity such as the cytoplasmic tail deletion of gp41 and also using 
protease inhibitors to test their effect on AuNP-KR13 induced virolysis [350, 
360, 361].  
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This unique action by KR13 can be used to study several unknown aspects of 
fusion as well as maturation that still need a lot attention. Further the virolysis by 
AuNP-KR13 is so strong that it forms much larger pores making it a much more 
effective inhibitor. This design therefore can be emulated on other inhibitors that 
have low inhibitory effects and can be used to enhance their effect by 
conjugating to AuNP. This therefore provides new insight into understanding the 
virolytic activity by peptide triazole thiols and further lead to potent microbicide 
development that can target multiple stages of the virus lifecycle making this a 
different form of combination therapy.  
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CHAPTER 5: FUTURE DIRECTIONS  
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5 Introduction 
The work elaborated in this thesis has led to several novel discoveries and further 
several methodologies that are very valuable for the virology field. The discoveries in 
this work have led to 5 research grant proposal of which 3 grants that have awarded 
as well as the Schlumberger Fellowship which I obtained to complete my work. One 
of the most novel discoveries in this work was the discovery of a new class of peptide 
triazoles that have additional virus breakdown effects including gp120 shedding and 
p24 release leading to complete virus lysis. The other discovery was the development 
of a multivalent construct of the peptide triazole that led to several rules that can be 
translational in the biology and engineering field. The AuNP-KR13 size and density 
dependent analysis led to the layout of rules necessary for developing one of the most 
potent inhibitors by using multivalent displays. This work has also led to the one of a 
kind immunogen that is the first immunogen that can be custom made for each 
infected individual that can lead to generation of antibodies specific to the 
immunodominant viral protein, gp41. Further the inhibitors developed here can target 
multiple stages of the HIV-1 lifecycle involving entry, fusion, vironeogenesis as well 
as latent population of the virus. This composition of work therefore has led to 
microbicide, immunogen as well as multivalent drug like construct development that 
can help reduce the viral load and further lead towards eradication of HIV-1. Even 
though several interesting projects that have high potential have been developed in 
this thesis, there is still a lot of work to be done in order to lead these projects in the 
right direction to further develop them into innovative products and methodologies 
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that can be great contributions toward one ultimate goal, hinder HIV spread and 
eventually eradicate this life threatening disease.  
This section therefore is dedicate to giving suggestions and ideas for each of the 
discoveries made through this thesis work in order to direct it in the right direction it 
further.  
 
5.1 Peptide triazole thiols 
 
Peptide triazole thiol was first developed as one of my projects with the help of Dr. 
Kantharaju Kammana a post doc in our lab. This was initially synthesized in order to 
conjugate to gold nanoparticles (AuNPs) in order to form a multivalent construct and 
thus enhance its potency. Although this was eventually achieved and we obtained 
over 20 fold enhancement of potency by using 20 nm AuNP, we also discovered the 
unique feature of this peptide. This was the irreversible lysis of the HIV-1 virion 
leading to p24 release from the virus core. This opened up the pathway to several 
other discoveries that are spelled out in this thesis. So far we have come to several 
conclusions a) the p24 release by KR13 is specific to HIV and irreversible. b) the 
thiol on the peptide is very important for its virolytic activity c) the peptide 
dependent HIV virus lysis follows a kinetic and biochemical pathway very similar to 
HIV-cell fusion (Table 5). d) This action is broad and is also effective for founder 
virions, and e) The residual virion post peptide induced lysis is highly immunoactive.  
 
The future directions that can be envisioned for peptide triazole thiols are as follows:  
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5.1.1 Structural understanding of the importance of thiol on peptide triazole 
thiol for HIV-1 virolysis 
 
This involves understanding specifically where the peptide triazole thiol 
(PTT) binds on gp120 and how it triggers this cascade action on the viral 
spike that later on translates to the viral membrane leading to poration. 
Also it is important to track the peptide thiol during this virolysis event in 
order to study the fate of the peptide which might help with the 
understanding the mechanism of action. Structural docking studies 
alongside mutational studies altering the disulfide on gp120 and studying 
the binding of PTT to gp120 will help better understand the importance of 
thiol.  
 
5.1.2 Study the 6 helix bundle formation post peptide triazole thiol induced lysis 
and compare it to virus-cell fusion 
 
The next important work to be conducted is to understand the 6 helix 
bundle formation during virolysis and compare it to virus-cell fusion. This 
will not only give us a better understanding of the virolysis mechanism but 
also shed light on how the virus-cell fusion takes place. This can be 
achieved by conducting mutational analysis on the different regions of 
gp41 that are important for the fusion process and are known to help with 
this process and see how this affects peptide induced virolysis. The next 
step would be to understand how fusion inhibitors that target different 
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established sites on gp41 and test how they affect peptide induced 
virolysis. Temperature arrest studies can be conducted in order to freeze 
the virolytic process at different stages and use antibody mapping and 
fusion inhibitors to understand the conformational changes of gp41 to 
breakdown the virolytic/poration process.  
5.1.3 The role of the HIV-1 membrane during peptide triazole thiol induced 
virolysis:                                                   
Post PTT treatment, HIV-1 goes through a sophisticated breakdown 
process, and the least explored arena is the alterations in the HIV-1 
membrane during this. Hence it is important to focus on the viral 
membrane, alter the membrane properties and study how this affects the 
poration process. Studies need to be conducted to test how the virion goes 
through the energy barrier required for the poration process [362, 363].   
 
5.1.4 Breadth of action of the peptide triazole thiol induced virolysis 
The breadth of the PTT induced virolytic event not only on replication 
competent but also primary isolates as well as patient samples at different 
stages of AIDS need to be conducted in order to better understand the 
overall breadth of this unique effect. This work therefore will not only 
provide a complete mechanistic breakdown of the virolytic process 
induced by KR13 but also give critical information of the HIV-1 – cell 
fusion which will be very important and valued by the scientific 
community.  
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The Figure 51 shows a breakdown of the studies that can be conducted in the 
future in order to better understand KR13 induced HIV-1 virolysis.  
 
 
 
 
Figure 51: Schematic showing the future directions of peptide triazole thiols. TAS- 
Temperature arrest state, 6HB- 6 helix bundle.  
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5.2  Gold Nanoparticle peptide triazole thiol 
 
The gold nanoparticle peptide triazole thiol was developed to create a multivalent 
conjugate in order to enhance the potency of the peptide triazoles. The multivalent 
conjugate was first created with 20 nm AuNPs and KR13 and this led to 
approximately 20 fold enhancement of KR13 antiviral potency. But in this work we 
discovered that AuNP-KR13 conjugate can also lead to p24 release and complete 
destruction of the HIV-1 virion. The mechanism by which the AuNP-KR13 leads to 
virolysis is completely different from the mechanism of KR13 dependent virolysis 
(Table 10). This therefore made me further explore this multivalent effect, which led 
to one of the most potent inhibitors ever created in our lab with a low picomolar IC50 
and EC50 of viral infection inhibition and viral p24 release respectively. The 
multivalent gold nanoparticle could be a prototype for enhancing other inhibitors that 
target virus or cell surface. This therefore led to a revolutionary discovery that can 
now guide future nanomedicine and develop nanocarriers that are efficient and can 
maximize their potential.  
 
5.2.1 Changing the nanoparticle backbone to a more biocompatible design 
 For future work on the development of the gold nanoparticle peptide triazole 
 thiol, it is important to identify a more biocompatible nanoparticle core that 
 maintains the same rigidly gold. Previous studies in our lab have shown that soft 
 core nanoparticle do not lead to the potent p24 release but still have infection 
 inhibition enhancement when peptides are decorated around its surface. Therefore 
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 materials like chitosan or stiff polymers can be used as alternatives to create 
 nanoparticle-peptide conjugates so that it can be as potent as gold nanoparticles 
 but can be used in clinical trials. It is also important to better understand the 
 mechanism of action of AuNP-KR13. Since AuNP has an advantage of high 
 electron density, it can be used as a marker in electron microscopy studies in 
 order to study the transformations of the virions post AuNP-KR13 treatment in 
 super resolution.  
 
5.2.2 HIV-1 membrane changes post AuNP-KR13 treatment 
  Further understand the membrane disruptions the virion goes through and the 
 stress induced on the viral membrane surface that leads to poration and complete 
 irreversible lysis.  
5.2.3 Further development of other anti-viral effects of AuNP-KR13 
 Another very interesting development in this thesis was the cell toxicity effect 
 by the AuNP-KR13 on cells expressing gp120. This might be very  advantageous 
 because this could be used to target one of the most difficult HIV-1 
 populations – the latent virions [364-366] which should be further explored. 
 Mutational analysis as well as breadth analysis is also important in order to 
 further understand the mechanism by which the AuNP-KR13 leads to poration of 
 the virion.  
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5.2.4 Future of AuNP-KR13 
 The work developed here is the preliminary steps for the creation of a 
 preventative drug design that can target the virion at the entry site. Therefore this 
 once this effect is reproduced in a much more biocompatible nanoparticle 
 construct with a much more efficient PTT (eg. peptidomimetic), it can be 
 developed into a preventative drug. For this it is best to be put the nanoparticle 
 construct in either a gel or film construct that is pH sensitive, and can lead to a 
 slow release of the nanoparticle conjugates during entry of the virion [367].  
 
Figure 52 has summarized the future directions of AuNP-peptide triazole thiol 
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5.3 The immunogen creation with the peptide triazole thiol 
 
The results from the peptide triazole thiol treatment of HIV-1 also lead to an striking 
result, the antigenicity of the residual virion. The residual virion post KR13 treatment 
had gp41 on the viral membrane that was immunologically active. Initially this the 
observation of this activity was set aside in order to better understand the mechanism 
of virolysis, but once the high binding of the gp41 to already known neutralizing 
antibodies of gp41 2f5 and 4E10 this had to be further explored. There are very few 
Figure 52: Schematic showing the future directions of AuNP-KR13. NP- 
nanoparticle 
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immunogens that are currently being created in order to be used to generate 
antibodies that can target this high genetically variant virus [368]. Therefore there is 
an urgent need to develop an immunogen that can generate broadly active 
neutralizing antibodies in humans against infection of a broad range of HIV-1 
subtypes. This project is still taking in its preliminary stages but the results are very 
promising. Hence it is important to explore further the immunoreactivity of the 
residual virion post peptide triazole treatment. This study introduces the concept of 
custom made immunogen in which the infected host’s virions are used to boost their 
immune reaction against the disease progression. In order to confirm that we are 
generating neutralizing antibodies it is important to explore the exact site to which 
these antibodies are generated. DNA priming is another technique that is currently 
initiated in the third set of immunization studies to boost the immune response 
against the residual virion and thus generate larger titers as well as a broad range of 
antibodies against the native gp41 on the virion with no modifications.  
 
To summarize, the scheme below represents the future directions of each individual 
concept revealed in this thesis. The peptide triazole thiols and the gold nanoparticle 
peptide triazole thiol conjugates are the first generation of virolytic agents that are 
broadly active, can inhibit multiple stages of the virus lifecycle and are highly potent. 
These agents can be used as leads for developing more stable versions which can be 
sustained in the body and can be used either as microbicides or as preventatives for 
PreP (Pre-exposure prophylaxis). The immunogen creation is still in development but 
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once the preliminary data is established, it is a project with high potential for the 
future of HIV-1 infection prevention (Figure 53).  
 
 
Figure 53: Schematic summarizing the potential future directions of the lead drug 
candiadates developed in this thesis against HIV-1 infection 
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TABLES 
Table 1: Potencies of inactivation and breakdown of BaL HIV-1 pseudotyped and 
replication competent virions by peptide triazoles.  The extents of loss of cell infection, 
p24 release and gp120 shedding were measured for KR13, KR13b, KR13s and HNG156 
treatment of BaL pseudovirus.  * Designates the EC50 and IC50 values of the viral 
infection inhibition, gp120 shedding and p24 release, respectively, obtained for fully 
infectious HIV-1 BaL virions induced by KR13 and HNG156.  All of the IC50 and EC50 
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values were determined from dose response profiles (Figure 17 and Appendix Fig.1 ) 
using Origin Pro.8 (Origin Lab). ± designates the standard deviation of the mean, n > 3. 
 
 
 
 
 
 
 
 
 
 
Peptide Viral Inactivation 
EC50  (nM) 
p24 Release 
IC50 (nM) 
gp120 Shedding 
IC50 (nM) 
HNG156 803 ± 120 
*5500 ± 1100 
>500,000 
*>200,000 
500 ± 230 
*1800 ± 1000 
KR13 23 ± 45 
*639 ± 71 
500 ± 80 
*4400 ± 930 
32 ± 20 
*1200 ± 930 
KR13s >500,000 >500,000 >500,000 
KR13b 52 ± 35 >100,000 120 ± 43 
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Table 2: Potencies of effects of fusion inhibitors on inactivation and breakdown of BaL 
HIV-1 pseudotypedvirions by peptide triazoles.  The extents of loss of cell infection and 
p24 release for T20, C34, C37, N36 and 5 Helix treatment of BaL pseudovirus with or 
without KR13 are summarized.  All of the IC50 and EC50 values were determined from 
dose response profiles (Figure 26) using Origin Pro.8 (Origin Lab). ± designates the 
standard deviation of the mean, n > 3. 
FUSION 
INHIBITORS 
IC50 OF VIRAL INFECTION 
INHIBITION 
EC50 OF P24 RELEASE 
WITHOUT 
KR13 (NM) 
WITH 500 NM 
KR13 (NM) 
WITHOUT 
KR13 (NM) 
WITH 1 µM 
KR13 (NM) 
T20 8.2 ± 1.2 < 0.001 > 5000 0.5 ± 0.2 
C34 NA NA > 5000 7.84 ± 1.8 
C37 65.7 ± 4.6 ~ 0.001 > 5000 3230 ± 800 
N36 107.3 ± 24.2 ~ 0.01 > 5000 3.23 ± 0.8 
5 HELIX 4.5 ± 0.4 <0.001 > 5000 0.26 ± 0.8 
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Table 3: Antibody panel against gp120 and their binding sites. The dilution that is 
specified in the third column is the dilution used for the antibody mapping in Figure 28. 
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Table 4: Antibody panel against gp41 and their binding sites. The dilution that is specified in the 
fourth column is the dilution used for the antibody mapping in figure 25. 
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Table 5: A table showing the similarities between KR13 induced virolysis and virus-cell 
fusion 
 
Peptide triazole thiol  
(PTT) Induced Virolysis 
HIV – Cell fusion  Supporting Data 
The steps of HIV-1 
virolysis by PTT include 
gp120 shedding 
followed by a slower 
rate limiting p24 release 
from the viral lumen 
During virus cell fusion the 
rate limiting step is the relative 
content mixing of the virion 
and cell membrane release of 
the p24 core of the virion into 
the cell lumen 
Figure 20 and Figure 21, 
Chien et al. 2008 
Gp120 is shed off from 
the virion surface post 
PTT binding 
Gp120 is shed off from the 
virion post CD4 binding 
Figure 17, 18 and 20  
Moore et al. 1990 and Haim 
et al. 2009 
The gp41 on the HIV 
virion post PTT 
treatment leads to 
MPER exposure 
The gp41 on the HIV virion 
post CD4 and coreceptor 
binding leads to MPER 
exposure 
Figure 21, Dimitrov et al. 
2007, Monetro et al. 2008 
Fusion Inhibitors 
inhibit PTT induced 
virolysis 
Fusion inhibitors inhibit HIV-
cell fusion 
Figure 22 and Figure 26, 
Chan et al. 1998 
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Table 6: Potencies of inactivation and breakdown of BaL HIV-1 pseudotyped AuNP-
KR13 conjugates of different diameters.  The extents of loss of cell infection and p24 
release AuNP-KR13 treatment of BaL pseudovirus.  The average numbers of peptides per 
AuNP were measured using amino acid analysis and the peptide coverage per nm2 was 
calculated.  All of the IC50 and EC50 values were determined from dose response profiles 
(Figure 31) using Origin Pro.8 (Origin Lab). ± designates the standard deviation of the 
mean, n > 3. 
 
 
Diameter 
Viral infection 
inhibition  
IC50 (nM) 
 p24 release  
EC50 (nM) 
Average Number 
of peptides per 
AuNP  
Peptide density 
per nm2  
13.2nm 60 ± 10 10.94735 ± 1.66 34 0.062 
19.9nm 0.9 ±0.2 14.1626 ±  1.52 73 0.059 
42.8nm 0.18 ± 0.1 12.09586 ± 0.83 139 0.024 
92.6nm 0.02 ± 0.01 9.85039 ±  0.61 220 0.008 
123.4nm 0.01 ± 0.01 5.70828 ±  0.60 652 0.014 
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Table 7: Potencies of inactivation and breakdown of BaL HIV-1 pseudotyped AuNP-
KR13 conjugates with varying peptide coverage density.  The extents of loss of cell 
infection and p24 release AuNP-KR13 treatment of BaL pseudovirus.  The average 
number of peptides per AuNP were measured using amino acid analysis and the peptide 
coverage per nm2 was calculated.  All of the IC50 and EC50 values were determined from 
dose response profiles (Figure 33) using Origin Pro.8 (Origin Lab). ± designates the 
standard deviation of the mean, n > 3. 
 
 
No of KR13 
Per AuNP 
Viral infection 
inhibition  
IC50 (nM) 
p24 release  
EC50 (nM) 
Peptide density 
 per nm2 
68.6  0.42 nM 1.64 nM 
0.055 
28.8 1.1 nM 6.2 nM 
0.023 
10.9 8.1 nM 19.5 nM 
0.009 
0 >50 nM AuNP >50 nM AuNP 
NA 
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Table 8: Potencies of inactivation and breakdown of BaL HIV-1 pseudotyped AuNP-
KR13 conjugates of different diameters with same amount of peptide per nm2.  The 
extents of loss of cell infection and p24 release AuNP-KR13 treatment of BaL 
pseudovirus.  The average number of peptides per AuNP were measured using amino acid 
analysis and the peptide coverage per nm2 was calculated.  All of the IC50 and EC50 values 
were determined from dose response profiles (Figure 33) using Origin Pro.8 (Origin Lab). 
± designates the standard deviation of the mean, n > 3. 
 
Inhibitor Used 
Viral Infection 
Inhibtion IC50 
(nM) 
P24 release 
EC50 (nM) 
Coverage density  
(no. of peptides)  
Peptide 
density per 
nm2 
KR13 196.6 ± 36.29 3250 ± 567 1 1 
AuNP-KR13 (20.2 
nm) 5.3 ± 1.14 9.7 ±  1.07 96 0.075 
AuNP-KR13 (42.3 
nm) 0.7  ±  0.14 1.2 ± 2.5 430 0.077 
AuNP-KR13 (80.2 
nm) 0.05 ± 0.06 0.2 ± 0.4 1387 0.069 
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Table 9: Potencies of inactivation and breakdown of BaL HIV-1 pseudotyped AuNP-
KR13 (20.2 nm) conjugate (left) and KR13 alone (right) with HIV-1 pseudotyped with 
increasing amount of mutant spikes (S375W).  The extents of loss of cell infection and 
p24 release AuNP-KR13 treatment of BaL pseudovirus.  The amount of spike density 
was calculated as shown in methods section 4.1 and summarized in figure 36.  All of the 
IC50 and EC50 values were determined from dose response profiles (Figure 36) using 
Origin Pro.8 (Origin Lab). ± designates the standard deviation of the mean, n > 3. 
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Table 10: A table summarizing the differences between KR13 and AuNP-KR13 
 
 
 
 
 
 
 
 
 
 
 
 
 
Similarities Differences Supporting Data 
Both p24 and gp120 is 
released from the HIV-1 
virion post treatment 
AuNP-KR13 treatment has a 
faster rate of both p24 and 
gp120  release from the virion 
compared to KR13 
Figure 35 
Lead to morphological 
alteration to the virion  
The physical effect of AuNP-
KR13 on the virion is more 
dramatic and irregular 
compared to KR13 which gives 
more shrunken particles 
Appendix Fig. 4 and 
Appendix Fig. 13 
The gp41 remains on the 
virion post treatment 
AuNP-KR13 treatment does not 
expose MPER on gp41 
Figure 21 and Figure 35 
Both result in gp120 
shedding from the HIV-1 
producer cells leading to 
inactive virus production 
AuNP-KR13 treatment also 
leads to cytotoxicity and 
eventually death of these virus 
producer cells 
Figure 39, Figure 40 
The p24 release is only 
observed with peptide 
triazoles with thiol 
The free thiol on KR13 is 
important for virolysis only for 
KR13 alone and not AuNP-
KR13. The p24 release by KR13 
is inhibited by DTNB and 2G12, 
blocking free thiols as well as 
disufide rich regions of gp120.  
Figure not shown 
The thiol for KR13 is 
important for function  
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6 APPENDIX 
 
Control optical biosensor analysis to rule out non-specific T20-KR13 interaction:  
As part of confirmation of the specificity of the T20 inhibition of HIV-1 lytic 
deformation by KR13, a competition surface plasmon resonance experiment was 
conducted. Since T20 requires a small amount of DMSO for adequate solubility, all of 
the SPR experiments with T20 were conducted in PBS + 0.005% Tween-20 containing 
2% DMSO as running buffer. Direct binding of KR13 and T20 respectively was also 
conducted separately by injecting 0.3 nM to 156 nM of the above peptides in 2% DMSO-
containing buffer over the gp120 surface. This was done to monitor the binding of the 
peptides in the presence of 2% DMSO (Appendix Fig. 5). For KR13/T20 competition 
experiments, serial dilutions of the T20 (starting from 5 µM) with a constant 
concentration of KR13 (300 nM) were pre-mixed for 30 minutes and injected over the 
gp120 surface. Controls included buffer alone, KR13s (300 nM) alone and T20 (5 µM) 
alone. Data were ﬁt to the Langmuir 1:1 binding equation to estimate steady state aﬃnity 
in BiaEvaluation version 4.0 (GE) (direct binding) as noted above. The sensorgrams 
obtained (Appendix Fig. 5) demonstrated lack of interference of KR13 binding to gp120 
by T20.  This is consistent with lack of nonspecific binding of T20 to KR13. 
 
Cell-Culture and Cytotoxicity Test:  
 
The AuNP-KR13 conjugates were tested for stability in physiological conditions 
(Appendix Fig. 9A), as well as cytotoxicity test in vitro using the using the tetrazolium 
salt premix reagent, WST-1 from Takara Bio Inc. following the manufacturer’s protocol. 
The formazan product was measured using the microplate reader at absorbance 
wavelenght 460 nm (Molecular Devices) (Appendix Fig. 9B).  
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APPENDIX FIGURES 
 
Figure 1: Western blot gel images showing gp120 shedding from HIV-1BaL pseudovirus 
as a function of dose of KR13, HNG156, KR13b and KR13s. The western blots were 
stained using the primary anti-gp120 antibody D7324 and secondary anti-sheep HRP. 
Controls shown were intact virus (IV, treated with PBS) and recombinant gp120(200 
ng/ml).  The gp120 control was the YU2 recombinant gp120 obtained by 293F cell 
expression and contains monomeric and aggregate bands as observed previously [25]. 
The gp120 from the virions ran at a different size compared to the monomeric gp120 
most likely due to a different extent of glycosylation on the surface of these proteins 
when expressed in 293T cells. 
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Figure 2: Inhibition of infection of HOS CD4+ve CCR5+ve cells by recombinant viruses 
pseudotyped with the envelope for VSV-G (a) and AMLV (b) by the peptides HNG156, 
KR13, KR13b and KR13s at concentrations ranging from 250µM to 0.01 nM. The data 
were normalized to 100% infection activity in the absence of peptide triazole.  
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Figure 3: Measurement of gp41 content in HIV-1 BaL pseudotype treated with KR13 
and HNG156, respectively, as detected by mAb 98-6. Soluble protein (6% Optiprep) and 
residual virion (18.2 - 19% Optiprep) fractions of the gradient purified, peptide treated 
virus (HIV-1 BaL pseudotyped) were separated by polyacrylamide gel electrophoresis 
and transferred to a PVDF membrane. Bands were detected with anti-gp41 mAb 98-6.  
Band intensities were normalized to total gp41 content present in intact virus control 
(virus treated with PBS). Error bars represent the standard deviation of the mean, n = 3. 
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Figure 4: Raw TEM images used to determine the diameter distributions in Figure 21. 
The intact virus field was obtained for viruses treated with PBS for 30 minutes at 37 °C 
before fixing the virions with 0.1% paraformaldehyde and loading on epoxy for TEM 
analysis.  Separate samples of virions were treated for 30, 720 and 1440 minutes with 
KR13 at 37 °C before fixing with paraformaldehyde. The epoxy samples were cut into 
100 nm thick slices using a Leica EM UC6 Cryo-ultramicrotome and loaded onto a holey 
carbon TEM 200 mesh grid for TEM analysis. The grids were stained with 1% uranyl 
acetate and loaded onto the JEM 2100 microscope system (JEOL, Japan) operated at 120 
kV.  
 
 
 
 
 
 
 
 
 
 
 
 
 
253 
 
 
Figure 5: SPR analysis to test for possible artifactual binding of T20 to KR13.  All the 
samples were diluted in buffer that contained 2% DMSO and 0.005% tween 20 due to the 
low solubility of T20 in SPR buffer alone. (a) Sensorgrams for direct binding of KR13 to 
chip-immobilized soluble WT YU2 gp120. Data show proportionally increasing binding 
responses to immobilized gp120 at increasing concentrations of KR13. (b) Steady state fit 
analysis of the Req values for each concentration of the peptide from (a) calculated using 
the BiaEvaluation software, with separate kon and koff fit analysis using  the Langmuir 
equation described in Appendix Text section  (c) Sensorgrams for direct KR13 binding to 
chip-immobilized gp120 in the presence of T20.  Samples of T20 (0 µM to 5 µM – 
shown in the legend) and constant concentration of KR13 (300 nM) were pre-mixed (30 
min) and injected into the sensor flow cell. The binding profiles were observed on the 
same WT monomeric gp120 chip as in (a). As a baseline control, PBS (Buffer) alone was 
injected, T20 at 5 µM and KR13s at 300 nM were used as a negative controls.  Data show 
lack of significant dose-dependent effect of T20 on KR13 binding to gp120.  The 
negative control surface used was chip immobilized with non-specific EGFR antibody 
cetuximab. All curves were plotted using Biaevaluation 4.0 software (GE).  
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Figure 6: Dose responses of the effects of peptide triazoles, KR13 and HNG156 on HIV-
1 BaL pseudovirus induced infection inhibition of HOS CD4+ve CCR5+ve and HOS CD4-
ve CCR5+ve cells.  Extent of cell infection was measured using a single round infection 
assay.  Origin Pro. 8 was used for sigmoidal curve fitting, n=3. The x-axis represents 
Relative Luminescence Units (RLU) which was calculated by subtracting the background 
signal (approximately 120 RLU).  
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Figure 7: Viral infection inhibition of the T20 resistant mutant viruses by (A) T20 and 
(B) KR13. The data were normalized to 100% infection activity in the absence of peptide 
triazole.  Origin Pro. 8 was used for sigmoidal curve fitting, n=3. 
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Figure 8: (A) Stability of the gold and gold conjugates in physiological conditions shown 
in x-axis. The absorbance peak of the AuNP, AuNP-KR13 (20 nm diameter) as well as 
AuNP:BSPP at different physiological conditions, Phosphate Buffer (PB), DI-water, 
PBS, NaCl (17 mM) and HOS CD4+ve CCR5+ve growth media. (B) Cell toxicity assay 
using WST-1 reagent for the effect of AuNP-KR13 (20 nm diameter) and KR13 alone on 
HOS CD4+ve CCR5+ve 48 hours post addition.; no statistically significant differences 
measured, P<<<0.05, n =3 using a t test. 
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Figure 9: Flocculation assay of the AuNP in order to estimate the amount of peptide 
(KR13) required for stable conjugation. Equal concentration of AuNP is vigorously 
stirred with increasing concentration of KR13 for 30 minutes at room temperature. 
Following 1 M NaCl is added to the mixture and the absorbance at the surface plasmon 
resonance absorbance of AuNP (532 nm) is measured using a spectrophotometer. When 
the absorbance is stabilized, this shows that the conjugate is stable and no longer leads to 
aggregation, that concentration of the peptide to AuNP ratio is used for conjugation.  
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Figure 10: Zeta potential measurements from the zetasizer of the AuNP prior and post to 
KR13 addition. The diameters that are on the x-axis of the AuNP-KR13 is based off on 
the TEM and DLS measurements.  
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Figure 11: (A) Shows the activity of the HIV-1 BaL pseudotyped that have different 
levels of S375W mutant incorporated. The No. of spikes on the y-axis (red) is calculated 
from the gel image in the inset, assuming that one virus has 2500 molecules of p24 (Thali 
et al. 1994) and also that all spikes have three monomers incorporated. The gp120 content 
was measured using western blot analysis, the p24 release was measured using p24 
ELISA and virus infection was measured using single round luciferase reporter gene 
assay as explained in detail in the methods. (B) Shows the gp120 monomer standard 
curve from the western blot analysis and the linear fit equation in the inset which was 
used to calculate the gp120 monomers in the HIV-1 BaL pseudotyped that have different 
levels of S375W mutant incorporated. 
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Figure 12: Comparing the anti-viral effects of KR13 (A) versus AuNP-KR13 (20 nm) 
(B). This data is summarized from the raw data plots of viral infection inhibiton and p24 
release of KR13 and AuNP-KR13 presented in figure 34 respectively. This shows that the 
higher the value of the hills coefficient the sharper the slope of the curve and  the lower 
the anti-viral effect on the virion.   
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Figure 13: Representative images of the TEM images taken for intact virus, AuNP-KR13 
(20 nm) and AuNP-KR13 (80 nm) at  50 nM concentration and treated with the HIV-1 
BaL pseudotyped for 10 minutes at 37°C and fixed as explained in the methods. The 
samples are stained with 1% uranyl acetate and loaded onto a TEM copper grid and 
imaged using the JEM 2100 operated at 120 kV (JEOL, Japan).   
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Figure 14: (A) KR13 and KR13b structure and bottom right shows how KR13 is 
conjugated on 20 nm AuNP. (B) Viral infection inhibition of HOS CD4+veCCR5+ve cells 
by KR13 (black) KR13b (red) and AuNP-KR13 (blue) and the IC50 values are 52.1 ± 3.4 
nM, 147.3 ± 6.4 nM and 1.2 ± 2.4 nM respectively (C) p24 release from KR13, KR13b 
and AuNP-KR13 treated HIV-1 BaL pseudovirions. The samples are plotted using 100% 
as virions treated with 1% triton X and 0% as PBS treated virions. The EC50 values of the 
p24 release caused by KR13 and AuNP-KR13 are 3.15 ± 1.5 µM and 6.3 ± 5.1 nM.  
Origin Pro. 8 was used for sigmoidal curve fitting, n=3. Error bars represent standard 
deviation of n=3.  
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Figure 15: Testing the viral infection of the virions collected from producer 293T cells 
that are incubated with increasing concentrations of AuNP alone or AuNP-KR13s. The 
virions were collected and purified using a 6-20% iodixanol gradient and loaded onto a 
HOS CD4+veCCR5+ve and tested for infection 48 hours post addition. Error bars represent 
the standard deviation of the mean, n = 3. 
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Figure 16: Cell viability of CHOK1 cells after 24 hours post KR13, KR13b and AuNP-
KR13 treatment. The WST-1 pre-mix was used in order to test the cell viability and the 
absorbance was measured at 450 nm. CHOK1 cells treated with PBS for 24 hours were 
used as the 100% viability control. Error bars represent the standard deviation of the 
mean, n = 3. 
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Figure 17: Cell viability of 293T  cells transfected with S375W virion DNA and BAL-
WT DNA, in the presence of KR13 and AuNP-KR13. 24 hours post KR13  and AuNP-
KR13 treatment WST-1 pre-mix was used in order to test the cell viability and the 
absorbance was measured at 450 nm. 293T cells treated with PBS for 24 hours were used 
as the 100% viability control. Error bars represent the standard deviation of the mean, n = 
3. 
 
 
